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1. Introduction
1.1 The human immune system
The human immune system
form a complex network of cellular and humoral defense mechanisms that protects the
diseases caused by pathogens
(toxins).
Figure 1-1. The human immune system
asterisk) of both the innate (orange
features of each subsystem are indicated at the bottom of the panel. Figure modified from Dranoff, 2004
Furthermore, based on its ability to di
immune system also plays a significant role in the defense against cancer
its protective functions, the immune system is equipped with a wide array of mechanisms that
normally enable it to recognize, neutralize
I n t r o d u c t i o n
(Figure 1-1) consists of specialized molecules
(bacteria, viruses, fungi and parasites) and harmful substances
. Shown are the cellular and humoral components (marked with
background) and adaptive (blue background) human
stinguish between healthy and maligna
cells
, and eventually eliminate immunological threats. The
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recognition of pathogens or cancer cells is mediated through highly specific so-called
immunoreceptors that engage pathogen- or cancer cell-specific antigens, which, by definition, are
self-molecules (or parts thereof) that can stimulate an immune response. The human immune
system is divided into an innate and an adaptive immune system (Figure 1-1). The innate immune
system is characterized by (i) an immediate response after an immunological challenge, (ii) a
constant set of germline-encoded immunoreceptors that recognize a limited number of specific
antigens, and (iii) the absence of an immunological memory. The opposite is true for the adaptive
immune system, which features (i’) a delayed immune response against an immunological threat,
(ii’) a vast immunoreceptor repertoire, obtained by somatic recombination, that allows the
recognition of an almost indefinite number of antigens, and (iii’) the presence of immunological
memory. Although both systems have their own characteristics and distinct arms of cellular and
humoral defense mechanisms (Figure 1-1), it is the complex yet dynamic and powerful interplay of
both systems that makes the immune system so effective.
1.1.1 Immunoreceptors employed by the innate immune system
The recognition of pathogens by components of the innate immune system is mediated by
invariable, germline-encoded and constitutively expressed pattern recognition receptors (PRRs).
PRRs detect evolutionary conserved pathogen-associated molecular patterns (PAMPs) that are
common to many pathogens. This explains why a relatively small number of invariant PRRs can
detect a large number of diverse pathogens. Furthermore, the constitutive expression of PRRs by a
large population of innate immune cells explains why the innate immune system can essentially
respond instantaneously to an immunological threat. An example for a PRR are the Toll-like
receptors (TLR), which can for instance recognize lipopolysaccharides present on the outer
membrane of Gram-negative bacteria or double-stranded (ds) RNA, which is typical for some virus
families with ds RNA genomes. A different type of PRR is represented by the mannose-binding
lectin (MBL), which recognizes a broad array of pathogens based on their carbohydrate surface
patterns.
The NK cell receptors, which in addition to the PRRs also constitute a large group of
innate immunoreceptors, are discussed in Section 1.2.1.
I n t r o d u c t i o n
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1.1.2 Immunoreceptors employed by the adaptive immune system
The adaptive immune system employs receptors that have been selected based on their high
specificity for a particular antigen. The membrane-bound B cell receptors (BCRs) or their soluble
derivatives, the antibodies, recognize antigens that are exposed on the pathogen’s surface, while the
membrane-bound T cell receptors (TCRs) recognize pathogen-derived peptides that are presented
by MHC class I and/or II molecules on the surface of antigen-presenting cells (APCs). At any
given time, a healthy human individual features billions of naive B and T cells, each of which is
equipped with a unique receptor on its cellular surface that entails a unique specificity for a
particular antigen2, 3. Furthermore, each day millions of new B and T cells with new receptor
specificities are generated, while at the same time old B and T cells are eliminated. In this way, the
receptor repertoire is continuously turned over and can therefore easily adapt to new
immunological challenges. This diversity in the B and T cell repertoire is achieved by a genetic
mechanism termed somatic recombination during which V, (D) and J gene segments are randomly
selected from corresponding gene pools, followed by their ordered assembly to produce a unique,
functional immunoreceptor phenotype. During the subsequent process of clonal selection, only
those naive B and T cell clones start to proliferate (clonal expansion) that were selected from the
human body’s pool of B and T cells based on their ability to bind to one of the pathogen’s antigens
via their highly specific BCRs and TCRs, respectively. This in turn explains the high antigen
specificity that is so typical for B and T cell receptors4, 5. The clonal expansion process takes time
and is therefore the reason for the significantly longer time delay between immunologic challenge
and immune response, when compared to the innate immune system.
1.2 Natural killer cells
Natural killer (NK) cells were first described in 1975 and named according to their ability to
‘naturally’ kill tumor cells without prior sensitization and in a major histocompatibility complex
(MHC) molecule independent fashion6-8. Nowadays, NK cells are recognized as a population of
large granular cytotoxic lymphocytes that (i) belong to the innate immune system, (ii) are
characterized by the absence of the (T cell) surface marker CD3, and (iii) can be subdivided into
two subpopulations depending on the abundance and presence of the surface markers CD56 and
CD16 (the FcγIII receptor), respectively9-11. NK cells comprise 15 % of the overall lymphocytes
and are of pivotal importance in the cellular immunosurveillance of viral pathogens and cancer
cells12-16. They recognize virus infected or malignant host cells either indirectly via their FcγIII 
receptors that bind to target cell-bound IgG antibodies and trigger a process known as antibody
4 | P a g e
dependent cellular cytotoxicity (ADCC),
receptors17, 18. Upon activation, NK cells stimulate other immune cells through the release of
cytokines or destroy their target cells
called perforins and granzymes9
membrane, while the simultaneously released granzymes d
target cell where they trigger apoptotic cascades that lead to the self destruction of the virus
infected or degenerated host cell. Whether
stimulatory effects depends on its phenotype
cytokines but no perforins and consequently exhibit immunomodulatory functions
opposite is true for CD56dim CD16
mediated cytotoxicity9, 11.
Figure 1-2. NK cell recognition. Shown
infected with the virus, pathogenic host cells
as MIC and ULBP molecules on their cellular surface
engaging the the activating NKG2D immunoreceptor
stimulate other immune functions and/or kill
granzymes. The schematic representations of the MIC and ULBP molecules were
Trowsdale, 200719. The figure was modified from
structure is based on pdb code 1hyr20.
I n t r o d u c t i o n
or directly via sets of activating and inhibitory NK cell
through the release of cytotoxic granules filled with
(Figure 1-2). The perforins create pores in the target cell
iffuse through these pores inside the
an individual NK cell exhibits cytotoxic or immune
. CD56bright CD16- NK cells produce high amounts of
+ NK cells, which are predominantly involved in NK cell
is one possible way by which NK cells detect viral pathogens
upregulate stress-inducible MHC class I-like self
. These self-ligands can activate patrolling NK cells by
. Upon activation the NK cells release cytokines
the virus infected cells through the release of perforins and
modified
Cerwenka & Lanier, 200112. The displayed
proteins
, while the
. Once
-ligands such
that
from Eagle &
NKG2D
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1.2.1 NK cell receptors
NK cells as well as B and T cells all constitute subpopulations of human lymphocytes. However, in
contrast to B and T cells, NK cells lack the ability of somatic recombination and therefore the
ability to generate highly antigen-specific receptors. Instead NK cells mainly comprise large sets of
germline-encoded activating and inhibitory receptors that, based on their molecular structures,
either belong to the immunoglobulin superfamily (IgSF) or the superfamily of proteins containing a
C-type lectin-like domain (CTLD), respectively17, 18, 21-24. An additional feature by which the NK
cell receptors differ from BCRs and TCRs (as well as from PRRs) is that most of them do not
detect foreign antigens but instead monitor the abundance of particular activating and inhibitory
self ligands on the surface of host cells. An increase in activating or a decrease in inhibitory self
ligands upon viral infection or transformation of a host cell will result in the activation of NK cells
and the subsequent NK cell-mediated killing of the abnormal cell.
A) C-type lectin-like proteins
CTLD containing proteins (CTLDcps) were first discovered as carbohydrate recognition domains
(CRDs) in proteins that bind carbohydrates (lectins) in a Ca2+ (C-type) dependent fashion25-29.
Subsequently, many CTLDcps that were deficient in both their carbohydrate and Ca2+ binding
capabilities were identified. The corresponding domains instead had evolved to recognize other
ligands such as proteins, lipids and even inorganic compounds27. A prominent group of non-
carbohydrate binding CTLDcps is represented by the protein-binding, homo- and heterodimeric C-
type lectin-like NK cell receptors (CTLRs) which, based on their overall domain architecture,
constitute a distinct subfamily of vertebrate CTLDcps26, 27, 30. The CTLR protomers are type II
transmembrane proteins and consist of four characteristic regions: an N-terminal cytoplasmic tail, a
transmembrane region, a short stalk region and a C-terminal CTLD (Figure 1-4).
B) Immunoglobulins
The IgSF is comprised of proteins that feature a common Ig-like fold. Among them are the
classical immunoglobulins, or Igs, (antibodies, and their membrane-bound forms, the B-cell
receptors) that gave the fold and the superfamily their names. Over time, many proteins were
identified that were not classical Igs but nonetheless were partly or entirely composed of Ig-like
domains31. Nowadays the heterogenic group of IgSF proteins includes enzymes, chaperones,
cytokine receptors, adhesion molecules, muscle proteins, viral coat proteins, proteins relevant for
the nervous system, proteins relevant for the immune system (classical Igs, T-cell receptors, MHC
I n t r o d u c t i o n
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molecules a.s.o.) and many others31-33. The term ‘Ig-fold’ is often used instead of ‘Ig-like fold’
when one refers to the fold of classical immunoglobulins.
Ig-like domains feature seven to nine antiparallel β-strands that assemble to form two 
distinct β-sheets. The two sheets pack against each other, forming a β-sandwich. Although Ig-like 
domains all have the same topology, their domain size varies considerably, owing to the varying
lengths of their loops and additional -strands present in some variants31, 34-36. Nevertheless, typical
characteristics for all Ig-like domains can be defined that include (i) their extreme sequence
heterogeneity that makes it difficult to define a sequence signature of this fold and therefore often
hampers the prediction of Ig-like folds based on a protein’s primary sequence33, 35, (ii) their
common structural core comprised of β-strands b/e (sheet 1) and c/f (sheet 2)35 and (iii) an
additional 3 - 5 β-strands that form the positional and conformationally flexible strands at the edges 
of the sheets35. Based on the number and location of the edge strands (i. e. differences in the
molecular shape) as well as sequence criteria, at least 5 topological subtypes of Ig-like domains, the
C1, C2, V, H and I types, can be distinguished from one another31-33. A selection of these sybtypes
is presented schematically in Figure 1-335. Classical Ig domains are either of the C1 (constant) or V
(variable) type, which in addition to the abovementioned criteria can also be distinguished by the
number of residues that lie between two b and f-strand cysteines that in many Ig-like proteins form
a disulfide bridge. A residue number of 65 - 75 indicates a V-type, while 55 - 65 residues indicate
the presence of a C-type domain31. The mentioned disulfide bridge between strands b and f was
originally considered as one of the cornerstones of the Ig-like fold, and was thought to be essential
for its stability35. Over time, however, many more structures of proteins containing Ig-like domains
were solved, and these revealed that the number and the locations of the disulfide bridges are quite
variable, with some Ig-like domains having no disulfide bridge at all35.
Figure 1-3. Ig-like domain subtypes
(C – constant), C2, H (H – hybrid)
Ig-like fold are represented by
right (sheet 2) handside. The number below each panel indicates the number of
each particular subtype. Depending on the position of
subspecies that are either composed of
was drawn after Bork et al., 1994
C) Gene loci of NK cell receptors
In humans, the genes encoding NK cell receptors of the IgSF or CTLD are
The CTLRs are encoded in the natural killer gene complex
Ig-like receptors such as the killer Ig
called leukocyte Ig-like receptors
in the leukocyte receptor complex
I n t r o d u c t i o n
. The four panels show the 2D β-strand topolog
and V (V – variable) Ig-like subtypes. The core and edge
red and green arrows, respectively, and are labeled on the left (sheet
β
β-strand a in the V-type immunoglobulins,
3+6 or 4+5 β-strands can be distinguised from each other. The figure
35 and modified based on Halaby et al., 199933.
(NKC)17, 21 on chromosome 12, while
-like receptors (KIR), the Ig-like transcri
(LIR) and the natural cytotoxicity receptors (NCR) are encoded
(LRC) on chromosome 1921, 24.
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genetically clustered37.
pts (ILT) that are also
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1.2.1.1 Inhibitory NK cell receptors
An immune response by cytotoxic T lymphocytes (CTL) is critically dependent on the presentation
of viral or tumor cell specific antigens by MHC class I molecules on the surface of virally infected
or malignant host cells, respectively. Therefore, in order to subvert an antiviral or anti-tumor
immune response viruses and tumor cells have devised strategies to downregulate the peptide
presenting MHC class I self proteins38, 39. However, according to the ‘missing-self hypothesis’ that
was first formulated by Ljunggren and Kärre, a hampered MHC class I surface expression results in
a decreased engagement of MHC class I-specific inhibitory NK cell surface receptors, and
consequently in a loss of inhibitory signals that, in the receptor’s unengaged state, are usually
provided by tyrosine phosphorylated immunoreceptor tyrosine-based inhibitory motifs (ITIMs)
located in the receptor’s cytoplasmic tail40-43. The loss of inhibitory signals may in turn lead to the
activation of the engaging NK cell, and therefore the elimination of the abnormal cell. However,
NK cell activity is not solely dependent on receptors that inhibit NK cell activation, but rather
tightly regulated by the integration of signals from a multitude of both inhibitory and activating NK
cell receptors44, 45.
1.2.1.2 Activating NK cell receptors
In contrast to inhibitory NK cell receptors, activating NK cell receptors do not monitor the
downregulation of self-ligands but instead their upregulation. According to the ‘induced-self
hypothesis’, an increased host cell surface expression of stress-inducible self-ligands results in an
increased engagement of activating NK cell surface receptors. Different from the inhibitory
receptors the signalling of activating receptors is often mediated by adaptor molecules. These
normally pass on the signal via tyrosine phosphorylated immunoreceptor tyrosine-based activation
motifs (ITAMs) that are, similar to the ITIMs of inhibitory receptors, located in the proteins
cytoplasmic tail41-44, 46.
1.2.2 The activating NK cell receptor NKG2D
The immunoreceptor NKG2D (natural-killer group 2, member D) is a powerful activating,
homodimeric CTLR that mediates NK surveillance of stressed cells such as virus infected or
degenerated host cells (Figure 1-4)19, 43, 47, 48. However, in addition to its original classification as a
NK-cell receptor, NKG2D is also expressed by distinct subsets of T cells such as CD8+ αβ and γδ T 
cells as well as natural killer T cells, NKT47, 49. Ex vivo studies with human NK cells showed that
I n t r o d u c t i o n
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the surface expression of NKG2D is modulated upon exposure to certain types of cytokines. While
interleukins (IL) 2, 10, 12, 15 and IFN-α stimulate the upregulation of NKG2D42, 50-52, the opposite
was observed for the cytokines TGF-β and IL2153, 54. In humans, NKG2D transduces signals into
the interior of the cell by associating with DAP10 adaptors (DAP12 in mice47) that pass on the
signal via a phosphatidylinositol-3-kinase (PI-3K) dependent pathway (Figure 1-4)41, 42, 47, 55.
However, the quality of the signal is different. While NKG2D transmits activation signals in case
of NK cells, the signal transmitted in case of the T cell subsets has a costimulatory character56, 57.
As is typical for human CTLRs, NKG2D is encoded in the NKC. Together with its distant
homologs NKG2A, C and E, NKG2D comprises the NKG2 receptor family of CTLRs. Although
the NKG2 receptor family members are genetically clustered in the NKC and structurally related
due to their C-type lectin-like fold, NKG2D stands clearly out among them as a distinct receptor
for the following reasons47, 58: (i) it is only distantly related to the other NKG2 receptors, (ii) it is a
homodimeric protein whereas the other members are CD94-NKG2 heterodimers, (iii) it specifically
binds to MIC (MHC class I chain related molecule) and ULBP (UL16 binding protein) ligands
(Figure 1-4) instead of human leukocyte antigen E (HLA-E), and (iv) in contrast to many other
immunoreceptors, NKG2D features a fairly promiscuous ligand binding mode, allowing it to
recognize an array of at least eight diverse MHC class I-like ligands that are upregulated in a cell
stress-associated manner and in this way allow for the immunorecognition of infected or
transformed cells (for details see Section 1.2.3)19. Two rather different explanations of the
mechanism behind this promiscuous ligand binding mode exist47, 59-61. One group claims that
NKG2D recognizes its diverse array of ligands by an induced fit mechanism that requires NKG2D
to undergo certain conformational adjustments, while another group argues for a rigid adaptation
mechanism59-61. The latter mechanism is based on a rigid NKG2D binding site that consists of a set
of predominantly hydrophobic residues, which can adjust their spatial positions in order to
accommodate the largely different interface amino acid residues provided by the set of diverse
NKG2D ligands59, 60. The question arises what the biologic meaning of this remarkable redundancy
of NKG2D ligands might be? A common hypothesis addressing this question proposes that the
NKG2D ligand diversity may be explained as a host response to the selective pressure exerted by
viral immunoevasins (see Section 1.2.3)14, 19. However, it was also argued that cancer cells may be
an additional driving force for the observed NKG2D ligand diversification19.
1.2.3 Ligands of the activating NK cell receptor NKG2D
As mentioned above one of the most intriguing characteristics of the human NKG2D
immunoreceptor is its promiscuous ligand binding mode allowing it to engage eight MHC class I-
I n t r o d u c t i o n
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like ligands (Figure 1-4)14, 19, 43, 47. These ligands belong to either of two diverse protein families,
the MIC and ULBP families, that are upregulated upon cellular stress, as caused for example by
viral infections, heat shock, DNA damage or ultraviolet (UV) radiation (Figures 1-2 and 1-4)16, 62.
The MIC family includes MICA and MICB, both of which comprise an ectodomain, a
transmembrane domain and a cytoplasmic tail63, 64. The ectodomain is composed of a membrane
distal MHC class I-like α1α2 platform domain that is connected to a membrane proximal MHC 
class I-like α3 Ig-like domain63, 64. The α1α2 and α3 domains are linked together via a flexible 
hinge region that leads to an elevated interdomain flexibility (Figure 1-4)63, 64. In contrast to
classical MHC class I molecules, MICs do not associate with β2-microglobulin (β2m) or bind 
peptides20, 61, 63, 64.
The ULBP family, as the name implies, was originally discovered based on the ability of
some family members to engage the human cytomegalovirus (HCMV) protein UL1665. It currently
consists of ULBP members 1 to 6 that, based on their relationship to the retinoic acid early
inducible 1 (Rae1) proteins in mice, are also sometimes referred to as retinoic acid early transcript
(RAET) proteins (Figure 1-4)19, 43, 66, 67. The ULBP ectodomains, like those of the MICs, are
comprised of an MHC class I-like α1α2 platform domain47, 61. In contrast to MICA and MICB,
however, the ULBPs lack α3 Ig-like domains (Figure 1-4). Other aspects in which ULBPs show 
similarities to or differ from the MICs concern the way in which particular ULBP ectodomains are
linked to the cellular membrane, and their allelic diversity (i. e. their genetic polymorphism)19, 47, 57,
68. Like the MICs, ULBPs 4 and 5 represent type I transmembrane proteins and are inserted into the
membrane by their particular transmembrane domains (Figure 1-4). ULBPs 1-3 and ULBP6, on the
other hand, are anchored into the membrane via fatty acids that are part of the glycolipid
glycosylphosphatidylinositol (GPI)69. These so-called GPI-anchors represent a covalent
posttranslational modification at the C-terminus of a protein that allows the protein to become
membrane-associated even in the absence of a transmembrane domain. In terms of polymorphism,
MICA and MICB can be considered highly polymorphic as they give rise to 70 and 22 allelic
variants (www.ncbi.nlm.nih.gov/gv/mhc), respectively, whereas only very few allelic variants have
so far been described for the ULBPs70.
Figure 1-4. Ligands of the activating NK cell immunoreceptor NKG2D
Shown are the schematic representations of the eight, currently known MHC class I
The three-dimensional structure of MICB
indicated is the selective engagement of the NKG2D ligands by the HCMV immunoevasin UL16, which is
drawn on top of its NKG2D ligand ta
left is a schematic of the activating
DAP10. The C-type lectin-like domains (CTLDs) of the NKG2D protomers (purple and gree
as three-dimensional structures.
the C-type lectin-like receptors (CTLR) encoded in the natural killer gene complex (NKC)
cytoplasmic tail, TM – transmembrane domain, ST
further characterized by six invarient cysteines that form intra
NKG2D structure is based on
figure was modified and updated from Eagle & Trowsdale, 2007
Many studies have shown that even proteins with little similarity in their primary amino acid
sequences may nonetheless give rise to protein families with the same structural fold (or parts
thereof) and as a consequence of this structura
functions. A prominent example of this type can be found in the IgSF. However, this is also true for
the ULBP and MIC families. Both families exhibit surprisingly similar structures even though the
MICs share as little as 21 -
The sequence homology within each group is significantly higher: the MICs share 83
residues in their α1α2 platform domain, while the ULBPs share 38 
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. Pathogenic cell memb
on the right hand side illustrates the MHC class I
rgets as a blue half-moon. NK cell membrane (top): Presented on the
NK cell immunoreceptor NKG2D and its associated adaptor molecule
The schematic on the right shows the four regions
– stalk region and CTLD. The
-chain disulfide bonds. ‘C’, cysteine. The
pdb code 1hyr20, while the MICB structure is based on
19.
l similarity may eventually exhibit very similar
29 % identical residues in their α1α2 platform domain with the ULBPs. 
– 59 %
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rane (bottom):
-like NKG2D ligands.
-like fold. Also
n) are displayed
that typically constitute
17: Cyt –
CTLD of the CTLRs is
pdb code 1je664. The
% identical
amino acid sequence
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identity in the same region. Based on these data one may wonder how tightly the MICs and ULBPs
interact with NKG2D. A parameter that indicates the binding strength or complex stability, is the
dissociation constant (KD) of the interaction that is also commonly referred to as the affinity of the
complex. Although all MICs and ULBPs were shown in functional studies to bind NKG2D, affinity
data are unfortunately only available for MICA (0.9 µM), MICB (0.8 µM) and ULBP1 (1.1 µM)57,
60. Nevertheless, this data suggests that NKG2D is able to bind both NKG2D ligand families with
similar affinity.
1.3 Herpes viruses
The order Herpesvirales is comprised of the virus families Alloherpesviridae (fish and frog viruses)
Malacoherpesviridae (a bivalve virus) and Herpesviridae (mammal, bird and reptile viruses)71. The
family of Herpesviridae consists again of three subfamilies, the α, β and γ Herpesvirinae, each of
which is in turn composed of four genera. Herpesvirus species belonging to eight out of these
twelve genera have been shown to cause illness in humans, and are named human herpes virus
(HHV) 1-8 71, 72.
Herpes viruses are 200 - 250 nm in diameter and contain a linear dsDNA genome of
125 - 245 kbp73. Based on these features, herpes viruses are among the largest and most complex
viruses currently known. Additional characteristics of herpes viruses are (i) an icosahedral
nucleocapsid that is 125 nm in diameter and contains the dsDNA, (ii) the tegument, which consists
of amorphous virus-coded proteins and encloses the capsid, and (iii) a lipid bilayer envelope on the
outside that contains several viral glycoproteins73, 74.
All herpes viruses replicate in the nucleus of the host cell75. Upon infection the herpesvirus
undergoes a complete replication cycle that leads to the production of functional viral particles and
entails the lysis of host cells and then establishes a latent life-long infection, the latter being
characterized by the presence of replication-competent viral genomes in the absence of infectious
viral particles74, 76. However, latency phases alternate periodically with rather short acute phases
during which the virus reenters its lytic replication cycle76.
1.3.1 Human cytomegalovirus
The ubiquitous human cytomegalovirus (subfamily Betaherpesvirinae, genus Cytomegalovirus) or
human herpesvirus 5 (HHV5) is the largest virus in the family of herpesviridae71, 72, 75. In case of
the strain AD169 the HCMV genome is comprised of 230 kbp and encodes 208 functional open
reading frames (ORF)77. Two adjacent unique long (UL) and unique short (US) ORF sequence
I n t r o d u c t i o n
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clusters, which are separated by other ORFs referred to as internal repeat sequences (ILS and IRS),
form the center of the linear HCMV genome. This center is flanked on both sides by ORFs named
terminal repeat sequences (TLS and TRS)77. Depending on the time of expression these HCMV
genes can also be classified in early and late genes75.The HCMV life cycle is illustrated in Ref.75.
After infection, HCMV usually causes lifelong asymptomatic (latent) infections in healthy
individually but can also lead to severe illness in immunocompromised individuals and very young
children74. HCMV is usually transmitted via saliva, body excretions or sexual contact but can also
infect embryos or fetuses by transmission through the mothers placenta (intrauterine
transmission)74. The latter type of infection typically causes the cytomegalic inclusion disease
(CID) that is often characterized by acute manifestations such as pneumonia or hepatitis and (in
case of survival) long-term effects such as mental retardation or blindness74. The mortality rates
range from 5 % in case of congenital and 10 % in case of transplantation-associated HCMV
infections74.
1.3.2 HCMV immune evasion strategies
A feature that distinguishes HCMV from other viruses is its unique multitude of strategies to evade
both innate and adaptive mechanisms of human immunosurveillance. Accordingly, HCMV is also
referred to as a paradigm of viral immune evasion78. A small selection of these immune-modulatory
strategies is presented in the following paragraphs and in Figure 1-514, 39, 78-80.
1.3.2.1 Interference with MHC class I peptide presentation
The detection and killing of a virus infected host cell by cytotoxic T cells (CTL) is critically
dependent on the presentation of viral peptides by MHC class I molecules on the surface of the
infected cell. HCMV efficiently subverts CTL responses by means of several US and UL
immunoevasins, which interfere with the intracellular processes that lead to the generation of
functional MHC class I–peptide complexes14, 78. The immunoevasin UL83 interferes with the entry
of viral proteins in the proteasome, thereby hampering the production of viral peptides (Figure 1-5).
An additional immunoevasin, US6, blocks the ‘transporter associated with antigen processing’
(TAP) that is required to transport peptides generated by the proteasome from the cytosol into the
ER, the cellular compartment where the obtained viral peptides are mounted onto the MHC class I
molecules (Figure 1-5). Finally, a number of Ig-like glycoproteins named US2, US3, and US11 can
directly interact with the MHC class I molecules and lead to their retention in the ER (US3) or
facilitate the degradation of MHC class I (US2, US11) molecules by mediating their dislocation to
14 | P a g e
the cytoplasm (Figure 1-5)78. Although this
affecting MHC class I molecules it needs to be pointed out that also the peptide presentation by
MHC class II molecules, which is pivotal in eliciting immune responses by T helper cells, is
compromised81.
Figure 1-5. Mechanisms of immune evasion by HCMV.
by HCMV to subvert antiviral immune responses mediated by T cells and NK cells. T cell responses are
hampered by HCMV immunoevasins US2,
viral peptides by MHC class I molecules. NK cell responses on the other hand are impeded by
immunoevasins UL18, UL40, UL16, UL142 and UL141. UL18 and the HLA
complex both serve as ligands for inhibitory NK cell receptors, while immunoevasins UL16, UL142, UL141
and the miRNA of UL112 downmodulate the surface expression of activating NK cell receptor ligands by
retaining those ligands in the ER (UL16, UL112 and UL141) or by sequestering their mRNA (miR
respectively. UL16 selectively targets the NKG2D ligand
NKG2D ligands such as ULBP3, ULBP4 and ULBP5 can escape UL16 engagement. The NKG2D ligand
MICA, which can also escape UL16, is retained by yet another immunoevasin, UL142. The schematic
representations of the MIC and ULBP molecules were
was modified from Lanier, 200814.
I n t r o d u c t i o n
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of HCMV
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1.3.2.2 Molecular decoys of inhibitory NK cell receptor ligands
As outlined above, the downmodulation of surface MHC class I molecules will result in a
decreased engagement of NK cell inhibitory receptors and, as a consequence, to the activation of
NK cells. To avoid this, HCMV employs the immunoevasin UL18, a structural homolog of
classical MHC class I proteins that, like the majority of other structurally defined virulence factors
that are homologous to human proteins, was most likely acquired through hijacking of MHC class I
encoding host genes. As is typical for MHC class I molecules, UL18 also has the ability to bind
peptides and associate with β2m. In HCMV immune evasion UL18 is believed to serve as a 
molecular decoy for the inhibitory NK cell receptor ILT-2 (also known as LIR-1) that specifically
recognizes an epitope in the α3 domain of most MHC class I molecules (Figure 1-5)14. Thus, UL18
serves as a means to conceal the HCMV caused downregulation of MHC class I molecules from
NK cells. This function of UL18 as an ILT-2 decoy is supported by the crystal structure of the
UL18–β2m–ILT-2 complex and affinity measurements that place the affinty between UL16 and 
ILT-2 in the nanomolar range, which is significantly higher than observed for the interactions
between ILT-2 and its native ligands82, 83.
In addition to the monitoring of the MHC class I protein surface expression through direct
interactions of the MHC class I molecules with inhibitory NK cell receptors, another, more
indirect, monitoring strategy involves the non-classical MHC class I protein HLA-E, which has the
special ability to bind a set of peptides that are derived from signal sequences of MHC class I
molecules (Figure 1-5)39, 78. The formation of HLA-E–peptide complexes is a prerequisite for the
transport of HLA-E to and its expression on the cellular surface, where it suppresses the activation
of NK cells by engaging the inhibitory C-type lectin-like receptor CD94-NKG2A39, 78. The MHC
class I derived peptides will only be mounted onto HLA-E after their transport into the ER by TAP.
Unfortunately, upon infection of a cell with HCMV, the latter is blocked by US639. It follows that
the inability to mount HLA-E with peptides will result in a reduced surface presentation of HLA-E
leading to a decreased engagement of CD94-NKG2D and therefore the activation of NK cells79. To
avert such an NK cell response, HCMV encodes the immunoevasin UL40, which has a signal
peptide (VMAPRTLIL) that is identical to the signal peptides typical for classical HLA-C
proteins78, 79. Moreover, the UL40 peptide can be mounted onto HLA-E after its transport into the
ER in a TAP-independent fashion (Figure 1-5)78. In this manner, HCMV is able to maintain high
surface expression levels of HLA-E when MHC class I derived peptides are missing in the ER due
to US6 activity.
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1.3.2.3 Downmodulation of activating NK cell receptor ligands
Several diverse and independent immune evasive strategies employed by HCMV aim to avert an
NKG2D-mediated immunorecognition, which emphasizes the importance of this particular
surveillance system. As described above, the activating immunoreceptor NKG2D stimulates anti-
viral and anti-tumor effector responses of human cytotoxic lymphocytes such as NK cells when
engaged by one of its eight stress-inducible MHC class I-like ligands. One of the most well-known
and extensively studied strategies of HCMV to subvert NKG2D-mediated immune responses is
mediated by the HCMV glycoprotein UL16, which counteracts NKG2D-mediated antiviral
immune responses by intracellular retention of the distantly related NKG2D ligands MICB,
ULBP1, ULBP2 and ULBP6 (RAET1L) in the ER and Golgi network compartments (Figures 1-4
and 1-584-87. However, other NKG2D ligands such as the MICB-homolog MICA, the ULBP2-
homolog ULBP5 (RAET1G) and other ULBPs such as ULBP3 and ULBP4 are not targeted by
UL1665, 88-90. Currently, a common hypothesis addressing the remarkable redundancy of NKG2D
ligands proposes that NKG2D ligand diversification may be explained as a host response to the
selective pressure exerted by viral immunoevasins14, 19. The importance of the NKG2D-mediated
immunosurveillance of HCMV infections was further emphasized when other immunoevasins such
as UL142 and the microRNA (miRNA) of the UL112 gene (hcmv-miR-UL112) were discovered
(Figure 1-5)91, 92. UL142 retains full-length MICA alleles in the cis-Golgi apparatus and in this way
complements the function of UL16 to prevent the surface expression of NKG2D ligands91, 93.
Interestingly, UL142 is unable to downregulate MICA*008, a common MICA allele that is
characterized by a truncated transmembrane region and the absence of a cytoplasmic tail91, 93. This
result suggests that MICA*008 represents an evolutionarily selected MICA escape variant that can
bypass UL142 retention and therefore gives additional support to the hypothesis that the
diversification of NKG2D ligands has been driven by viral immunoevasins. MicroRNAs are small
noncoding RNAs that allow the host to posttranscriptionally regulate the expression of particular
genes92. In order to perform this function, specific miRNAs bind to their corresponding mRNAs
and in this way label them for degradation. Recent reports indicated that viruses can also express
miRNAs94-96. In this respect the HCMV encoded UL112 miRNA was shown to specifically target
MICB mRNAs during viral infection therefore leading to a decreased surface expression of MICB
and subsequently to a decreased engagement of NKG2D and activation of NK cells92.
Another activating NK cell receptor ligand that is targeted by HCMV is CD155. CD155,
also known as the poliovirus receptor (PVR), is a cellular surface protein involved in intercellular
interactions79. Under normal conditions these interactions prevent the exposure of CD155 to the
environment. It is assumed that these intercellular interactions are at least partially disrupted upon
viral infection, which entails the exposure of CD155 and therefore its accessibility by patrolling
NK cells79. These recognize CD155 via their activating receptors DNAM
(TACTILE) and in this way become activated
detection as it accumulates in the ER and hinders CD155 to reach the cellular surface
1-5)78.
1.3.2.4 The UL16 protein
UL16 was first described in 1992 as a
human fibroblasts97. UL16’s immunomodulatory function
years later in context with a new family of human NKG2D ligands, the ULBPs
transmembrane glycoprotein that was shown to be expressed by HCMV infected fibroblasts but to
be nonessential for HCMV replication
correspond to a molecular weight of 26.1 kDa and can be divide
1-6): a signal peptide (26 aa), a large luminal domain (164 aa) with eight potential N
sites that indicates heavy glycosylation, a transmembrane domain (17 aa) and a cytoplasmic tail (23
aa) with a YQRL motif that could explain why UL16 preferentially accumulates in the ER and
Golgi network84-86. Additional reports suggested that UL16 can also traffic through the plasma
membrane and the nuclear envelope
remained elusive as no structural homologs
sequence and because a crystal structure of UL16 or a UL16
determined.
Figure 1-6. UL16 full length sequence.
HCMV strain AD169 prior to signal peptide cleavage in the ER.
colors are the distinct regions of the UL16
orange, ER/Golgi-luminal domain
Cysteine residues are colored in pink.
reticulum.
I n t r o d u c t i o n
78, 79. The immunoevasin UL141 impedes this kind of
HCMV encoded protein that is dispensable for the
(see Section 1.3.2.3
97. The UL16 protein consist of 230 amino acids (aa) that
d into four distinct sections
98, 99. The structure of the UL16 luminal domain has so far
could be predicted from UL16’s
-NKG2D ligand complex has yet to be
Shown is the full length amino acid sequence
Indicated by the four different
protein (see also Figure 2-4A): ER signal peptide (SP)
– blue; transmembrane domain (TM) – yellow
Potential N-glycosylation sites are colored in yellow. ER,
P a g e | 17
-1 (CD226) and CD96
(Figure
growth of
) was reported nine
65. UL16 is a type 1
(Figure
-glycosylation
primary amino acid
of UL16 as encoded by
background
– bright
; cytoplasmic tail (Cyt).
Endoplasmic
I n t r o d u c t i o n
18 | P a g e
1.4 Aims
The primary objectives of this work were (i) to elucidate the molecular basis for the promiscuous
but highly selective binding of the HCMV immunoevasin UL16 to diverse NKG2D
immunoreceptor ligands, (ii) to obtain insights into the molecular adjustments of NKG2D ligands
that escape UL16 engagement, and (iii) to address the question whether selective pressure exerted
by UL16 may have contributed to the diversification of NKG2D ligands. In order to achieve these
goals, structural and functional analyses of the protein-protein interaction between UL16 and the
NKG2D ligand MICB were performed using X-ray crystallography and surface plasmon resonance
(SPR).
In detail, the experiments presented in this thesis were designed to answer the following questions:
 What is the three-dimensional structure of UL16? Why can the UL16 structure not be predicted
from its primary amino acid sequence? Is this because UL16 exhibits a new type of structural fold or
because there is too little amino acid sequence identity between UL16 and its structural homologs?
 What are the structural features allowing UL16 to (partially) recapitulate the
promiscuous engagement of highly diverse ligands by NKG2D? Do UL16 and NKG2D
(despite the lack of any sequence similarity between them) share certain structural elements to engage
similar epitopes on NKG2D ligands, or do they exhibit completely different binding modes?
 What are the binding parameters (kinetic rate constants and affinities) of the individual
UL16-NKG2D ligand interactions?
 What is the structural basis for the binding of UL16 to some diverse NKG2D ligands
(MICB, ULBP1, ULBP2) and for the inability to bind other NKG2D ligands (MICA,
ULBP3, RAET1G) that are highly related to some of the former ligands? How are the latter
ligands able to escape from UL16 binding without compromising NKG2D binding?
 Can structural data provide support for the hypothesis that the diversification of
NKG2D ligands resulted from selective pressure exerted by viral immunoevasins?
M a t e r i a l s a n d M e t h o d s
P a g e | 19
2. Materials and Methods
2.1 Materials
2.1.1 Hardware
2.1.1.1 General purpose equipment
Pipettes Pipetman (2 µl - 1 ml) Gilson, Middleton, USA
Ultrapure water Biocell Millipore, Schwabach, SUI
Autoclave VX-95 Systec, Wettenberg, GER
Scale 323S-OCE Sartorius, Göttingen, GER
Scale 4202S-OCE Sartorius, Göttingen, GER
Scale Genius Sartorius, Göttingen, GER
Centrifuge 5414 D Eppendorf, Wesseling-Bertzdorf, GER
Centrifuge Multifuge 1L-R Kendro, Langenselbold, GER
Icemaker AF 80 Scotsman, Milan, ITA
Microwave NN-E203 WB Panasonic, Hamburg, GER
pH meter PB-11 Sartorius, Göttingen, GER
Transilluminator Universal Hood II Bio-Rad, Munich, GER
Transsonic T 460 (ultrasonic water bath) Elma, Singen, GER
2.1.1.2 Molecular biology
Gel Doc XR imaging system Bio-Rad, Munich, GER
PCR iCycler Bio-Rad, Munich, GER
Photometer NanoDrop ND-1000 Thermo Scientific, Waltham, USA
Photometer SmartSpec Plus Bio-Rad, Munich, GER
Quartz cuvette (75 μl)  Helma, Jena, GER 
Mini Sub-Cell GT Bio-Rad, Munich, GER
2.1.1.3 X-ray crystallography
24 well crystallization plates Hampton research, Aliso Viejo, USA
22 mm siliconized cover slides Hampton research, Aliso Viejo, USA
96 well Intelli-Plates Art Robbins, Sunnyvale, USA
Sealing for 96 well plates HJ-Bioanalytik, Mönchengladbach, GER
Capillaries (Ø 0.3 and 0.5 mm) Hampton Research, Aliso Viejo, USA
Crystallization robot Freedom Evo 150 Tecan, Männedorf, SUI
Depression wells Hampton research, Aliso Viejo, USA
Fiber loops (0.1 - 0.7 mm) Hampton research, Aliso Viejo, USA
Magnetic bases for fiber loops Hampton research, Aliso Viejo, USA
Microscope MZ16 Leica, Wetzlar, GER
Microscope S6E Leica, Wetzlar, GER
Cryosystem X-Stream Rigaku/MSC, The Woodlands, USA
Detector Mar345dtb image plate Mar research, Hamburg, GER
Detector PILATUS at SLS Paul Scherrer Institute (PSI), Villigen, SUI
VariMax HF optics Rigaku/MSC, The Woodlands, USA
Rotating Anode Micromax-007 HF Rigaku/MSC, The Woodlands, USA
Vacuum grease Baysilone GE Bayer Silicones, Leverkusen, GER
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2.1.1.4 Surface Plasmon Resonance
Biacore 2000 GE Healthcare, Uppsala, SWE
2.1.1.5 Protein production: Eukaryotic
Hera Safe Clean bench ThermoFisher Sci., Waltham, USA
Hera Cell culture flask incubators ThermoFisher Sci., Waltham, USA
Hera Cell roller bottle incubators ThermoFisher Sci., Waltham, USA
Steritop Express Plus filter (0.22 µM) Millipore, Schwabach, SUI
Neubauer improved counting chamber Marienfeld, Lauda-Königshofen, GER
Beckmann Centrifuge J2-21 BeckmanCoulter GmbH, Krefeld, GER
Water bath SWB20 PD-Industriegesellsch. mbH, Dresden, GER
Microscope DM IL Leica, Wetzlar, GER
Mr. Frosty freezing container ThermoFisher Sci., Waltham, USA
2.1.1.6 Protein production: Procaryotic
High pressure homogenizer EmulsiFlex Avestin, Ottawa, CAN
Sonicator Digital Sonifier 250 Branson, Danbury, USA
Incubation Shaker Unitron InforsHT, Bottmingen-Basel, SWI
Shaker DOS-10L NeoLab, Heidelberg, GER
Shaker Intelli-Mixer NeoLab, Heidelberg, GER
Centrifuge Sorvall RC-6 Kendro, Langenselbold, GER
Sorvall rotor SS34 Kendro, Langenselbold, GER
Sorvall rotor SLC4000 Kendro, Langenselbold, GER
2.1.1.7 Chromatography
Analytical FPLC SMART GE Healthcare, Uppsala, SWE
Analytical FPLC Ettan GE Healthcare, Uppsala, SWE
Preparative FPLC Äkta prime plus GE Healthcare, Uppsala, SWE
Preparative FPLC BioLogic Duo Flow Bio-Rad, Munich, GER
Peristaltic EconoPump Bio-Rad, Munich, GER
HiTrap Protein A HP 5 ml affinity column GE Healthcare, Uppsala, SWE
HiTrap Benzamidine FF 1 ml affinity column GE Healthcare, Uppsala, SWE
HiTrap HisTrap HP 1 ml affinity column GE Healthcare, Uppsala, SWE
HiTrap Phenyl HP 5 ml affinity column GE Healthcare, Uppsala, SWE
Superdex 75 PC 3.2/30 column GE Healthcare, Uppsala, SWE
Superdex 200 PC 3.2/30 column GE Healthcare, Uppsala, SWE
Superdex 75 10/300 GL column GE Healthcare, Uppsala, SWE
2.1.1.8 Protein Analytics
Mini-PROTEAN 3 Cell Bio-Rad, Munich, GER
Mini-PROTEAN 3 Multi-Casting Chamber Bio-Rad, Munich, GER
PowerPac Basic Bio-Rad, Munich, GER
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2.1.2 Software
2.1.2.1 X-ray data processing and structural analysis
B-factor analysis CCP4 package100: Bavarage
Mar345dtb Marresearch GmbH, Hamburg, GER
Indexing, Integrating, Scaling XDS101
Model building Coot102
Molecular Replacement CCP4 package100: PHASER
Refinement PHENIX101
Structural figures Pymol103
Sugar modeling GlyProt104: www.glycosciences.de
TLS group assignment TLSMD: www.skuld.bmsc.washington.edu
TLS refinement PHENIX101
Matthews Probability Calculator www.ruppweb.org/Mattprob/
Structure validation WHAT_IF: www.swift.cmbi.ru.nl
CCP4 package100: PROCHECK
Comparison of 3D protein structures SSM: www.ebi.ac.uk
DALI: www.ekhidna.biocenter.helsinki.fi
Exploration of molecular interfaces PISA: www.ebi.ac.uk
2.1.2.2 Surface Plasmon Resonance
BIAsimulation 2.1 GE Healthcare, Uppsala, SWE
BIACORE 2000 control 3.2.1 GE Healthcare, Uppsala, SWE
BIAevaluation 4.1 GE Healthcare, Uppsala, SWE
2.1.2.3 Data analysis
Origin 8 Pro OriginLab, Northampton, USA
2.1.2.4 Chromatography
PrimeView GE Healthcare, Uppsala, SWE
2.1.2.5 Reference management
EndNote X2 Thomson Reuters, Philadelphia, USA
2.1.2.6 Online tools and databanks
Protein properties ProtParam: www.expasy.org
Protein profile search Blastp: www.ncbi.nlm.nih.gov/blast
SMART: www.smart.embl-heidelberg.de
3D protein structures PDB: www.pdb.org
N-glycosylation site prediction NetNGlyc 1.0 Server: www.cbs.dtu.dk
Literature search PubMed: www.ncbi.nlm.nih.gov
Codon usage optimization GCUA: www.gcua.schoedl.de
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Signal peptide prediction SignalIP: www.cbs.dtu.dk
Transmembrane region prediction TMHMM: www.cbs.dtu.dk
Align two sequences (protein) SIM-Prot: www.expasy.org
Blastp: www.ncbi.nlm.nih.gov
Align two sequences (nucleotide) Blastn: www.ncbi.nlm.nih.gov
Protease cleavage sites Peptide cutter: www.expasy.org
DNA to protein translation www.expasy.org/tools/dna.html
Primer design DNACalc: www.sigma-genosys.com
Restriction enzyme specificity NEB cutter: www.tools.neb.com
Invert / complement DNA sequences Manipulate DNA: www.vivo.colostate.edu
Protein to DNA translation Backtranslation tool: www.entelechon.com
Protease cleavage sites in proteins PeptideCutter: www.expasy.org
2.1.3 Consumables
2.1.3.1 Chemicals
Unless noted otherwise, all chemicals were analytical reagent (AR) grade. Additional chemicals and
solutions that were of importance to a specific application are listed in the corresponding sections.
Ammoniumperoxodisulphate (APS) Roth, Karlsruhe, GER
Ammonium sulphate Sigma Aldrich, Munich, GER
Arginine Roth, Karlsruhe, GER
Bromophenol blue Roth, Karlsruhe, GER
Disodium hydrogen phosphate (Na2HPO4) Sigma Aldrich, Munich, GER
EDTA, disodium salt Roth, Karlsruhe, GER
Ethanol, abs. J. T. Baker, Deventer, NET
Ethylene glycol Sigma Aldrich, Munich, GER
Glacial acetic acid Roth, Karlsruhe, GER
Glutathione, reduced Sigma Aldrich, Munich, GER
Glutathione, oxidized Sigma Aldrich, Munich, GER
Glycerol Roth, Karlsruhe, GER
Glycine Roth, Karlsruhe, GER
HEPES Roth, Karlsruhe, GER
Imidazole Sigma Aldrich, Munich, GER
L-Arginine Roth, Karlsruhe, GER
Methanol, p.a. Sigma Aldrich, Munich, GER
MgCl2 Sigma Aldrich, Munich, GER
Nickel chloride Roth, Karlsruhe, GER
Polyethylene glycols (various) Hampton research, Aliso Viejo, USA
Rotiphorese Gel 30 37.5:1 Roth, Karlsruhe, GER
SDS Roth, Karlsruhe, GER
Sodium cacodylate trihydrate Sigma Aldrich, Munich, GER
Sodium chloride (NaCl) Roth, Karlsruhe, GER
Sodium dihydrogen phosphate (NaH2PO4) Sigma Aldrich, Munich, GER
Sodium hydroxide Roth, Karlsruhe, GER
TEMED Roth, Karlsruhe, GER
TRIS base Sigma Aldrich, Munich, GER
Triton X-100 Sigma Aldrich, Munich, GER
Urea Roth, Karlsruhe, GER
β-mercaptoethanol (β-ME) Sigma Aldrich, Munich, GER 
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2.1.3.2 Eukaryotic cell culture
Geneticin (G-418) Invitrogen, Karlsruhe, GER
PSN antibiotic mixture (100x) Invitrogen, Karlsruhe, GER
Penicillin/Streptomycin (100x) Invitrogen, Karlsruhe, GER
Ultra-Low IgG FCS Invitrogen, Karlsruhe, GER
Opti-MEM-I Invitrogen, Karlsruhe, GER
Dulbecco’s PBS (without Ca2+/Mg2+) PAA, Cölbe, GER
Trypan blue stain (0,4 %) Invitrogen, Karlsruhe, GER
Lipofectamine 2000 Invitrogen, Karlsruhe, GER
Trypsin /EDTA (1x) 0,05 % in DPBS Invitrogen, Karlsruhe, GER
L-glutamine 200 mM (100x), liquid Invitrogen, Karlsruhe, GER
Sodium pyruvate 100 mM (100x), liquid Invitrogen, Karlsruhe, GER
CELLMASTER roller bottles Greiner, Frickenhausen, GER
CELLSTAR cell culture flasks Greiner, Frickenhausen, GER
α-MEM  Invitrogen, Karlsruhe, GER 
DMSO Sigma Aldrich, Munich, GER
CELLSTAR cell culture dishes Greiner, Frickenhausen, GER
Protein A/G UltraLink resin Thermo Scientific (Pierce), Waltham, USA
2.1.3.3 Prokaryotic (bacterial) cell culture
Isopropyl-β-D-thiogalactopyranoside (IPTG)  PeqLab, Erlangen, GER 
Agar-agar Roth, Karlsruhe, GER
Ampicillin, sodium salt Sigma, Munich, GER
Kanamycin sulphate Sigma Aldrich, Munich, GER
Chloramphenicol Sigma Aldrich, Munich, GER
LB medium, complete Sigma Aldrich, Munich, GER
Peptone Roth, Karlsruhe, GER
Yeast extract Roth, Karlsruhe, GER
Complete protease inhibitor tablets (EDTA) Roche, Mannheim, GER
2.1.3.4 Protein purification and analysis
Spin-X centrifuge tube filters (0.22 μm)  Corning, Corning, USA 
Microcon YM3 Millipore, Schwabach, GER
Amicon Ultra 4 and Ultra 15 Millipore, Schwabach, GER
Membrane filters (0.45 and 5 μm)  Millipore, Schwabach, GER 
Syringe top filters (0.22 μm)  VWR International, Vienna, AUT 
Steritop Express Plus filter (0.22 µM) Millipore, Schwabach, SUI
Acrylamide-Bisacrylamide Rotiphorese Gel 30 Roth, Karlsruhe, GER
Bradford Protein Assay Bio-Rad, Munich, GER
Coomassie Brilliant Blue R-250 Bio-Rad, Munich, GER
PageRuler unstained protein ladder Fermentas, St. Leon-Rot, GER
Rotiphorese SDS-PAGE buffer (10x) Roth, Karlsruhe, GER
Bradford reagent: Bio-Rad Protein Assay Bio-Rad, Munich, GER
Spectra/Por Dialysis Membrane 6 - 8 kDa MWCO Spectrum, DG Breda, NED
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2.1.3.5 Molecular biology
StarPure Agarose, research grade StarLab, Ahrensburg, GER
6x loading dye for agarose gels Fermentas, St. Leon-Rot, GER
QIAquick PCR Purification Kit Qiagen, Hilden, GER
QIAquick Gel Extraction Kit Qiagen, Hilden, GER
dNTPs Promega, Mannheim, GER
Minipreps Wizard Plus SV Promega, Mannheim, GER
O’GeneRuler 1 kb DNA Ladder Fermentas, St. Leon-Rot, GER
O’GeneRuler 100bp DNA Ladder Fermentas, St. Leon-Rot, GER
6x Orange Loading Dye solution Fermentas, St. Leon-Rot, GER
10x Pfu Ultra HF reaction buffer Stratagene, La Jolla, USA
Buffers for restriction enzymes from NEB NEB, Frankfurt/Main, GER
BSA solution for restriction enzymes from NEB NEB, Frankfurt/Main, GER
Quick Ligation Kit NEB, Frankfurt/Main, GER
Rapid DNA Ligation Kit Fermentas, St. Leon-Rot, GER
Plasmid Maxi Kit Qiagen, Hilden, GER
2.1.3.6 Crystallization Screens (commercial)
Crystal Screens 1, 2 and light Hampton research, Aliso Viejo, USA
Grid Screen Ammonium Sulfate Hampton research, Aliso Viejo, USA
Wizard I and II Emerald BioSystems, Bainb. Island, USA
PEG/Ion 1 Hampton research, Aliso Viejo, USA
2.1.3.7 Surface Plasmon Resonance
Sensor Chip CM5 (research grade) GE Healthcare, Uppsala, SWE
Surfactant P20 GE Healthcare, Uppsala, SWE
Protein A/G (soluble) BioVision, Mountain View, USA
Amine Coupling Kit GE Healthcare, Uppsala, SWE
Biacore Maintenance Kit GE Healthcare, Uppsala, SWE
EDTA 0.5 M Sigma Aldrich, Munich, GER
2.1.3.8 Enzymes
DNAse I (10 mg/ml) Roche, Mannheim, GER
EndoH (500 ,000 U/µl) NEB, Frankfurt/Main, GER
PfuUltra HF DNA polymerase (2.5 U/µl) Stratagene, La Jolla, USA
Taq LC polymerase (1U/µl) Fermentas, St. Leon-Rot, GER
T4 DNA ligase (1 U/µl) Fermentas, St. Leon-Rot, GER
Thrombin (1U/µl) GE Healthcare, Uppsala, SUI
PreScission protease GE Healthcare, Uppsala, SUI
Restriction enzymes XhoI and NdeI (Table 2-1) NEB, Frankfurt/Main, GER
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Table 2-1. Restriction enzymes
Name Recognition sequence Digestion type BSA Heat inactivation NEBbuffer
Nde I Sticky ends No 65 °C; 20 min 4
Xho I Sticky ends Yes 65 °C; 20 min 21)
1) In case of a double digestion together with NdeI NEB buffer 4 was used as recommended by NEB.
2.1.3.9 Proteins
ULBP1/Fc chimera (50 µg) R&D Systems, Minneapolis, USA
ULBP2/Fc chimera (50 µg) R&D Systems, Minneapolis, USA
ULBP4/Fc chimera provided by Dr. M. Wittenbrink
(Working group of Prof. Dr. A. Steinle)
ULBP5/Fc chimera provided by Dr. M. Wittenbrink
(Working group of Prof. Dr. A. Steinle)
2.1.4 Plasmids and primers
2.1.4.1 Plasmids (eukaryotic expression)
pcDNA3.1(-) Invitrogen, Karlsruhe, GER
Features:
 Human cytomegalovirus (CMV) promoter permits efficient, high-level expression of
recombinant proteins in eukaryotic cells through high level transcription by RNA
polymerase II
 SV40 origin allows episomal replication of plasmid in eukaryotic cells expressing the SV40
large T antigen (e. g. HEK293T cells)
 Neomycin resistance gene allows for selection of the vector in eukaryotic cells with
geneticin (G418)
 pUC origin allows for high-copy number of plasmid in E.coli
 Ampicillin resistance gene allows for selection of the vector in E.coli with ampicillin
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2.1.4.2 Plasmids (prokaryotic expression)
pET-21a(+) Merck (Novagen), Darmstadt, GER
Features:
 T7 promoter permits efficient, high-level expression of recombinant proteins in E.coli
through high level transcription by the T7 RNA polymerase
 Ampicillin resistance gene allows for selection of the vector in E.coli with Ampicillin.
 C-terminal hexahistidine (His6-tag) for affinity purification of the recombinant protein with
Ni-NTA columns
2.1.4.3 Primers
All primers (Table 2-2 and Table 2-3) were purchased from biomers.net (Ulm, GER).
Table 2-2. Cloning primers
Source DNA Sequence (5’→ 3’) Tm [°C]
MICBα1-α3 in
pET-21a(+)
Forward TCAGCGTACATATGGAGCCCCACAGTCTTCGTTA 71
Reverse-11) CAGAAGAACCACGCGGCACCAGACCACCTGTTCTCCTGATGGCCACCCCGGATTTC 90
Reverse-21) TCATTCTACTCGAGTCAATGATGATGATGATGATGATGATGGCCAGAAGAACCACGCGGCACCAGACCA 89
1) Reverse overhanging primers were used to introduce a thrombin cleavage site and an His8-tag
Table 2-3. Sequencing primers
Plasmid Sequence (5’→ 3’) Tm [°C]
pcDNA3.1(-)
Forward TAATACGACTCACTATAGGG 39
Reverse TAGAAGGCACAGTCGAGG 45
pET-21a(+)
Forward TAATACGACTCACTATAGG 34
Reverse GCTAGTTATTGCTCAGCGG 48
2.1.5 Growth media, buffers and solutions
If not stated otherwise, buffer solutions were adjusted to the desired pH at 4 °C since the pH values
of many of the commonly used buffer solutions (e. g. Tris or HEPES buffers) are significantly
temperature dependent. Furthermore, buffers were passed through a 0.45 µm filter and degassed
(using either an ultrasonic water bath or a water driven vacuum pump) before usage in FPLC
applications.
2.1.5.1 Cultivation of bacterial cells
Table 2-4. LB medium
Composition Preparation (pro l ddH2O)
LB medium, complete 25g
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Table 2-5. LB agar plates
Composition Preparation (pro l ddH2O)
LB medium, complete see Table 2-4
Agar-agar 15g
Table 2-6. SOB medium
Composition Preparation (1 l)
LB medium, complete see Table 2-4
KCl 10 mM
MgSO4 20 mM
2.1.5.2 Cultivation of eukaryotic cells
Table 2-7. CHO Lec 3.2.8.1 cell media
Composition Selection mediumConcentration
Non-selection medium
Concentrations
Medium: α-MEM  - -
Penicillin G
Streptomycin
100 U/ml
100 µg/ml
100 U/ml
100 µg/ml
L-glutamine 2 mM 2 mM
Sodium pyruvate 1 mM 1 mM
Ultra-Low IgG FCS 7.5 % 10 %
Geneticin (G418) 1.5 mg/ml1)
1) To determine the concentration of G418 a kill curve was generated (see Section 2.2.2.5)
Table 2-8. CV-1 cell media
Composition Concentrations
Medium: DMEM -
Penicillin G
Streptomycin
100 U/ml
100 µg/ml
L-glutamine 2 mM
Sodium pyruvate 1 mM
Ultra-Low IgG FCS 7.5 %
Geneticin (G418) 2.0 mg/ml
Table 2-9. Cryo solution
Composition Concentrations
Ultra-low IgG FCS 90 % (v/v)
DMSO 10 % (v/v)
2.1.5.3 Protein expression, refolding and purification
Table 2-10. TBS buffer
Composition Concentrations
Tris base1) at 4 °C 20 mM
NaCl 130 mM
KCl 2 mM
1) The pH is indicated in the respective Sections
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Table 2-11. Lysis buffer
Composition Concentrations
Tris base pH 8 at 4 °C 20 mM
NaCl 130 mM
KCl 2 mM
DNAseI grade II 10 µg/ml
MgCl2 10 mM
PMSF 0.1 mM
Glycerol 5 %
Complete Protease Inhibitor tablet (EDTA free) 1 x
Table 2-12. Triton X-100 and Triton-free wash buffers
Composition Triton X-100 wash bufferConcentrations
Triton X-100 free wash buffer
Concentrations
Tris base pH 8 at 4 °C 50 mM 50 mM
NaCl 50 mM 50 mM
Triton X-100 0.5 % (w/v) -
Table 2-13. Urea buffer
Composition Concentrations
Tris base pH 8 at 4 °C 100 mM
Glycine 50 mM
Urea 8 M
Table 2-14. Refolding buffer
Composition Concentrations Dialysis step
Tris base pH 8 at 4 °C 100 mM -
L-Arginine  0.4→0.1 M Step 4
PMSF 0.1 mM (1x) -
EDTA 1 mM -
Urea  4→2→1→0 M Step 1-3
Table 2-15. IMAC (Ni-NTA) chromatography buffers
Composition Ni-NTA binding bufferConcentrations
Ni-NTA elution buffer
Concentrations
NaH2PO4 pH 7.4 at 4 °C 20 mM 20 mM
NaCl 0.5 M 0.5 M
Imidazole 30 mM 500 mM
Table 2-16. Protein A chromatography buffers
Composition Protein A binding bufferConcentration
Protein A elution solution
Concentration
Glycine pH 9 173 mM -
Arginine pH 4.11) - 0.5 M
NaCl 0.5 M 10 mM
1) adjust pH carefully as no buffer is present
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Table 2-17. HEPES reservoir buffer
Composition Concentration
HEPES pH 9 0.5 M
Table 2-18. HIC chromatography buffers
Composition HIC binding bufferConcentration
HIC elution buffer
Concentration
Na2HPO4 pH 7.4 50 mM 50 mM
NaCl 1 M -
2.1.5.4 Native protein deglycosylation
Table 2-19. Endo H buffer
Composition Concentration
NaAc pH 5.2 at 25 °C 0.1 M
2.1.5.5 SDS-PAGE
Table 2-20. Transformation buffer solutions
Composition ConcentrationsTfb I
Concentrations
Tfb II
RbCl 100 mM 10 mM
CaCl2 20 mM 75 mM
MnCl2 50 mM -
KAc 30 mM -
Glycerol 15 mM 15 mM
MOPS - 10 mM
pH 5.8 at RT with KOH 6.8 at RT with KOH
Table 2-21. SDS sample buffer compositions
Composition Reducing SDS sample bufferVolume
Non-reducing SDS sample buffer
Volume
SDS 10 % 1.6 ml 1.6 ml
Glycerol 2.8 ml 2.8 ml
Tris 1.5 M pH 6.8 0.5 ml 0.5 ml
β-mercaptoethanol, β-ME 0.4 ml -
ddH2O 2.5 ml 2.9 ml
Bromophenol blue Add spatula tip Add spatula tip
Total volume 7.8 ml 7.8 ml
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Table 2-22. SDS gel compositions
Composition 4 % stacking gel (4 gels) 15 % separation gel (4 gels)
ddH2O 6.1 ml 3.5 ml
Tris 1.5 M pH 6.8 2.5 ml -
Tris 1.5 M pH 8.8 - 3.7 ml
SDS 10 % (w/v) 100 µl 100 µl
Acrylamide-bisacrylamide 1.3 ml 7.5 ml
TEMED 10 µl 7.5 µl
APS 10 % (w/v) 100 µl 150 µl
Total volume ~10.1 ml ~15.0 ml
Table 2-23. Coomassie staining and destaining solutions
Composition StainingVolume / Mass
Destaining
Volume
Coomassie brilliant blue 0.5 g -
Methanol 250 ml 25 ml
Glacial acetic acid 30 ml 37 ml
ddH2O 220 ml 438 ml
Total volume 500 ml 500 ml
2.1.5.6 Agarose gel electrophoresis
Table 2-24. TAE buffer
Composition Concentration
Tris base1) 2 M
EDTA pH = 8 50 mM
Glacial acetic acid 57 % (w/v)
1) The pH of this buffer is not adjusted and should be close to 8.5
2.1.5.7 Surface Plasmon Resonance
Table 2-25. HBS-EP buffer
Composition Concentrations
HEPES pH 7.4 at 25 °C 10 mM
NaCl 150 mM
EDTA 3 mM
P20 0.005 % (v/v)
2.1.5.8 Crystallization
Table 2-26. Mother liquor of crystallization condition
Composition Final concentrations
Sodium cacodylate trihydrate, pH 6.5 10 mM
Ammonium sulphate 20 mM
PEG8000 25 % (v/v)
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2.1.6 Bacterial strains and eukaryotic cell lines
2.1.6.1 Bacterial strains
For a detailed description of the features of the used E.coli strains please refer to the Novagen
Competent Cells brochure.
Rosetta 2 (DE3) Merck (Novagen), Darmstadt, GER
Features:
The E.coli Rosetta 2(DE3) cells are IPTG inducible and supply seven rare tRNAs on two separate
plasmids with chloramphenicol (Cam) resistance. The rare tRNAs will allow for the efficient
translation of mRNAs containing eukaryotic codons rarely used in E.coli.
NovaBlue Merck (Novagen), Darmstadt, GER
Features:
The E.coli NovaBlue cells are used for cloning purposes and are characterized by a high
transformation efficiency and a tetracycline (Tet) resistance.
2.1.6.2 Eukaryotic cell lines
CHO Lec 3.2.8.1 cells Personal stock of Prof. Dr. T. Stehle
A number of distinct CHO Lec cell lines were developed by Pamela Stanley in 1989105. Each cell
line is deficient in a number of Golgi glycosyltransferases and/or Golgi nucleotide-sugar
transporters and therefore produces a specific glycoprotein phenotype. The phenotypic composition
of each cell line was determined by testing the cells ability to bind individual members from a set
of defined lectins (Lec). The CHO Lec 3.2.8.1 cell line, which exhibits four individual Lec
phenotypes, has been shown to be useful for X-ray crystallographic applications106. Its inability to
produce hybrid and complex glycans usually leads to a significantly reduced and much more
homogeneous glycan moiety of a glycoprotein, which in turn can facilitate the glycoprotein’s
crystallization. For more details see Section 3.2.3.
CV-1 cells stably transfected with UL16-Fc Personal stock of Prof. Dr. A. Steinle
The CV-1 cells, stably transfected with the UL16-Fc construct (described in Section 2.2.3.5.1),
were provided by Dr. Jessica Spreu. At the beginning of the UL16-MICB project Dr. Jessica Spreu
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also provided purified UL16-Fc protein that had been produced in CV-1 cells in the laboratory of
Prof. Dr. Alexander Steinle. During the later stages of the project the author used the UL16-Fc
expressing CV-1 cells (provided by Dr. Jessica Spreu, see above) for the production of UL16-Fc in
the laboratory of Prof. Dr. Thilo Stehle.
2.2 Methods
2.2.1 Methods in molecular biology
2.2.1.1 Competent cells
Bacterial cells that are harvested during their logarithmic growth phase and that up to that point
have grown in media supplemented with monovalent and divalent cations (e. g. Ca2+, Mn2+ and
Rb+), have the ability to take up foreign DNA in a process called transformation.
Protocol: A volume of 100 ml SOB medium was inoculated with 1 ml of bacterial o/n (overnight)
culture and grown up to an OD600 of 0.4 - 0.6. Bacteria were cooled on ice for 10 min and harvested
by a 10 min centrifugation step at 1,700x g at 4 °C. The supernatant was discarded and the bacterial
pellet resuspended in 20 ml ice-cold TfbI (Table 2-20). After an incubation time of 10 min the
bacteria were again harvested by a 10 min centrifugation step at 1700x g at 4 °C, followed by their
resuspension in 4 ml ice-cold TfbII (Table 2-20). Finally 100 µl aliquots of this bacterial
suspension were frozen at -80 °C and used for transformation processes (see Section 2.2.1.9).
Note: E.coli strains that carry no antibiotic resistance genes whatsoever (e. g. NovaBlue) have to be
treated under sterile conditions (i. e. by using a clean bench with laminar flow capabilities) to avoid
contamination with other bacteria. However, some E.coli strains as for example Rosetta 2(DE3)
cells feature special characteristics such as the ability to produce rare tRNAs and to express the T7
lysozyme for a more controlled expression of proteins. These features are based on additional
plasmids that usually carry additional resistance genes. These plasmids should be selected for at all
times and allow for a convenient way to avoid contamination during the preparation of competent
cells.
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2.2.1.2 Polymerase chain reaction (PCR)
The polymerase chain reaction (PCR) allows for the exponential amplification of a DNA sequence
in vitro. It is based on a simple three step cycle, which is usually repeated 30-40 times in a so-
called thermocycler: (Step 1) During ‘denaturation’ the temperature of the DNA containing PCR
solution is increased to 95 °C, which leads to the efficient thermal denaturation of the DNA double
helix and therefore eventually results in two single DNA strands. The PCR solution also contains
two short synthetic oligonucleotides (primers). One of the two primers is hereby complementary to
the sense DNA strand while the other is complementary to the antisense DNA strand and both
primer together flank the region of the DNA that is supposed to be amplified. (Step 2) During
‘annealing’ the temperature is lowered to 50 - 70 °C so that both synthetic primers can specifically
anneal to their corresponding single DNA template strand. (Step 3) Finally, during ‘elongation’ the
temperature is increased again to 72 °C, which allows a thermostable DNA polymerase to create
the complementary DNA strand of each of the two single template DNA strands by efficiently
elongating each of the two primers in 5’→ 3’ direction. 
The DNA polymerase classically used in PCR reactions is Taq from Thermus aquaticus
(processivity: 2800 n/min). However, a clear disadvantage of Taq is its missing 3’→5’ 
proofreading activity, which makes the elongation of the newly synthesized DNA strand more error
prone. This is the reason why Taq is nowadays used less frequently in standard cloning procedures.
Instead, Pfu from Pyrococcus furiosus (processivity: 4500 n/min), which features a 3’→ 5’ 
proofreading activity, is used for these applications.
Protocol: PCR samples were prepared according to the pipetting scheme shown in Table 2-27 and
then transferred to a thermocycler. The subsequent standard PCR program is described in Table
2-28.
Table 2-27. PCR pipetting scheme
Components Stock concentration Final concentration Volume per PCR vial [µl]
DNA (plasmid) 100 ng/µl 100 ng 1
Primer 1 100 µM2) 2 µM 1
Primer 2 100 µM2) 2 µM 1
dNTPs1) 10 mM 200 µM 1
Pfu Ultra HF buffer 10 x 1 x 5
Pfu Ultra HF 2.5 u/µl 2.5 u 1
ddH2O - - 40
Total volume 50
1) total concentration: 10 µM dNTP corresponds to 2.5 µM of each of the four deoxynucleotides
2) 100 µM primer equals 100 pmol/µl
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Table 2-28. Standard PCR program
Temp. [°C] Time [s] Step Number of cycles
95 60 Initial denaturation 1
95 30 Denaturation (Step 1)
3550-70 30 Annealing (Step 2)
72 60 Elongation (Step 3)
72 600 Final elongation 1
4 ∞ Storage 1
2.2.1.3 Purification of PCR fragments
After a PCR, the solution not only contains the desired PCR product but also the DNA polymerase
as well the deoxynucleotides and primers that are usually not used up during a PCR reaction. These
contaminants can later on interfere with the restriction digestion of the PCR product and therefore
have to be removed beforehand.
Protocol: The PCR product was purified and the contaminants were removed by using the
QIAquick PCR Purification Kit and by following the manufacturer’s instructions. After the
procedure, the PCR product was eluted from the silica columns in 30 µl of ddH2O.
Note: This protocol is not suitable if unspecific PCR fragments are produced during the PCR
reaction. In this case it is advisable to perform an agarose gel electrophoresis followed by the gel
extraction of the desired PCR product (see Sections 2.2.1.4 and 2.2.1.5).
2.2.1.4 Agarose gel electrophoresis
Agarose gel electrophoresis is a standard method for the separation and purification of DNA
molecules such as plasmids or PCR products. The separation itself is hereby mainly dependent on
three factors: (i) the molecular weight of the DNA, (ii) the conformation of the DNA (plasmids run
faster in the following order and from left to right: relaxed/nicked, linear, supercoiled), and (iii) the
density of the agarose gel, which is again dependent on the agarose amount used for casting the gel.
To visualize the DNA in the agarose gel matrix after electrophoresis, the gel is stained with
ethidiumbromide, a substance that intercalates between two stacked base pairs and shows a strong
fluorescence when excited with electromagnetic radiation between 254 and 366 nm (UV light). A
valuable asset in agarose gel electrophoresis is a DNA marker. These markers are comprised of
DNA fragments of defined lengths that are also separated during electrophoresis and allow for a
very exact determination of the molecular weight of DNA fragments.
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Protocol: 0.4 - 1 g StarPure Agarose were dissolved in 50 ml TAE buffer (Table 2-24) to prepare
0.8 - 2 % (w/v) agarose gels. The agarose TAE suspension was repeatedly heated in a microwave
until all agarose was completely dissolved. The clear agarose solution was then cast into an agarose
gel casket for cooling and polymerization. After the solution had reached at temperature of about
50 °C during this process, 1µl of ethidiumbromide solution [0.5 µg/ml] was added. When the
agarose had completely polymerized, the gel was submerged into an electrophoresis chamber filled
with TAE buffer (Table 2-24). DNA samples were diluted in sample buffer (6x Orange Loading
Dye Solution) and loaded into separate gel pockets. In addition, 7 µl of marker (either O’GeneRuler
1 kb DNA Ladder or O’GeneRuler 100 bp DNA Ladder) were loaded into a separate gel pocket.
The electrophoresis was carried out at 90 V for 60 - 70 min and then analyzed under UV light.
2.2.1.5 Agarose gel extraction
During an agarose gel electrophoresis, DNA molecules are not only separated according to their
molecular weights but are also purified from other contaminants such as nucleotides and primers.
Each DNA band on an agarose gel therefore corresponds to a purified DNA species. These purified
DNA species (e. g. plasmids cut by restriction enzymes or PCR products) are valuable as they will
facilitate the subsequent cloning steps such as the restriction digestions of the PCR product or the
ligation of this product into the cut vector. The extraction of the purified DNA species from the
agarose gel is usually performed by using an agarose gel extraction kit.
Protocol: The DNA species were extracted from agarose gels by using the QIAquick Gel
Extraction Kit and by following the manufacturer’s instructions. The DNA was eluted from the kit-
supplied silica columns with 30 µl of ddH2O.
2.2.1.6 Restriction digestion of plasmids and PCR products
Restriction enzymes (see Section 2.1.3.8) are bacterial type II endonucleases that recognize
palindromic sequences in a DNA double helix such as a PCR product or plasmid. In the latter case,
diverse recognition sequences for a number of different restriction enzymes usually cluster in a
region that is called the multiple cloning site (MCS). Restriction enzymes cleave the DNA
backbone by hydrolyzing the phosphodiester bonds between the 3’-OH group of an upstream
nucleotide and the 5’-phosphate group of an adjacent downstream nucleotide. Depending on the
exact cut locations in both strands, a specific restriction enzyme can give rise to the formation of
either sticky ends or blunt ends. DNA fragments with sticky ends feature unpaired nucleotides at
their ends, while DNA fragments with blunt ends do not.
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Protocol: Restriction digestion samples containing either plasmid or PCR product were prepared
according to the pipetting scheme shown in Table 2-29. The samples were incubated at 37 °C for
1 - 24 h, followed by heat inactivation of the restriction enzymes according to the manufacturer’s
instructions. The final DNA purification was either performed using a QIAquick PCR Purification
Kit (see Section 2.2.1.3) or by agarose gel electrophoresis (see Section 2.2.1.4).
Table 2-29. Pipetting scheme for restriction digestions
Components Stock solution
Composition
Plasmid
digest
Composition
PCR product
digest
Volume [µl]
Plasmid variable 2 µg - x
PCR product variable - 1 µg y
Restriction enzyme buffer 10 x 1 x 1 x 2
Restriction enzyme 1 20 u/µl 20 u 20 u 1
Restriction enzyme 2 20 u/µl 20 u 20 u 1
BSA1) 10 x 1 x 1 x 2
ddH2O - - - 20 - 6 - x or y
Total volume - - - 20
1) before use, the supplied 100x BSA solution was diluted 10 fold.
2.2.1.7 Ligation
Prior to ligation, a preliminary circular plasmid is formed by filling the gap of a restriction enzyme
(see Sections 2.1.3.8 and 2.2.1.6) digested plasmid with a PCR product that was treated with the
same set of restriction enzymes. However, to create an intact plasmid it is not enough to simply
close the plasmid gap with the PCR product. In addition also the DNA backbone breaks at the
contact areas between PCR product and plasmid have to be covalently sealed in a process called
ligation. The ligation process itself is mediated by an enzyme that is generally referred to as DNA
ligase (most often the T4 ligase; see Section 2.1.3.8), which catalyzes an energy (ATP) consuming
and Mg2+ dependent reaction that creates a covalent phosphodiester bond between the 3’-OH group
of an upstream nucleotide and the 5’-phosphate group of an adjacent downstream nucleotide.
Protocol: Ligation samples were prepared according to the pipetting scheme shown in Table 2-30
and
Equation 2-1, followed by an o/n incubation at 16 °C. The DNA ligase was heat inactivated at 65
°C for 10 min prior to transformation. Alternatively, plasmid and PCR product were ligated using
either a Quick Ligation Kit or Rapid DNA Ligation Kit and by following the manufacturer’s
instructions.
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Table 2-30. Ligation pipetting scheme
Components Stock solution Final solution Volume [µl]
Plasmid variable Equation 2-1 x
PCR product variable Equation 2-1 y
Ligase buffer 10 x 1 x 2
T4 ligase 1 u/µl 2 u 2
ATP 50 mM 5 mM 2
ddH2O - - 20-6-x-y
Total volume - - 20
݊݃(݅݊ ݁ݏ ݎݐ) = 3 ∙ ݊݃ (݌݈ ܽ݉ݏ ݅݀ ) ∙ ݌ܾ (݅݊ ݁ݏ ݎݐ)
݌ܾ(݌݈ ܽ݉ݏ ݅݀ ) Equation 2-1
2.2.1.8 Agar plates
Agar plates are used for the growth and selection of bacteria after their transformation with a
recombinant plasmid.
Protocol: 25 g of ready-to-use Luria Broth media (Table 2-4) was supplemented with 15 g agar-
agar and dissolved in 1 l ddH2O. The solution was autoclaved and then left to cool down to about
40 °C before antibiotics were added. Then, a lab bench was wiped with 70 % (v/v) ethanol and the
neck of the bottle that contained the antibiotic supplemented LB media flamed with a Bunsen
burner. The antibiotic supplemented LB media was subsequently poured into Petri dishes and the
plates were left at room temperature for several hrs until the agar had polymerized. Finally, agar
plates were stored at 4 °C for up to two months.
2.2.1.9 Transformation
Transformation is the process by which E.coli cells take up foreign circular DNA (plasmids).
Protocol: 100 µl competent E.coli cells were thawed on ice and supplemented with 5 - 10 µl of a
ligation mixture. After incubation on ice for 30 min the bacterial suspension was subjected to a
heat-shock at 42 °C for 1 min, followed by an additional incubation on ice for 2 min. After
incubation, LB medium without antibiotics (preheated at 37 °C) was added to the suspension and
the solution incubated at 37 °C for 1 h. Bacteria were then harvested by centrifugation at 800x g for
2 min, and the supernatant (except for 50 µl) discarded. The bacteria were then resuspended in the
remaining LB media and plated on agar plates supplemented with the appropriate antibiotics and
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then incubated o/n at 37 °C. After 16 hrs, agar plates were evaluated and grown bacterial colonies
used for a colony-PCR to test for the presence of the insert.
2.2.1.10 Colony PCR
A colony PCR is based on the same principle as a normal PCR. It is a very useful technique to test
high numbers of bacterial colonies in a short time for the presence of the desired DNA insert after
transformation. An alternative, but more laborious and time consuming, technique is that of a
restriction enzyme test digestion after which the ligated insert is cut out of the plasmid and
visualized on an agarose gel.
Protocol: Each bacterial colony was clearly labeled by marking the bottom of the Petri dish
directly below the colony with a felt tip pen. The same number was then used to label the
corresponding PCR tube. Each PCR tube was filled with 50 µl of the PCR master mix (Table 2-31)
and then inoculated with a tiny amount of the bacterial colony, obtained by scratching off a bit of
the colony by using a sterile pipet tip. The PCR-tubes were transferred to the PCR iCycler and the
colony PCR program (Table 2-32) started. Finally, in order to determine the presence of the insert
for each colony, the PCR products were analyzed by agarose gel electrophoresis.
Table 2-31. Colony PCR master mix
Components Stock concentration Concentrations Volume per PCR vial [µl]
Bacteria from colony - - Pipet tip
Primer 11) 100 µM 2 µM 1
Primer 21) 100 µM 2 µM 1
dNTPs2) 10 mM 200 µM 1
MgCl2 25 mM 1.5 mM 3
Taq LC buffer 10 x 1 x 5
Taq LC polymerase 2.5 u/µl 2.5 u 1
ddH2O - - 38
Total volume - - 50
1)100µM primer equals 100 pmol/µl
2) total concentration: 10 µM dNTP corresponds to 2.5 µM of each of the four deoxynucleotides
Table 2-32. Colony PCR program
Temp. [°C] Time [s] Step Number of cycles
95 480 Initial denaturation 1
95 30 Denaturation (Step 1)
3050-70 30 Annealing (Step 2)
72 60 Elongation (Step 3)
72 600 Final elongation 1
4 ∞ Storage 1
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2.2.1.11 Bacterial overnight cultures
Bacterial o/n cultures have the sole purpose of growing bacteria (i) to prepare glycerol stocks for
long term storage, (ii) to extract their plasmids for subsequent cloning procedures, or (iii) to
inoculate larger amounts of LB media (e. g. for protein expression).
Protocol: 10 ml of LB media supplemented with the necessary antibiotics were inoculated with a
single bacterial colony picked from an agar plate, or with a sample of bacteria from stocks that
were stored at -80 °C.
2.2.1.12 Glycerol stocks of E.coli cells
Glycerol is a very potent cryoprotectant and is therefore widely used to protect (bacterial) cells
from being damaged during the freezing and thawing procedures that are necessary for their long
term storage.
Protocol: 750 µl of a bacterial o/n culture were mixed with 250 µl of sterile glycerol and frozen at
-80 °C.
2.2.1.13 Isolation of plasmid DNA from E.coli
The isolation of plasmid DNA from E.coli is based on the alkaline lysis of the bacterial cells and
the subsequent purification of the plasmids using small spin columns filled with a silica matrix.
Protocol: Plasmid isolation was performed using a Miniprep Wizard Plus SV Kit and by following
the manufacturer’s instructions. The DNA was eluted from the spin column with 30 µl of ddH2O.
For larger plasmid preparations a Plasmid Maxi Kit was used. In the latter case the DNA pellet was
dissolved in 1 ml of ddH2O. Although plasmids are fairly stable in water, a higher stability can be
achieved by eluting the DNA in 10 mM Tris pH 8.5. DNA sequencing of recombinant plasmids
was performed by MWG (Ebersberg, Germany), while the author of this thesis provided the
recombinant plasmids as well as the appropriate sequencing primers (Table 2-3).
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2.2.1.14 Photometric determination of DNA concentration and purity
Based on the aromatic ring systems of purine and pyrimidine bases, nucleic acids show an
absorbance maximum at 260 nm. Due to an effect called hyperchromicity ss DNA absorbs more
strongly than ds DNA (Table 2-33).
Table 2-33. Absorbance of ds and ss DNA
ds DNA [µg/ml] ss DNA [µg/ml]
OD260 of 1 equals 40 33
While DNA absorbs strongest at 260 nm, proteins do so at 280 nm. By measuring the absorbance
ratio of a DNA sample at these two wavelengths one can estimate the purity of the DNA sample. A
260/280 nm ratio of 1.8 indicates the presence of pure ds DNA (i. e. plasmid), while a ratio below
1.8 can indicate a contamination with protein.
Protocol: DNA stock solutions were diluted in ddH2O and absorbance values of the solution
measured at 260 and 280 nm with a 75 µl quartz cuvette and a spectrophotometer in order to
calculate the DNA concentration and to estimate the DNA purity. Alternatively, the absorbance of
DNA samples at 260 nm and 280 nm was measured with a Nanodrop ND-1000 photometer.
2.2.2 Methods in cell biology
2.2.2.1 Cultivation of eukaryotic cells
Cells were grown at 37 °C and 5 % CO2 in a water-vapor-saturated atmosphere. Cell growth was
monitored every second day using a light microscope. Untransfected CHO Lec 3.2.8.1 cells105 (see
Section 2.1.6.2) were grown in CHO Lec culture medium (Table 2-7). CHO Lec 3.2.8.1 cells are
adherent cells and were passaged when the culture had reached a confluency of about 90 %. The
medium was removed and the cells washed with 37 °C preheated 1x PBS (without Ca2+/Mg2+).
Cells were then overlayed with a thin layer of 37 °C preheated 1x trypsin/EDTA solution and
incubated for 3 - 5 minutes, during which the cells detached from the culture flask bottom. The
trypsin/EDTA cell suspension was transferred to a conical centrifugation tube (50 ml Falcon type),
quickly centrifuged at 300x g for 3 min and the trypsin/EDTA supernatant decanted. The pelleted
cells were resuspended and diluted 3 - 10 fold in 37 °C preheated CHO Lec culture medium (Table
2-7), followed by their transfer into new cell culture flasks. After stable transfection with the
pcDNA3.1(-) plasmid (see Section 2.1.4.1), CHO Lec 3.2.8.1 cells were grown in CHO Lec
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selection medium (Table 2-7) that contained 1.5 mg/ml geneticin (G418) and the protein (UL16-
Fc) containing supernatant collected before each passaging of the cells. The supernatant was stored
at 4 °C.
The cultivation of CV-1 cells was essentially performed as described in this section for CHO Lec
3.2.8.1 cells. The main difference was the type of basal culture media that was used. CHO Lec
3.2.8.1 cells were grown in α-MEM (Tables 2-7), whereas CV-1 were grown in DMEM (Table 
2-8).
2.2.2.2 Roller bottle setup with CHO Lec 3.2.8.1 cells
Roller bottles represent a convenient way to scale up the protein production of adherent eukaryotic
cells as they provide a significantly larger growth surface compared to normal cell culture flasks.
As a consequence, roller bottles reduce (i) the space requirements to grow the cells, (ii) the material
costs and (iii) the amount of labor necessary to maintain the cells and harvest the protein containing
supernatant.
Protocol: Four 90 % confluent (175 cm2) cell culture flasks containing CHO Lec 3.2.8.1 cells (see
Section 2.1.6.2) were trypsinated as described in Section 2.2.2.1, followed by the transfer of all
pelleted cells to a single roller bottle, containing 200 ml of 37 °C preheated CHO Lec culture
medium (Table 2-7). The culture medium (instead of selection medium) was used to reduce the
stress exerted by the selection marker in order to favor target protein (i. e. UL16-Fc) production.
The protein (UL16-Fc) containing medium was collected after 7 days and replaced by fresh CHO
Lec 3.2.8.1 culture medium. Roller bottles with cells having grown for 4 weeks were discarded and
replaced with new roller bottles containing fresh cells. Cells were grown throughout at 37 °C, 5 %
CO2 in a water-vapor-saturated atmosphere.
2.2.2.3 Cryoconservation of eukaryotic cells
Cells were trypsinated as described in Section 2.2.2.1. However, instead of resuspending the
pelleted cells in medium (Tables 2-7 and 2-8), cells were resuspended in 1 ml of cryo solution
(Table 2-9) and transferred into a 2 ml cryo tube. The cryo tube was placed inside a 20 °C Mr.
Frosty freezing container, followed by the transfer of the container into a -80 °C fridge. At -80 °C,
the temperature inside the container decreases at 1 °C/min and therefore allows a very gentle
freezing of eukaryotic cells. After 4 hrs the cryo tube was removed from the container and stored in
liquid nitrogen.
M a t e r i a l s a n d M e t h o d s
42 | P a g e
Frozen cells were thawed quickly by placing the frozen cryo tube into a 37 °C water bath for
1 - 2 min and washed with 37 °C preheated PBS to reduce the DMSO concentration. After
centrifugation of the PBS solution at 300x g, the cell pellet was resuspended in 25 ml 37 °C
preheated medium (Tables 2-7 and 2-8) and transferred to a single (175 cm2) cell culture flask.
2.2.2.4 Counting of living cells
For some applications, such as the transfection of cells (see Section 2.2.2.6) or the generation of
kill curves (see Section 2.2.2.5), it is necessary to seed a defined number of cells. In order to do so
one needs to know the concentration of living cells in a given cell suspension. This concentration
can be determined by staining dead cells with the dye ‘trypan blue’, followed by the subsequent
counting of living (non-blue) cells in a Neubauer counting chamber.
Protocol: Adherent cells were trypsinated as described in Section 2.2.2.1 and resuspended in 15 ml
of the respective culture medium. 50 µl of this cell suspension were mixed with 50 µl of trypan
blue (dilution factor: 2) and pipetted below the cover slip of a Neubauer improved counting
chamber. Cells were counted using a light microscope and their concentration calculated using the
following equation:
ܿ= ܰ௔௩ ∙ ܨ௧௕
ܣ ∙ ݀
∙ 10ସ Equation 2-2
with
Nav Average number of cells per large square (average based on four large squares)
Ftb Dilution factor of trypan blue (equals 2; see above)
A Area of one large square (1 mm2)
d Depth of the chamber (0.1 mm)
A·d Volume of one large square (0.1 µl)
104 Nav/0.1µl → Nav/1 ml
c Cell concentration [cells/ml]
2.2.2.5 Kill curve
Kill curves are generated to determine the selection marker concentration that is necessary to kill
the complete population of a cultured, non-resistant cell line within 5 days. Knowing this kill-
concentration of the selection marker will turn out to be very useful when a cell population is
selected for cells that were stably transfected with a foreign plasmid during the process of
transfection (see Section 2.2.2.6). This is because after transfection basically two subpopulations
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exist: Cells belonging to subpopulation I are not resistant against the selection marker as they did
not take up the plasmid, which not only contains the gene of interest but also the resistance gene
that confers resistance against the selection marker. Cells belonging to subpopulation II however
did take up the plasmid and are therefore resistant against the selection marker. Consequently, by
exposing a cell population to the kill-concentration of the selection marker, all cells belonging to
subpopulation I will be dead after 5 days while the stably transfected cells of subpopulation II will
thrive.
Protocol: Untransfected cells were trypsinated as described in Section 2.2.2.1, followed by their
resuspension in culture medium without selection marker. Cells were then counted as described in
Section 2.2.2.4, followed by the seeding of 50,000 cells in each well of a 6-well plate. In each well
a different concentration of selection marker was generated (in case of G418 final concentrations
were 0.0, 0.5, 0.8, 1.0, 1.5, and 1.8 mg/ml). After 5 days cells were evaluated with a light
microscope and the kill-concentration determined as describe above.
2.2.2.6 Transfection
Transfection generally refers to the transfer of foreign DNA (usually a plasmid carrying the gene of
interest, i. e. the gene to be expressed, and a resistance marker gene) into eukaryotic cells. Two
different forms of transfection can be distinguished. During a transient transfection, the foreign
DNA is only temporarily taken up by the host cell and is usually degraded within a few days.
During a stable transfection, however, the foreign DNA is integrated in the host genome and is
therefore much more protected against aggregation. To ensure that the foreign DNA remains
integrated in the genome, stably transfected host cells have to be kept under the constant selection
pressure of the selection marker that is added to the growth medium of the cells.
Protocol: Stable transfections of CHO Lec 3.2.8.1 cells were performed with Lipofectamine 2000
and by following the manufacturer’s instructions. Cells were grown as described in Section 2.2.2.1.
In case of UL16-Fc, CHO Lec 3.2.8.1 cells were stably transfected with a recombinant
pcDNA3.1(-) vector (see Section 2.1.4.1) containing the genetic information of the UL16-Fc
construct described in Section 2.2.3.5.1. After transfection, cells were grown as described in
Sections 2.2.2.1 and 2.2.2.2.
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2.2.2.7 Subcloning
By performing a stable transfection many cells of the cell population are transfected with the
foreign DNA. It is known, however, that individual cells exhibit different phenotypes in terms of
protein expression after successful transfection. In other words stably transfected cells, after their
selection, can be considered as polyclonal in terms of protein expression. Subcloning is the
procedure to isolate individual protein expressing cells (the clones) in order to test them in terms of
protein expression. The clone with the highest level of protein expression is then expanded and
used to produce the protein. This single clone usually exhibits a much higher protein expression
level than the polyclonal culture.
Protocol: CHO Lec 3.2.8.1 cells were trypsinated as described in Section 2.2.2.1. Cells were
resuspended in CHO Lec selection medium (see Table 2-7) and the cell concentration counted as
described in Section 2.2.2.4. This stock cell suspension was further diluted to a final cell
concentration of 1 cell/200 µl and 200 µl of this suspension transferred to each well of a flat bottom
96-well plate. This should theoretically result in the seeding of 1 cell (clone) per well. Statistically,
however, also wells with zero or more than one clone can also be found. The determination of the
clone number per well is performed using a light microscope and by counting the number of cell
colonies, each of which is easily visible and based on one seeded cell. Eventually, only the
populations that were found in wells with only one colony were expanded and analyzed for protein
expression by performing a Protein A/G pull-down assay.
2.2.2.7.1 Protein A/G pull-down assay
The bacterial cell wall proteins Protein A and Protein G were isolated from Staphylococcus aureus
and group G streptococci, respectively. They exhibit molecular weights of 42 (Protein A) and 35
kDa (Protein G) and bind the Fc region of immunoglobulin G (IgG) type antibodies with
nanomolar affinity107. This binding feature is exploited in Protein A and/or Protein G mediated
purifications, pull-downs, or immunoprecipitations of IgG subclass antibodies and Fc-tagged
proteins, respectively107, 108. Note that recombinant versions of Protein A and Protein G have been
developed (e. g. recombinant Protein A/G) in order to improve and/or combine the features of the
two individual proteins.
Protocol: Each UL16-Fc expressing CHO Lec 3.2.8.1 cell clone was grown in a separate well of a
6-well plate until a confluency of 100 % was reached. The old medium was exchanged against 2 ml
fresh CHO Lec 3.2.8.1 culture medium (Table 2-7), and the cells were incubated for 2 days. 750 µl
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of the UL16-Fc containing supernatant of this culture were removed and filtered using a Spin-X
centrifuge tube filter (0.22 µm). In addition 10 µl of Protein A/G UltraLink resin slurry were
transferred to a 1.5 ml reaction vial and washed 3 times with 1 ml of Protein A binding buffer
(Table 2-16). During each washing step, Protein A/G beads were resuspended in Protein A binding
buffer followed by centrifugation and the disposal of the wash solution in the supernatant. All
centrifugation steps using Protein A/G beads were performed at 4,000x g. The Protein A/G pellet
obtained after the third centrifugation step was mixed with 750 µl of filtered UL16-Fc supernatant
(see above) and the entire suspension incubated for 2 hrs at 4 °C. UL16-Fc bound Protein A/G
beads were washed as described above. The UL16-Fc containing Protein A/G pellet obtained after
the third centrifugation step was dissolved in 20 µl of reducing SDS sample buffer (Table 2-21),
boiled and analyzed by SDS PAGE for UL16-Fc expression that should result in a UL16-Fc protein
band at 60 kDa. The clone with the best UL16-Fc expression (indicated by the strongest UL16-Fc
band at 60 kDa on the gel) was then used for further UL16-Fc production.
2.2.3 Methods in protein biochemistry
2.2.3.1 Protein concentration determination
Over the years, various assay types have been developed to measure the protein concentration in a
given solution. Two of the most common assay types are the Bradford assay and the λ280 assay109,
110.
2.2.3.1.1 Bradford assay
The Bradford assay is based on the dye Coomassie Brilliant-Blue G-250. Coomassie binds to
arginine and/or hydrophobic amino acid side chains of proteins and absorbs light at 595 nm in this
protein-bound state. In general, the Bradford assay is performed in two steps: (Step 1) A number of
five to ten BSA samples with distinct, known protein concentrations are prepared and then mixed
with Bradford reagent. After a short incubation period the absorption of each sample is measured at
595 nm (A595 value) and plotted against the corresponding (known) BSA concentrations in order to
derive a standard curve. (Step 2) Then the protein sample with the unknown protein concentration
is subjected to the same reaction as the BSA samples and its concentration determined by relating
the measured A595 value to a protein concentration via the standard curve obtained after step 1.
Protocol: The Bradford assay was performed with the Bradford Protein Assay reagent and by
following the manufacturer’s instructions. The absorption of the sample was measured at 595 nm
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(A595) using a spectrophotometer and a 1 ml plastic cuvette. The protein concentration was then
calculated based on an equation (Equation 2-3) that had been derived by Pierre Schelling from a
BSA calibration curve.
ܿ = ܣହଽହ− 0.0040.051 ∙ ݒ Equation 2-3
with
A595 Absorption at 595 nm
v Sample volume in µl
c Concentration in mg/ml
2.2.3.1.2 λ 280 assay 
By measuring the absorbance of a protein solution at 280 nm (A280) and by knowing the theoretical
extinction coefficient of the protein at this wavelength (ε280) one can determine the protein
concentration in mg/ml using a modified form of Lambert-Beer’s law (see Equation 2-4)111.
ܿ= ܣଶ଼଴ ∙ ܯ௪
ߝଶ଼଴ ∙ ݀
Equation 2-4
with
A280 Absorption at 280 nm
ε280 Molar decadic extinction coefficient [M-1cm-1]
d Path length of light [cm] = 1
Mw Molecular weight [g/mol]
c Concentration [mg/ml]
The extinction coefficient is calculated as shown in Equation 2-5.
ߝଶ଼଴ = ்݊௥௬௣௧௢௣௛௔௡ ∙ 5500 + ்݊௬௥௢௦௜௡௘ ∙ 1490 + ஼݊௬௦௧௜௡௘ ∙ 125 Equation 2-5
with
n number of the particular amino acid in the protein
The extinction coefficients and molecular weights (without glycosylation) for UL16-Fc, UL16mon,
MICBshort and MICBlong are listed in Table 2-34 and were calculated with the online tool
ProtParam.
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Table 2-34. Extinction coefficients and molecular weights
Components ε280 [M-1 cm-1] Molecular weight [g/mol]
UL16-Fc 62715 44400
UL16mon 27055 18524
MICBshort 25502 23011
MICBlong 46535 32702
Protocol: First a reference sample containing pure protein buffer was used to blank the
spectrophotometer. Then, 70 µl of protein buffer were added to 5 µl of protein sample followed by
the transfer of this mixture into a 75 µl quartz cuvette. The absorption of the sample was measured
at 280 nm (A280) and the concentration of the sample determined using Equation 2-4. The obtained
concentration value was then corrected by taking the dilution factor into account. Alternatively, the
absorbance at 280 nm of undiluted protein samples was measured with a Nanodrop ND-1,000
photometer.
2.2.3.2 Discontinuous SDS-PAGE
The discontinuous SDS-PAGE is an analytical method to separate proteins based on their
molecular weight. Moreover, the use of protein markers, which are comprised of proteins with
defined molecular weights, allows for the determination of the molecular weight of the separated
proteins. However, to perform this kind of analysis protein samples have to be first diluted in SDS
containing sample buffer (Table 2-21) and then boiled for 5-10 minutes. Together, both heat and
SDS denature the proteins entirely. The negatively charged SDS also performs a second function. It
can bind to the denatured protein (1.4 g SDS per g protein in a 1 % SDS solution) with its
hydrophobic portion and thereby coats the protein evenly with the negative charges of its sulphate
head group. As a consequence, all proteins will obtain a similar charge/mass ratio, which in turn
will lead to the same electrophoretic mobility of each protein during electrophoresis. This explains
why proteins during a SDS-PAGE are solely separated by their molecular weight and not by a
combination of their molecular weight and native charge.
Protocol: Solutions for the SDS stacking and resolving gels were prepared as described in Table
2-22. Gels were cast using a casting chamber. Protein samples were mixed with the appropriate
amount of 4x sample buffer, loaded onto the SDS-Gel and run for 1.5 hrs at 120 V. Gels were
transferred to Coomassie staining solution (Table 2-23) and heated in a microwave until the
Coomassie solution was hand warm, followed by a staining period of 1 h on an orbital shaker. Gels
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were then transferred to destaining solution (Table 2-23), heated again in a microwave until the
solution was hand warm, and then left to destain for about 30 min. Finally, gels were evaluated and
scanned for documentation.
Note that protein crystals can also be analyzed by SDS PAGE (see Section 3.3.1). However, to
detect the nanogram quantities of protein that is present in a protein crystal, a silver stain of the
respective SDS gels was performed following a protocol developed by Nesterenko et al.112. The
detection limit of a normal Coomassie staining lies in the range between 50 - 100 ng of protein,
while the detection limit of a silver stained gel lies between 1 - 10 ng.
2.2.3.3 General aspects of protein purifications performed with FPLC systems
The available chromatographic techniques for the purification of (recombinant) proteins can be
divided in four groups based on the protein’s properties that are exploited.
 Size exclusion chromatography, SEC (also called gel filtration (GF) chromatography)
exploits the protein’s size but is also dependent on the proteins shape
 Ion exchange chromatography (IEX) exploits the protein’s charge
 Hydrophobic interaction chromatography (HIC) exploits the protein’s hydrophobicity
 Affinity chromatography (AC) exploits the protein’s biorecognition.
In AC methods a ligand (i. e. protein, peptide or small molecule) is coupled to the matrix of a
chromatographic column and the solution containing soluble protein is passed over this matrix.
Proteins in the solution will recognize their immobilized native ligands, bind to it (biorecognition),
and will therefore be retained. However, often this biorecognition property is not a feature of the
protein itself but instead conferred by a so-called protein-tag (i. e. a short peptide stretch or a
complete protein) that is fused to either the N- or the C-terminus of the protein sequence. These
proteins are therefore also called ‘fusion proteins’.
In general, protein purifications using one of the chromatographic techniques described above are
carried out at 4 °C. The main reason for this is that the cells that produce the recombinant protein
also express proteases for their own metabolism. If released during the purification procedure,
these proteases can cleave and therefore harm the expressed protein. Lower temperatures combined
with protease inhibitors are usually sufficient to minimize protease activity in a cellular lysate or in
any other sample that contains protein.
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Protocol: All FPLC purification steps were carried out at 4 °C. Buffers were adjusted to the
desired pH at 4 °C and were degassed and filtered before use. The FPLC systems that were used in
each purification are listed in the respective sections.
2.2.3.4 Constructs, expression, refolding and purification of MICBshort and MICBlong
2.2.3.4.1 Constructs
The original MICB construct (Figure 2-1) was provided by Prof. Dr. Alexander Steinle and
consisted of gene sequences encoding ectodomains α1, α2 and α3 of MICB*002 (named MICBlong),
which encompassed MICB residues 1-276 that were fused via a two amino acid (Leu-Glu) linker
region (not shown in Figure 2-1) to a C-terminal His6-tag. This construct had been cloned into a
pET-21a(+) vector (see Section 2.1.4.2 for details) using the restriction enzymes Nde I and Xho I
(see Sections 2.1.3.8 and 2.2.1.6). Using the original MICB construct as a template, a shorter
MICB construct (named MICBshort) was designed that consisted of gene sequences encoding only
ectodomains α1 and α2 (the so-called platform-domain) of MICB (residues 1-184), which were 
fused to a C-terminal thrombin cleavage site followed by a His8-tag (Figure 2-1). Like the MICBlong
construct, also the MICBshort construct was cloned into the pET-21a(+) vector using the restriction
enzymes Nde I and Xho I (see Sections 2.1.3.8 and 2.2.1.6). The full length sequence of MICB
(UniProt: Q29980) is shown in Figure 2-2.
The molecular weights of recombinant proteins MICBlong-His6 and MICBshort-His8 were
calculated as 32.7 kDa and 23.0 kDa, respectively.
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Figure 2-1. MICB constructs. (A-C) Schematic representation
cleavage in the ER (panel A) and the designed c
expressed in E.coli. Color codes are as follows:
domain – orange; α3-domain – red; transmembrane domain
green, thrombin cleavage site – purple and His
the beginning and end of the protein regions are indicated above
represent the amino acid recognition sequence of thrombin
MICBshort and its His8-tag. The capital letter
residue in the MICB constructs that is not part of the original MICB sequence.
α1α2 platform-domain and the membrane proximal α3 domain 
colored as in panels A-C.
Figure 2-2. MICB full length sequence.
peptide cleavage in the ER. The five protein regions of MICB (signal peptide,
domain, transmembrane region and cytoplasmic tail are
pink.
s of native MICB protein prior to signal peptide
onstructs of MICBlong (panel B) and MICB
ER signal peptide (SP) – bright orange,
(TM) – yellow; cytoplasmic tail
8/6-tags – green. Amino acids in the MICB sequence that mark
the tubes. The six purple letters in
 located between the α1α2 platform
‘M’ in panels B and C stands for a N-terminal methionine
(D) Ribbon tracing
of MICB (pdb code: 1je664
Shown is the full length sequence of MICB allele 002 prior to signal
α1α2 platform
colored as in Figure 2-1. Cysteines
short (panel C)
α1α2 platform-
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2.2.3.4.2 Expression
For decades, E.coli has been the first choice for the expression of recombinant proteins. This is
owed due to the many beneficial features of E.coli: (i) The most widely used E.coli strain is the
K12 strain, which represents a cultivated strain that has lost its ability to thrive in the human
intestine and is therefore very safe to work with. (ii) In addition, foreign genes can be easily
introduced into E.coli and efficiently selected for with the use of bacterial antibiotics. (iii)
Furthermore, E.coli not only exhibits exponential growth rates but also high protein expression
rates. And last but not least (iv) culturing and storing of E.coli cells is usually very straight forward
and inexpensive.
Protocol: Both His-tagged MICBlong and MICBshort constructs were expressed and purified with the
same strategy (Figure 2-3): E.coli Rosetta 2(DE3) cells (see Section 2.1.6.1) transformed (see
Section 2.2.1.9) with the appropriate expression construct were grown in LB medium (Table 2-4),
supplemented with 50 µg/ml ampicillin and 34 µg/ml chloramphenicol, to an optical density
(OD)600 of 0.5 - 0.6. Protein expression was then induced by adding IPTG to the bacterial
suspension to make a final concentration of 1 mM, followed by a 4 h incubation period at 37 °C.
Bacterial cells were centrifuged at 4,000x g for 20 min and the bacterial pellet resuspended in 150
ml lysis buffer (Table 2-11). Cells were lysed using a high pressure homogenizer followed by the
centrifugation of the bacterial lysate at 27,000x g for 20 min. After centrifugation, the bacterial
lysate consisted of two distinct solid layers below a clear supernatant. The supernatant was
discarded and the soft upper layer carefully removed with a spatula. The hard and brownish lower
layer contained the MICB inclusion bodies (IB).
2.2.3.4.3 Refolding
The E.coli expression system has many benefits (see Section 2.2.3.4.2). However, the downside of
this system is that the production of soluble, natively folded forms of recombinant proteins remains
unpredictable. Often instead of soluble, natively folded recombinant proteins, insoluble and
misfolded E.coli inclusion bodies (IB) are obtained. Although many of the reasons for the
formation of IBs remain elusive, clearly (i) the reducing environment of E.coli, which prevents the
formation of disulfide bonds that are often essential for the proper folding and stability of
eukaryotic proteins, and (ii) the inability of E.coli to produce post-translational modifications such
as glycosylation, contributes to the formation of IBs. Using refolding methods the native form of
the recombinant protein can in some cases be reconstituted from the IBs. In a first step, the
misfolded proteins are completely unfolded to their random coiled state by strong denaturants such
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as urea or guanidine hydrochloride (GuHCl), followed by the stepwise (dialysis approach) or one-
step (rapid dilution approach) reduction of the denaturant in refolding buffer, during which the
proteins fold back into their native form.
Protocol: IBs were resuspended in Triton X-100 wash buffer (Table 2-12) using a 40 ml Potter
homogenizer. The inclusion body suspension was centrifuged at 27,000x g for 20 min. After
centrifugation, the supernatant was discarded and the inclusion body pellet again transferred into
the Potter homogenizer. This inclusion body cleaning cycle was repeated about 5 times until an
almost white inclusion body pellet was obtained. One last cycle was then performed to remove the
Triton X-100 detergent with Triton-free wash buffer (Table 2-12). Without disturbing the inclusion
body pellet after this last cycle, the centrifuge tube was filled with 25 ml of 8 M urea buffer (Table
2-13), sealed and rotated over night in the cold room. In the morning, the pellet had dissolved
completely, and oxidized and reduced glutathione (final concentrations of 0.5 and 5 mM,
respectively) were directly added to the MICB containing 8 M urea buffer, followed by another
24 h rotation of the sample at 4 °C. The inclusion bodies were refolded by stepwise arginine/urea
dialysis. Briefly, 8 M urea buffer (Table 2-13) containing MICB was dialyzed step by step (each
dialysis step taking 24 h) against refolding buffer (Table 2-14). During each of the three steps the
concentrations of urea (4M→2M→1M→0M) were decreased (see Table 2-14). In the fourth 
dialysis step, the arginine concentration was reduced from 400 to 100 mM, followed by a final
(fifth) dialysis step during which MICB was dialysed against TBS buffer (pH 8; see Table 2-10).
During this last step a significant portion of MICB precipitated and was removed by centrifugation
at 27,000x g for 20 min and subsequent filtration (0.22 µm) using a Steritop Express Plus filter
(0.22 µm). The obtained clear solution contained the soluble MICB and was concentrated using
either an Amicon Ultra 4 or 15 concentrator (MWCO: 5,000 Da). Finally, the concentrated MICB
sample was again filtered using a Steritop ExpressTM Plus filter (0.22 µm).
Figure 2-3. MICB expression and
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2.2.3.4.5 SEC purification
SEC is a very simple, fast and mild form of chromatography that separates proteins according to
their differences in size and shape. The stationary phase (the matrix) consists of beads that contain
pores of a defined average size that contain the same buffer used in the mobile phase. When a
mixture of different molecules is passing through the column, the small molecules can easily
penetrate into every part of the pore system. However, when the size of the molecule increases not
the whole pore system is accessible to it anymore. At some point the protein size exceeds the size
exclusion limit and no further permeation of the molecule into the pore system is permitted.
Eventually this translates to the fact that larger molecules will move faster through and elute earlier
from the column. However, all molecules (unless unspecificly bound to the matrix) will elute
before one total column volume of buffer has passed through the column. An important
characteristic of every SEC column is its resolution, which is dependent on many factors such as
the packing density, pore size, sample volume, flow rate and column length. In addition, SEC can
also be used to determine the size of proteins. To do so, a standard curve is created by plotting the
elution time or volume of standard proteins against their size. Having determined the time or
volume at which a protein with unknown molecular weight elutes from the column, the weight of
the protein can be determined by use of the standard curve.
Protocol: MICB was loaded on a Superdex 75 10/300 GL (column volume: 24 ml) equilibrated
with TBS (pH 8; Table 2-10) and connected to a BioLogic DuoFlow FPLC system. 0.5 ml MICB
samples were loaded on the column and eluted with 24 ml of TBS buffer (pH 8; Table 2-10).
Fractions of 0.5 ml volume were collected during the entire run and analyzed via SDS-PAGE.
MICB containing fractions were pooled, concentrated as described before (see Section 2.2.3.4.3),
filtered with a Spin-X centrifugal tube filter (0.22 µm) and finally stored at 4 °C. The entire SEC
run was performed at a flow rate of 0.5 ml/min and monitored using the BioLogic Duo Flow
software.
2.2.3.5 Constructs, expression and purification of UL16
2.2.3.5.1 Constructs
The original UL16 construct (see Figure 2-4) was prepared by Dr. Jessica Spreu and provided by
Prof. Dr. Alexander Steinle. It was used throughout this thesis without any alteration. Briefly, a
recombinant cDNA fragment including the N-terminal signal peptide (residues 1-26) and the
ectodomain (residues 27-184) of UL16 was fused to a C-terminal thrombin cleavage site followed
by the human IgG1-Fc sequence and cloned into a pcDNA3
details). The full length sequence of UL16
UL16 regions were predicted with
Figure 2-4. UL16 constructs.
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2.2.3.5.3 Protein A purifica
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Protein A binding buffer (Table 2-16
with 100 % arginine solution (Table
Fractions containing UL16-Fc were
concentrated using an Amicon Ultra 15
cleavage was performed with 1 U/mg recombinant
was filtered, diluted five-fold in Protein A
1 ml/min over two consecutive Protein A
benzamidine column (1 ml column volume) to remove cleaved Fc tag and thrombin, respectively.
Flow-through containing UL16 samples were
7.4; Table 2-10) for storage. For a schematic representation o
2-5.
Figure 2-5. UL16 expression and purification scheme.
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2.2.3.5.4 IMAC and SEC
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2.2.3.5.6 HIC purification
Hydrophobic interaction chromatography (HIC) exploits the interaction between hydrophobic
surface regions of the proteins and the hydrophobic resins of the column matrix. As the
hydrophobic regions of various proteins differ in size and hydrophobicity and therefore bind to the
hydrophobic resin with different strength, HIC can be used to separate those proteins from each
other. Normally, the hydrophobic regions of water-soluble proteins would only weakly interact
with the hydrophobic resin (or the hydrophobic regions of a neighboring protein molecule) as their
hydrophobic surface regions are shielded in aqueous solution by a cage of highly ordered (‘frozen’)
water molecules. However, by diluting a protein in high-salt buffer the protein’s frozen water layer
can be removed. The reason for this is that salt ions, as they become strongly solvated in aqueous
solution, do not only sequester the free water molecules but also hijack the protein’s frozen water
molecules once the free water molecules become scarce. The consequence of this so-called
‘salting-out’ effect is that hydrophobic surface regions of the proteins become exposed to the free
water, which facilitates their interaction with the exposed hydrophobic matrix resin. The stepwise
or gradient elution of the bound proteins from the column is achieved by stepwise or gradient
elution with salt free buffers. Two of the most important variables in HIC (which have to be
determined by ‘try and error’) are (ii) the type of hydrophobic resin used and (ii) the type of salt
used to dehydrate the proteins in the first place.
Protocol: Briefly, the UL16 monomer/dimer mixture was diluted in HIC-binding buffer, loaded at
a flow rate of 2 ml/min onto three serially connected phenyl sepharose columns (5 ml column
volume each) and washed extensively with HIC-binding buffer (Table 2-18). Bound UL16mon was
eluted in one step with 100 % HIC-elution buffer (Table 2-18) at a flow rate of 2 ml/min and
dialyzed against TBS buffer (pH 7.4; Table 2-10). The yield of monomeric UL16mon was 0.2 mg
per 1 liter of cell culture supernatant. All chromatographic steps, except the loading of the Protein
A columns with cell culture supernatant, were performed with an Äkta prime FPLC system and
monitored and evaluated using the PrimeView software. For a schematic representation of the
purification strategy see also Figure 2-7 and compare with Figure 2-5.
Figure 2-7. UL16mon purification scheme.
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Figure 2-8. Purification of the glycosylated UL16
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of molecules consist of two distinct
observed due to the formation of the
stopped and instead of analyte, running buffer
marks the beginning of the dissociation phase
is observed as complex molecules fall apart
continuous buffer stream. Binding parameters such as the association and dissociation rate
constants (ka and kd, respectively) and/or the dissociation
fitting the entire titration series to a predefined binding model with an appropriate software.
Figure 2-10. SPR data analysis. Shown is a typical SPR data set comprised of seven
sensorgrams, each of which corresponds to a defined but distinct concentration of
case UL16mon; see red slanting arrows). Each individual sensorgram is obtained
that is caused when the soluble analyte binds the surface immobilized ligand
in seconds). Also indicated are the regions of the individual sensorgrams that are used for the determination
of kinetic and steady-state binding parameters, respectively. The association and dissociation phases are used
to derive kinetic rate constants (ka and
constant (KD). Alternatively, the dissociation constant (K
by the relationship KD=kd/ka. The figure was modified from Müller
Protocol: ‘All SPR experiments were performed and evaluated as described
reference114. Using two consecutive flow cells on a CM5 biosensor chip,
ligands, respectively, were each covalently immobilized on th
(experimental) flow cell via amine-coupling chemistry following manufacturer’s instructions, while
phases. During the association phase an increase in response is
complex. However, at some point the analyte injection is
is passed over the biosensor surface. This point
. During the dissociation phase a decrease in response
and analyte is carried away from the surface in the
constant (KD) can then be determined by
double
injected
by plotting the
against time (measured usually
kd), while the steady-state phase is used to derive the dissociation
D) can also be calculated from kinetic rate constants
et al., 2010113 (see also Figure
MICBshort
e surface of the downstream
-referenced
analyte (in this
SPR response
3-25).
in detail in
and MICBlong
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the surface of the upstream (reference) flow cell was subjected to the same coupling reaction in the
absence of protein. Untagged, monomeric UL16 analyte was serially diluted in running buffer and
injected in series over the reference- and experimental (MICB) biosensor surface at 50 µl/min.
MICB coated CM5 chips were not regenerated. For the Protein A/G chip preparation, an amount of
3,500 RU (resonance units) of recombinant Protein A/G was covalently immobilized to the
upstream (reference) and downstream (experimental) flow cells of a CM5 biosensor chip by amine-
coupling chemistry. Fc-tagged ULBP1, ULBP2, ULBP3, ULBP4 and ULBP5 ligands89 were
diluted in HBS-EP (Table 2-25) and noncovalenty bound to the experimental flow cell Protein A/G
surface (regarding the used ULBP proteins see also Section 2.1.3.9). After each cycle using a
Protein A/G chip, the biosensor surface was regenerated (stripped of any remaining analyte and
ligand) with two 1 min injections of 10 mM glycine pH 1.7. Untagged, monomeric UL16 analyte
was serially diluted in running buffer and injected in series over the reference- and experimental
biosensor surface at 50 µl/min.’113
2.2.5 X-ray crystallography
2.2.5.1 X-rays and data collection
Objects are visible as they diffract electromagnetic radiation. However, in order to be diffracted by
the object, the wavelength of the electromagnetic radiation must be of the same size as the object
itself. This explains why visible light (λ = 350 - 750 nm) is diffracted by macroscopic and 
microscopic sized objects, while X-rays (λ = 0.1 - 10 Å) are diffracted by smaller objects such as 
atoms, which exhibit a diameter in the range between 1 - 5 Å. The wavelength of the
electromagnetic radiation also determines the so-called resolution limit (λ/2), which is defined as 
the shortest distance between two objects at which these objects can still be determined as two
singular entities by the observer. If the points are closer together than the resolution limit, they will
blur together, making it impossible to distinguish between them. Bonded atoms in macromolecules
such as proteins are about 1.5 Å apart from each other, which explains why protein crystals are
commonly exposed to X-ray wavelengths in the range between 0.5 - 2Å.
The wavelength used, can vary depending on the X-ray source available and the
experimental conditions. X-ray home sources such as in our laboratory make use of the K-shell
emission of a rotating copper anode that is positioned in a vacuum compartment and under
continuous fire by a beam of accelerated electrons from a heated filament (the cathode) at a
potential of 30 to 40 kV. When the accelerated electrons hit the anode, heat is produced. In
addition, some of the electrons will also displace electrons from the lowest electron orbital (the K-
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shell) of individual copper atoms. In the next step an electron from a higher orbital (the L or M
shell) will drop into the empty position of the displaced K-shell electron and thereby emit the
excess energy as X-ray photons. Electron transitions from the L→K shell and M→K shell will 
produce the Cu-Kα radiation (λ = 1.54 Å) and Cu-Kβ radiation (λ = 1.39 Å), respectively. Since the 
Kβ radiation is less intense than the Cu-Kα radiation and since furthermore it is pivotal to use only
monochromatic radiation in an X-ray experiment, a nickel filter is used to essentially eliminate the
Cu-Kß radiation.
A different source of X-rays are particle storage rings, which are called synchrotrons that
were originally invented to study the physics of subatomic particles. However, synchrotrons have
also turned out to be an invaluable asset in the X-ray structural analysis of protein crystals. If
compared to X-ray home source systems synchrotrons have many advantages that usually result in
better X-ray diffraction data quality: (i) A higher photon flux (i. e. more intense X-ray radiation
beams) that often helps to obtain crystal datasets with higher resolution, especially if very small,
very thin or very weakly diffracting crystals are measured. (ii) The tuneability of the X-ray
wavelength the crystal is exposed to, which allows for the implementation of specific experiments
that can help to solve the so-called phase problem. (iii) Detectors that are characterized by reduced
signal to noise ratios and shorter data read-out times, which eventually leads to higher data quality
and shorter overall measure times, respectively. (iv) And finally a smaller beam size that allows for
the testing of different areas of a single crystal.
2.2.5.2 Protein crystal symmetry
Protein crystals consist of a highly ordered three-dimensional array of molecules, which are held
together by non-covalent interactions. These non-covalent interactions between neighboring
molecules in combination with the high amounts of solvent in a protein crystal make protein
crystals very soft and fragile. The smallest identical repeating unit of a crystal is the unit cell,
which can be viewed as the smallest building block of the crystal that can generate the entire
crystal structure by means of translation operations in three dimensions. The unit cell is defined by
six parameters, the lengths of the three cell axes (a, b and c) and the three angles between them
(a/b→ γ , a/c→β and b/c→α). Defined constraints on these axial lengths and interaxial angles of a 
unit cell give rise to seven crystal systems (triclinic, monoclinic, orthorhombic, tetragonal, trigonal,
hexagonal and cubic) with lattice points at each corner of the cell. Besides these primitive (P) unit
cells, face (F), body (I) and side (C) centered unit cells can also exist in some crystal systems.
Taking these centered unit cells into account, 14 Bravais lattices can be described. During a
structural analysis, however, not the unit cell but instead the asymmetric unit (ASU) is at the focus
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of interest. This is because the content, i. e. the number and arrangement of the individual
molecules in each unit cell (proteins or protein complexes) can always be generated by application
of all symmetry operations of the space group to the contents of the ASU. Note, however, that due
to the chiral nature of proteins the only symmetry operations allowed and found in protein crystals
are translations, rotations, and combinations of both, the screw axes. This is also reflected in the
space group symmetry operations, which consist of (i) the abovementioned lattice translations of
the ASU (P, I, F, C), (ii) the additional combinations of ASU rotations about the lattice points
(point groups) and (iii) the combinations of the ASU rotations and translations about the lines
connecting neighboring lattice points (screw axes). Combining the 11 point groups allowed in
protein crystals with translations (screw axes) and centering operations (P, I, F, C) gives rise to 65
protein space groups. For a summary of the allowed symmetry operations in crystals with a chiral
and non-chiral ASU content, as well as the resulting number of point and space groups see Table
2-35.
Definition – Symmetry operation: An operation that leads to superimposition of an object on itself.
Definition – Symmetry element: An imaginary geometric entity about which a symmetry operation
takes place.
Table 2-35. Allowed symmetry operations in crystals with chiral or non-chiral ASU contents
ASU
content
Allowed symmetry
operations to generate
the unit cell
Symmetry element
Number of
crystal
systems
Number of
Bravais
lattices
Number of
point
groups
Number of
space
groups
Non-chiral
Rotation Rotation axis
7 14 32 230
Translation Translation vector
Inversion Inversion point
Reflection Mirror plane
Rotation + Translation Screw axis
Mirror + Translation Gliding plane
Rotation + Inversion Rotoinversion axis
Chiral
(proteins)
Rotation Rotation axis
7 14 11 65Translation Translation vector
Rotation + Translation Screw axis
2.2.5.3 Protein crystal growth
A fundamental requirement to solve the three dimensional structure of a molecule (e. g. of a protein
or a protein complex) by means of X-ray crystallography is the availability of protein crystals of
sufficient quality and size (ideally 50 - 1,000 µm). The size matters as very small crystals lead to
weak signals of the diffracted X-ray beams. The reason for this is that small crystals consist only of
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a relatively small number of scatterers (i. e. a relative small number of stacked unit cells). The
objective of most crystallization methods is to precipitate proteins from a supersaturated aqueous
solution by slowly increasing the concentration of a precipitant and the protein itself without
destroying the protein’s three-dimensional structure115-117. The latter is possible because crystals
normally contain high amounts (50 - 70 %) of solvent due to the irregular shape of the proteins.
The precipitants are usually salts or water-soluble polymers that, as they become solvated, hijack
the highly ordered water molecules from the water cages that automatically form around the
hydrophobic (non-polar) portions of a protein in aqueous solution. Therefore, as a consequence of
this so-called ‘salting-out’ effect, hydrophobic surface regions of the proteins become exposed to
the free water, which will facilitate their interaction with the exposed hydrophobic regions of other
proteins in the solution and thus eventually to the formation of intermolecular precipitates. The
most widely used crystallization method that is based on the ‘salting-out’ principle is vapor
diffusion. The course of a typical vapor diffusion crystallization experiment can be roughly divided
into three stages that are best illustrated by a phase diagram (Figure 2-11). (Stage 1) At the
beginning of a crystallization experiment, the protein solution is mixed with a precipitant
containing crystallization solution. The resulting mixture should ideally be undersaturated in terms
of protein (red zone in Figure 2-11) and is placed as a hanging or sitting drop in an air-sealed
compartment. This compartment also contains a significantly larger volume of the crystallization
solution in a spatially separated reservoir. (Stage 2) Then, as a result of the lower overall
concentration of solutes in the drop mixture compared to the reservoir solution, water will diffuse
from the drop into the reservoir. This vapor diffusion process causes a slow increase in protein and
precipitant concentration in the drop up to a point where the solution becomes supersaturated in
terms of protein. If during this process the crystal drop mixture reaches the supersatured
precipitation zone (blue zone in Figure 2-11) only amorphous precipitates will be obtained.
However, if the drop mixture reaches the moderately supersaturated nucleation zone (yellow zone
in Figure 2-11), crystal nuclei will form spontaneously and start growing. (Stage 3) As a
consequence of the continuous crystal formation and growth, the concentration of free protein in
the crystal drop will decrease, which will consequently move the drop mixture to the less
supersaturated metastable zone (green zone in Figure 2-11). In this zone nucleation ceases and only
crystal growth continues until an equilibrium between crystal growth and crystal decomposition is
reached. At this point the crystal growth eventually stops.
Crystal growth is dependent on many parameters, such as the initial protein and precipitant
concentrations, the temperature, the pH of the solution and the presence of additives. Unfortunately
there is no way to predict all these parameters and consequently the composition of a successful
crystallization condition for a given protein. This forces the crystallographer to systematically test
varying crystallization conditions
Experimentally this is done by using commercial
multifactorial sparse matrix screens
concentration and pH or precipitant
sparse matrix screens typically 3
analyses of conditions that have led to a successful crystallization of proteins in the past. Sparse
matrix screens are usually the starting point in the quest to find the optimal crystallization condition
as they allow for a coarse
quality can then be improved by refining the crystallization conditions through application
bifactorial grid screens.
Figure 2-11. The crystallization process in a vapor diffusion experiment.
the influence of the two crystallization parameters
formation and growth of protein crystals. The black circle marks the starting point of the crystallization
experiment (Stage 1), while the arrows i
diffusion (Stage 2) and crystal growth
Protocol: For initial screening the
Hampton Peg/Ion 1 Screen
Ammonium Sulphate were used. Initial hits in those screens were then refined through the
preparation and implementatio
experiments were used when crystal drops were set
mixed with an equal volume of the crystallization solution (of a grid or sparse matrix screen) and
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in order to identify the optimal crystallization condition.
or self-prepared bifactorial grid screens or
. In bifactorial grid screens only two factors,
concentration, and initial protein concentration are
- 4 parameters are varied where the composition is based on the
sampling of the crystal condition space. Crystals that may be of low
The displayed phase diagram shows
protein concentration and precipitant concentration
ndicate the change in both parameters during
(Stage 3). The figure was modified from Chayen, 2004
Hampton Crystal Screens 1 & 2, the Hampton
, the Emerald Wizard 1 & 2 Screens and the
n of self-made fine screens. The hanging drop vapor diffusion
up manually. 1 µl of the protein solution was
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115.
Light Screen, the
Hampton Grid Screen
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pipetted onto a siliconized cover slip. The cover slip was turned upside down and placed on top
over a single compartment of a 24-well crystallization plate filled with 500 µl of the crystallization
solution. The space between the cover slip and the rim of the compartment was sealed with grease.
In cases where a Freedom Evo 150 robot was used to pipet the crystal drops, the sitting drop
method in combination with 96-well crystallization plates was employed. The robot hereby pipets
the crystal drops (300 nl protein solution plus 300 nl crystallization solution) on a flat plateau
positioned above the reservoir solution (100 µl). All 96-well plates were sealed at once after the
last drop was set by using a self-adhesive transparent foil. Crystal plates were incubated at 4 and 20
°C.
2.2.5.4 Protein crystal freezing
Once a protein crystal of suitable size has been obtained through crystallization experiments (see
Section 2.2.5.4) it needs to be exposed to X-ray radiation in order to collect the diffraction data
from which the structure of the protein can be determined. However, collection of diffraction data
may be hampered as protein crystals are sensitive to radiation damage. This radiation damage is
caused by the high energy of the X-ray photons and by the way these photons interact with
electrons in the exposed matter. Either the primary photon’s energy is absorbed by the electron and
subsequently released as a secondary photon in a random direction but with the original energy
(coherent scattering, also known as Thomson scattering) or the primary photon’s energy results in
the release of an electron and the emission of a secondary photon in a random direction with
reduced energy (incoherent scattering, also known as Compton scattering). Note that the
crystallographic structure determination is based on the coherent scattering. Radiation damage is
caused by the incoherent scattering of the X-ray photons as the loss of atomic shell electrons results
in the formation of free radicals, very reactive chemical species that are very harmful for other
macromolecules.
One can reduce the radiation damage caused by free radicals by restricting their movement
in the crystal. This can be achieved by performing the X-ray data collection of the protein crystal at
very low temperature, which is maintained by a cryostream of nitrogen gas at 100 K. Before a
crystal can be placed in the cryostream it has to be protected from ice formation that can severely
harm the crystal. Thus, if the crystallization solution does not have cryoprotecting capabilities
itself, the protein crystal is first soaked with a cryosolution, consisting of the crystallization
solution (also called mother liquor) supplemented with a suitable cryoprotectant such as glycerol or
ethylene glycol, followed by mounting it in a fiber loop and flash freezing it in liquid nitrogen
(boiling point -196 °C) or directly in the cryostream118.
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Protocol: Using a quartz capillary (Ø 0.5 mm), crystals grown as described in Section 2.2.5.3 were
transferred from the crystal drop to a depression well containing 100 µl of mother liquor in order to
clean the crystal of precipitates and protein solution. In the next step the crystal was transferred to a
second well that contained 100 µl of cryosolution, consisting of the mother liquor (Table 2-26)
supplemented with cryoprotectant (e. g. polyethylene glycol or glycerol). After a 1 min soaking
period in the cryosolution, crystals were fished with an appropriately sized fiber loop, flash frozen
in liquid nitrogen and finally mounted on the goniometer head in a cryostream of nitrogen gas.
Alternatively, crystals were stored in a liquid nitrogen tank after fiber loop mounting.
2.2.5.5 X-ray diffraction
In order to collect crystallographic data the frozen crystal in its cryoloop is mounted on a
goniometer head, that places the crystal directly between an X-ray source and a detector. Once an
X-ray beam with a defined wavelength (λ), amplitude (A) and intensity (I ~ A2), hits the crystal, the
beam is diffracted into many separate beams that have the same wavelength but altered direction
and intensity. For each diffracted beam these two parameters can be determined by recording the
positions and intensities of the reflections (spots) that are generated when the diffracted beams hit
the detector. Although the reflections appear in two dimensions on the detector, they are actually
lattice points of a three-dimensional reciprocal lattice and can be described with the indices h, k
and l. The term ‘reciprocal’ refers to the inverse relationship between the lattice translations in the
crystal lattice and the lattice translations in the lattice recorded on the detector. Based on this
simple mathematical relationship it is possible to use the recorded positions of the reflections in
reciprocal space to determine the geometry (i. e. the Bravais lattice) and the dimensions (axes and
interaxial angles) of the real unit cell. Then, by applying a Fourier transform to the recorded
intensities of the reflections the content of (i. e. the number, arrangement and structures of the
molecules in) the real unit cell can be determined. Note here that all atoms in the unit cell
contribute to each of the many hkl reflections recorded in a crystallographic data set. This is
because all atoms in the unit cell function as X-ray diffraction centers, giving rise to spherical X-
ray waves that interfere with each other. The net result of this wave interference is displayed as a
diffraction image and strongly dependent on the relative positions of the scattering centers (i. e. the
atoms) in the unit cell that produced it. Furthermore, it is important to realize that the diffraction
pattern of the crystal, or the content of the myriad of regularly arranged unit cells that make up the
crystal lattice, is nothing else than the averaged and amplified diffraction pattern of a single unit
cell content sampled at the reciprocal lattice points.
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A simplified mathematical description that explains under which conditions the diffraction
process by a crystal lattice leads to constructive interference and thus to the presence of a
recordable reflection (h, k, l) is given by Bragg’s law (Equation 2-6 and Figure 2-12A)119. Bragg’s
law was developed by Sir William Lawrence Bragg in 1912, who treated the diffraction of the
incident beam as reflection from a set of equivalent, parallel real space lattice planes (h, k, l). This
explains why the diffraction spots are called ‘reflections’ and it also explains why both, the set of
real space lattice planes and the reciprocal space reflections, share the same set of hkl indices
(Figure 2-12A). In detail, Bragg’s law states that constructive interference between two diffracted
X-rays (i. e. the generation of a reflection) can only be observed if the path difference between the
two rays (that impinge upon lattice planes hkl with interplanar lattice spacing dhkl under an angle θ) 
is a multiple of the utilized wavelength λ. 
݊ ∙ ߣ= 2݀ ∙ ݅ݏ݊ߠ Equation 2-6
with
n 1, 2, 3…
λ wavelength of the X-ray waves [Å]  
dhkl lattice plane hkl spacing
θhkl Bragg angle of the hkl reflection
The sphere of reflection, which is also called the Ewald sphere or Ewald construction, named after
its inventor Paul Peter Ewald, is a graphical representation of Bragg’s law in reciprocal space
(Figure 2-12B)120. The crystal is positioned at the center of the Ewald sphere, which features a
radius (r) of 1/λ. The point where the incident direct beam exits the Ewald sphere is defined as the 
origin of the reciprocal lattice and is assigned the hkl indices (0,0,0). A reflection hkl on the
detector is observed when a reciprocal lattice point hkl comes in contact with the Ewald sphere. In
that case the incident, direct beam is diffracted in such a way that the diffracted beam exits the
Ewald sphere through the reciprocal lattice point that is in contact with the sphere. In real space this
situation corresponds to the diffraction of the incident, direct beam by the hkl set of real lattice
planes, which are indicated in the figure by a single blue plane that slices the crystal. The distance
(d*) between the origin of the reciprocal lattice (0,0,0) and the reciprocal lattice point hkl is
connected to the distance of the hkl real lattice planes by an inverse relationship.
Figure 2-12. Schematic representations of
wavelength, dhkl – lattice plane hkl spacing, θ
radius of the sphere, θhkl – Bragg angle of the hkl reflection, d*
indices h, k and l, O – origin of the
reflections caused by reciprocal lattice points
Selected areas of the reciprocal lattice are shown in
and diffracted (orange) X-ray beams. C, crystal.
2.2.5.6 Data collection
Detectors used in macromolecular crystallography are a
reflections at once in a
photostimulable phosphor plate (PSP)
crystalline phosphor material
image plate, thereby releasing the energy of the excited electrons in form of blue light that can be
measured using a photomultiplier
proportional to the stored electrons and those are again proportional to the intensities
that caused their excitation.
More sophisticated
pixels (arranged in an array) that accurately count the
therefore allow for a more
photons that hit a CCD pixel in a defined time frame leads to a proportional excitation of electrons
(charge) that accumulate in a
by row and the charges in the readout pixel row transferred one by one to an amplifier at the edge
of the row that converts the charge into a voltage, which is eventually recorded. The greatest
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Bragg’s law and the Ewald sphere. (A)
hkl – Bragg angle of the hkl reflection.
– 1/dhkl, P(h,k,l) – reciprocal lattice point with
reciprocal lattice. The black circles on the detector represent the
(dark blue spheres) that are in contact with the Ewald sphere.
light blue. The arrows mark the incident
rea detectors, which can collect many
defined direction. Image plates record X-rays that
result in the excitation and storage of
. The readout is performed by a laser that passes over each spot of the
. The recorded intensities of the emitted blue light are
X-ray detectors are charge-coupled devices (CCDs)
(X-ray) photons that strike them
precise measurement of a particular reflection’s intensity
positively charged region of the pixel. The readout is performed row
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Bragg’s law: λ – X-ray 
(B) Ewald sphere: r –
(bright orange)
by hitting a
electrons in the
of the X-rays
. CCDs consist of
and that
. Each of the
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advantage of CCD detectors compared to other detector types such as image plates is their fast
readout capability that allows for an extremely efficient data collection. However, the latest
advancement in detector technology is represented by two-dimensional hybrid pixel array detectors
such as the PILATUS (pixel apparatus for the SLS), which operate in single-photon counting mode
and are characterized by several advantages compared to modern CCD detectors, for example a
superior signal-to-noise ratio and readout times of only a few milliseconds. For more details see
Refs.121, 122.
Protocol: Measurements using synchrotron radiation were performed at the SLS (Villigen,
Switzerland) using the PXI (X06SA) and PXIII (X06DA) beamlines that were equipped with a
PILATUS 6M and a MAR225 CCD detector, respectively. Crystals measured at synchrotrons were
usually tested for diffraction using our in-house X-ray system, comprised of a MAR345dtb image
plate, a Rigaku MicroMax-007 HF rotating anode, and VariMax HF optics. For each X-ray
diffraction experiment, a single frozen crystal was mounted on the goniometer head of the X-ray
system and positioned in the path of the X-ray source beam in front of the detector. The crystal was
exposed to X-ray radiation of defined wavelength, and the generated reflections were recorded by
the detector system. During exposure, the crystal was rotated in small angle intervals (usually
between 0.25 - 2°) about a fixed axis perpendicular to the X-ray beam. Each interval corresponds to
a single recorded diffraction ‘frame’ (or ‘image’) by the detector. A set of recorded test frames was
used to guide the strategy of data collection in terms of (i) the optimal crystal to detector distance,
(ii) the optimal intensity of the X-ray beam and (iii) the minimal total angle the crystal has to be
rotated about in order to record a complete dataset comprised of all the crystal’s unique reflections.
2.2.5.7 Data processing
Data processing of the raw data (recorded images) obtained in Section 2.2.5.6 is performed in three
subsequent steps: Indexing, integrating and scaling (see subsequent sections). The objective of all
of these steps is to obtain a list of all measured reflections, in which every reflection is properly
indexed and is assigned a consistent intensity.
2.2.5.7.1 Indexing
Indexing is performed by using computer programs that search the collected data frames for
reflections and then assign hkl values to each one of them. Knowing the positions of the individual
reflections as well as the X-ray wavelength and the distance of the crystal from the detector allows
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the indexing program to determine the parameters of the unit cell by measuring the distances and
angles between the reflections. Therefore, at this stage one can already determine the crystal system
but not yet the space group of the crystal as to do so requires at least the raw intensities of the
individual reflections.
2.2.5.7.2 Integrating
The objective of the integration process is to assign a defined raw intensity to each recorded
reflection, many of which are actually redundant in a given dataset. This happens when, caused by
the rotation of the crystal during X-ray data collection, the same lattice point repeatedly hits the
Ewald sphere. Moreover, particular reflections may be distributed over more than one frame. These
reflections are called ‘partials’, whereas those that contribute to only one frame are called ‘fullies’.
Therefore, the first task for the indexing program is to identify the individual frames a single
reflection is recorded in. The second task of the indexing program is to analyze the reflections and
define their three-dimensional profile. In other words, the program defines which area (size and
shape) belongs to a reflection and which doesn’t (i. e. is background). During the actual integration
process, all partial and full reflections in each frame are fitted to the determined profile (profile
fitting), which means that only the reflection area (no matter if a partial or full reflection is
concerned) within the predefined profile is eventually added up to calculate the raw intensity of the
individual hkl reflection.
After the integration step a list of the observed hkl reflections (that still includes redundant
hkl reflections) and their corresponding raw intensities is obtained that can, in programs such as
XDS123, be analyzed in terms of systematic absences, regular patterns of reflections that are
missing (absent). Systematic absences are caused by certain internal symmetry elements (screw
axes) of the crystal’s unit cell. In combination with the determined Bravais lattice type systematic
absences can be used to determine the space group of the unit cell.
2.2.5.7.3 Scaling
The objective of the integration process is to determine the raw intensities of all recorded
reflections. Many of the recorded hkl reflections are symmetry related to each other and should
therefore theoretically exhibit the same intensity. However, this is usually not the case and instead
some variation in intensities of the symmetry related reflections is observed. These variations can
be caused by the (i) weakening diffraction of a crystal in the course of the experiment due to
radiation damage, (ii) changes in the intensity of the X-ray beam during the experiment, (iii)
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different X-ray path lengths through the crystal (crystal shape) and/or (iv) the presence of
anisotropy in the crystal itself. In order to correct for these intensity variations the scaling program
assigns scaling factors to each hkl reflection, which consequently results in a list of hkl reflections
with consistent intensities. However, the list still contains the redundant hkl reflections that were
already present in the list of reflections after the integration step. Therefore, as part of the scaling
process these redundant hkl reflections are merged to a single hkl reflection. This latter merging
step is a data reduction process and therefore sometimes called ‘reducing’. Eventually the output
file of the program consists of a table that contains a list of all unique hkl reflections as well as their
intensities. Furthermore, tables are generated whose statistical content can be used to define the
data quality (see Section 2.2.5.7.4) and the resolution limit of the data.
2.2.5.7.4 Data Quality
Several indicators are used to assess the quality of the data. As the quality of the measured
intensities decreases with increasing resolution all of the statistical indicators are calculated for
defined resolution bins. The data processing R-factors (reliability factors, also called residual
factor) measure quality as the ratio between the mean difference between the magnitudes of values
(A and A’) which should be the same (residual value) and the mean magnitude of the measured
value (A). The value obtained is a decimal number that is often expressed in % (e. g. 0.3 = 30 %).
Symmetry-related reflections should have the same intensity. In this respect Rsym (Equation 2-7)
assesses data quality by the difference in intensity between these symmetry-related reflections.
Equation 2-7
with
I intensity of the reflection hkl
ܫ mean intensity of symmetry-related reflections of a reflection hkl
i symmetry-related reflection to hkl
n number of independent measurements of the reflection hkl (multiplicity)
However, a serious disadvantage of Rsym is that its value increases when reflections are measured
several times, i. e. when the redundancy of the data is increased. This is counterintuitive as highly
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redundant data normally improves the quality of the data. Hence, Diederichs and Karplus
introduced the redundancy-independent R-factor, Rmeas (Equation 2-8)124.
Equation 2-8
with
I intensity of the reflection hkl
ܫ mean intensity of symmetry-related reflections of a reflection hkl
i symmetry-related reflection to hkl
n number of independent measurements of the reflection hkl (multiplicity)
Another important quality indicator is the ratio between the mean intensity I and the mean standard
deviation of intensities σI. The ratio I/σI is an intensity signal to noise ratio and decreases with
higher resolution. A resolution shell exhibiting an I/σI value of 2.0 - 3.5 is normally used as the
highest resolution shell (i. e. defines the resolution cutoff) unless other indicators such as the R-
factors described above argue against this. By plotting the natural logarithm of the mean intensity I
of a resolution shells against sin2θ/λ2 of the same shell, the latter term being an alternative way of
expressing the resolution of a shell, a Wilson plot can be derived125. Caused by solvent effects a dip
is observed at approximately 5 - 5.5 Å. However, beyond 4 Å the Wilson graph decreases linearly
and is only disturbed by secondary structure elements of the protein that can cause a positive peak
in the range between 3 - 3.5 Å. The negative slope of the Wilson graph is proportional to the
overall temperature factor (B-factor), which is a measure of the thermal motion within the unit cell.
Furthermore, the x-value at the intersection of the Wilson graph with the x-axis indicates the
approximate resolution limit of the recorded dataset.
Two other statistical parameters that indicate the quality of the data are called
completeness and redundancy and are described in Equation 2-9 and Equation 2-10, respectively.
ܥ݋݉ ݌݈ ݁݁ݐ ݊ ݁ݏݏ= ܰݑ݉ ܾ݁ ݎ݋݂ ݑ݊ ݅ݍݑ݁݁ݎ ݂݈ ݁ܿ ݅ݐ݋݊ ݏ݉ ݁ܽ ݏݑ݁ݎ ݀
ܶ݋ܽݐ ݈݊ݑ݉ ܾ݁ ݎ݋݂ ݑ݊ ݅ݍݑ݁݁ݎ ݂݈ ݁ܿ ݅ݐ݋݊ ݏ
Equation 2-9
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ܴ݁݀ ݑ݊݀ܽ݊ ܿݕ= ܶ݋ܽݐ ݈݊ ݑ݉ ܾ݁ ݎ݋݂ ݉ ݁ܽ ݏݑ݁ݎ ݀ ݁ݎ ݂݈ ݁ܿ ݅ݐ݋݊ ݏ
ܰݑ݉ ܾ݁ ݎ݋݂ ݑ݊ ݅ݍݑ݁݁ݎ ݂݈ ݁ܿ ݅ݐ݋݊ ݏ݉ ݁ܽ ݏݑ݁ݎ ݀
Equation 2-10
2.2.5.7.5 Matthews coefficient
The Matthews coefficient VM (also called packing parameter) is calculated as shown in Equation
2-11 and describes the volume [A3] within a unit cell that is occupied by protein126. While the
molecular weight (M) of the crystallized protomers (protein or protein complex) is known even
before a crystal is obtained, the unit cell volume (VEZ, calculated from the unit cell parameters) and
the number of asymmetric units (n, calculated from the space group) will only be known after the
unit cell and the space group have been determined. The only variable in the equation is the number
of protomers in the asymmetric unit (z). By trying out different integer numbers for z different VM
values are generated. Based on the comparison of the calculated VM values to VM values of already
solved crystal structures in a databank, a probability of the most likely z value can be calculated.
ெܸ = ܸܯ ∙ ݖ∙ ݊ Equation 2-11
with
VM Matthews coefficient [Å3/Da]
V unit cell volume [Å3]
M Molecular weight [Da]
z Number of protomers in asymmetric unit
n Number of asymmetric units per unit cell
Once a crystal structure is solved the number of protomers in the ASU can be determined and
therefore an accurately defined Matthews coefficient (VM) be calculated. Knowing the correct VM
value in turn allows one to calculate the solvent content of the crystal (Equation 2-12).
௦ܸ௢௟௩ = 1 − 1.23
ெܸ
Equation 2-12
with
Vsolv Solvent content of the crystal
VM Matthews coefficient based on structure determination
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2.2.5.8 Phasing
As described in Section 2.2.5.5, all atoms in the unit cell contribute to each of the many hkl
reflections recorded in a crystallographic data set. Expressed in mathematical terms, each recorded
hkl reflection and therefore each diffracted X-ray beam that causes this reflection, can be described
as a complicated periodic function that represents the sum (therefore called Fourier sum, F) of the n
superimposed individual periodic wave functions (called Fourier term, fhkl) that originate from each
of the n scatterers (i. e. each of the n atoms) in the unit cell. This mathematical relationship was
first found by J. B. J. Fourier and is described as a structure-factor equation in crystallography, the
mathematical expression of which is shown in Equation 2-13.
ܨ௛௞௟ൌ ෍ ௛݂௞௟
௡
௝ୀଵ
Equation 2-13
௛݂௞௟= ௝݂݁ ଶగ௜൫௛௫ೕା௞௬ೕା௟௭ೕ൯ Equation 2-14
with
Fhkl structure factor of reflection hkl (periodic wave generated by superimposition of waves fhkl)
fhkl atomic structure factor (waves created by individual atoms in the unit cell)
fj scattering factor of atom j (depends on the element the atom belongs to)
h,k,l reflection indices (represent three frequencies in each Fourier term)
i complex number
n number of all atoms in the unit cell
x,y,z Coordinates of atom j in the unit cell
In Equation 2-13 a structure factor Fhkl is described in terms of the diffraction contribution of each
individual atom in the unit cell to reflection hkl. A structure factor can also be described in terms of
the individual diffraction contribution of the electron density present in one infinitesimally small
volume element p of the unit cell that is centered at position (x,y,z).
ܨ௛௞௟= න
௏
݌(ݔ,ݕ,ݖ)݁ଶగ௜(௛௫ା௞௬ା௟௭)ܸ݀ Equation 2-15
with
Fhkl structure factor of reflection hkl (periodic wave generated by superimposition of waves fhkl)
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h,k,l reflection indices (represent three frequencies in each Fourier term)
i complex number
x,y,z Coordinates of volume element p in the unit cell
dV unit cell volume
Equation 2-15 allows one to describe the structure factors in a crystallographic data set in terms of
the electron density of the unit cell (Fourier analysis) and, this also works in the other direction,
which allows to describe the electron density of the unit cells in terms of the structure factors
(Fourier syntheses; see Equation 2-15). More generally, this reversible mathematical
transformation that connects the diffraction pattern (structure factors of the recorded reflections)
and the real object (the electron density) is called a Fourier transform.
݌(ݔ,ݕ,ݖ) = 1ܸ ෍ ෍
௞
෍
௟
ܨ௛௞௟
௛
݁ିଶగ௜(௛௫ା௞௬ା௟௭) Equation 2-16
with
p(x,y,z) electron density at position x,y,z
V the volume of the unit cell
Fhkl the structure factor amplitude of reflection hkl
h,k,l reflection indices (represent three frequencies in each Fourier term)
Equation 2-17 describes the electron density distribution inside the unit cell as a periodic function.
Note that due to the regular arrangement of the unit cells and their content in a crystal, also these
electron clouds can (just as the positions of the individual atoms) be described by a periodic
function. It is this periodic function of the electron density whose graphical representation is an
electron density map that essentially describes the surface properties of the atoms (or molecules) in
the unit cell, and therefore the molecular structure of the protein.
Since each structure factor represents a periodic function, one needs to know the (i)
amplitude, (ii) the frequency and (iii) the phase of each structure-factor in order to solve Equation
2-16. Unfortunately only the first two parameters can be determined from the obtained diffraction
data. The amplitude of the structure factor can be derived from the intensities of the observed
reflections (Equation 2-17), while its three frequency terms h, k and l are specified by the position
of the observed reflection. The phase information, however, is always lost when X-ray diffraction
data is collected on a detector, and therefore indirect methods were developed to solve this so-
called phase problem.
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ܫ௛௞௟= ݇ ∙ ܨ௛௞௟ଶ Equation 2-17
with
Ihkl the observed intensity of the reflection hkl
k constant
Fhkl the structure factor amplitude of the reflection hkl
In the easiest case one can estimate the phases of an unknown structure by using the phases from
structure factors of another protein, whose structure is already solved. However, in order for this to
work (i. e. for the phases to be similar enough), the model has to be highly homologous to the
unknown structure. This known structure is called the ‘phasing model’ or simply ‘model’. In a
computer-based two step search called molecular replacement (MR), the known structure is first
rotated (3 rotation dimensions) in Patterson space to search for the correct orientation and
subsequently translated in space (3 translation dimensions) in order to search for the correct
position of the unknown structure in the unit cell. The actual comparison of orientations between
model and unknown structure, i. e. the rotation search, is implemented by computing a rotation
function that evaluates the correlation between the Patterson map (named after Arthur Lindo
Patterson) of the unknown structure and the Patterson maps based on various orientations of the
model. A search solution is obtained when the orientation of the model in real space leads to a
Patterson map that correlates well with the Patterson map of the unknown structure. As there might
be several protomers with several orientations in the ASU also several rotation search solutions
may be found in the rotation search. However, to finally be able to superimpose the now properly
orientated model protomers correctly onto the unknown structure protomers, i. e. to find the right
location of the model protomers, the oriented model protomers have to be translated. This
translation search is implemented by computing the R-factor (see Section 2.2.5.9), which compares
the overall agreement between the amplitudes of the model structure factors with those of the
unknown structure. Again, as there might be several protomers with several locations in the ASU
also several translation search solutions may be found in the translation search. Now, distinct sets
of the found rotation and translation solutions can be used to superimpose the model structure upon
the protomer(s) in the ASU and therefore eventually allow to use the phases of the model structure
as the initial phases of the unknown structure in order to obtain the unknown structure’s electron
density map.
PHASER is one of the most commonly used computer programs to perform MR
operations100. To judge the quality of the found solution(s), PHASER uses two parameters, the log
likelihood gain (LLG) and the TF (translation function) Z-score. A high LLG indicates how much
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better the observed data can be described by the model compared to a random distribution of the
same atom. TF Z-score values indicate how likely it is that PHASER has found the initial phases to
solve the structure. As a guideline, TF Z-scores of 5-6, 6-7, 7-8 and above 8 indicate that is
unlikely, possible, probable and very likely that PHASER has solved the structure. If there is more
than one solution, i. e. more than one protomer in the ASU, the LLG and the Z-score should
increase with every additional solution.
With the initial phases determined by PHASER100, Equation 2-16 can now be solved in
order to calculate the desired electron density map (Fobs map) and display it with programs such as
Coot102. To minimize a potential model bias, however, not the Fobs map alone but a Fobs-Fcalc and a
2Fobs-Fcalc map are calculated and displayed on the screen. The electron density is model biased
because Fobs consists of measured intensities and frequencies from the data and phases from the
inaccurate model. However, an additional electron density map (Fcalc) can be calculated from the
model by performing a Fourier analysis. Subtracting this model map (Fcalc) from the model
influenced map Fobs will result in a so-called ‘difference map’ (Fobs-Fcalc) that emphasizes the errors
(i. e. the differences) between the current model and the true structure. Missing parts in the model
appear as positive electron density surface, while areas with misplaced model parts appear as a
negative electron density surface. The second map displayed on the screen on top of the difference
map (Fobs-Fcalc) is the 2Fobs-Fcalc map, which is model biased. The 2Fobs-Fcalc map basically shows
the features of the modeled molecule. For model building the 2Fobs-Fcalc and Fobs-Fcalc maps are
usually displayed at contour levels of 1σ and 3σ, respectively, where sigma is the electron 
background noise.
After initial phasing (e. g. using PHASER100) the electron density map is often very noisy
and difficult to interpret. To improve the initial phases and therefore the electron density map,
density modification methods are applied. Solvent flattening is based on the fact that the electron
density is generally high in regions where parts of the protein are present, while it should be low at
regions of disordered solvent. To perform solvent flattening a mask is generated that separates
protein from solvent. The average electron density in the solvent region is then subtracted from the
complete map which results in a less noisy electron density map with more detailed features of the
protein due to the improved signal to noise ratio. Another density modification is called non-
crystallographic symmetry (NCS) averaging. As mentioned before the asymmetric unit (ASU) is
the minimal unit of the crystal structure from which one complete unit cell can be generated by
application of all symmetry operations defined in the space group of the crystal. Nevertheless,
additional symmetry elements (NCS elements) can exist in the asymmetric unit that lead to the
superimposition of the protomer on itself. Assuming that the protomer structures are similar, these
NCS symmetry elements within the ASU can usually be used to average the molecules in the
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asymmetric unit, which like solvent flattening results in a better signal to noise ratio. This is
because the protein electron density signal is amplified due to the regular shape of the proteins,
while the solvent electron density signal is reduced due the disordered (non-regular shaped)
solvent.
2.2.5.9 Structure refinement
Structure refinement is an iterative process of cycles of real- and reciprocal space refinement steps,
during which one tries to obtain a more and more chemically and biologically accurate model of
the crystallized macromolecule.
The goal of the refinement process is to improve the agreement (i. e. minimize the
difference) between the calculated and observed structure factor amplitudes |ܨ௖௔௟௖| and |ܨ௢௕௦| by
optimizing the parameters of the overall model, which consists of (i) the atomic coordinates, (ii) the
occupancies, and (iii) the temperature factors (B factors) of each atom of the macromolecule as
well as atoms belonging to other ordered molecules (e. g. ordered water) and/or ions in the ASU.
Note that |ܨ௢௕௦| is available from the recorded data and that |ܨ௖௔௟௖| is obtained by a Fourier
transform of the current model. Mathematically, the refinement process is performed by fitting the
experimental data (|ܨ௢௕௦|) to a model |ܨ௖௔௟௖|, whose parameters are adjusted during the fitting
process in order to create a fit that deviates as little as possible from the experimental data. More
precisely, the fitting procedure relies on an algorithm, which optimizes parameter values by
minimizing the sum of the squared residuals (Equation 2-18). The residuals again are the difference
between the calculated |ܨ௖௔௟௖| and observed |ܨ௢௕௦| structure factor amplitudes.
Φ = ෍ ߱௛௞௟(|ܨ௢௕௦| − |ܨ௖௔௟௖|)௛௞௟ଶ
௛௞௟
Equation 2-18
with
φ sum of the squared residuals (squared residual = (|ܨ௢௕௦|-|ܨ௖௔௟௖|2))
Fobs observed hkl structure factor amplitude (based on data)
Fcalc calculated hkl structure factor amplitude (based on model)
ω optional weighting factor (reflects reliability of reflection hkl) 
The progress of refinement, i. e. the quality of the fit, is monitored by the so-called R (residual or
reliability) factor Rwork (Equation 2-19), which is either expressed as a decimal number or in
percent (e. g. 0.5 equals 50 %).
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R =
∑ ห|ி೚್ೞ|ି|ி೎ೌ ೗೎|ห
∑|ி೚್ೞ| Equation 2-19
with
R R factor (Rwork or Rfree depending on set of reflections used for Fobs)
Fobs observed hkl structure factor amplitude (based on data)
Fcalc calculated hkl structure factor amplitude (based on model)
Equation 2-19 implies that if the quality of the model is increased during a single refinement cycle
(that consists of a real- followed by a reciprocal refinement step), the Rwork should decrease. Initial
models usually result in Rwork values around 50 %, which is not far away from the theoretical
maximum value of 59 % that would be obtained from the same set of model atoms when randomly
distributed in the unit cell125. Well-refined models on the other hand exhibit Rwork values between
10 - 25 % depending on the quality of the dataset.
Care must be taken at this point not to overfit the data. Overfitting happens if too many
parameters are introduced into a model. This can be viewed as giving the fitting program more and
more options to combine parameter values in order to fit the data better. It is important to realize
that a fitting program does not care whether a determined parameter value makes sense but instead
it is interested in finding a combination of parameter values that (even if meaningless) will allow a
better fit of the data to the model (i. e. lead to a lower sum of the squared residuals). What prevents
overfitting is usually a high observable (independent reflections) to parameter ratio. While the
number of observables will not change for a given dataset the number of parameters depends on the
parameterization of the model. To judge at which ratio the overfitting actually starts another R
factor, the Rfree, was introduced that can be calculated in the same fashion as Rwork (Equation
2-19)127. For the calculation of Rfree a portion of 5 - 10 % of the overall reflections is set aside and
flagged as ‘free’. These ‘free’ reflections are not included in the crystallographic refinement
process. This means that the fitting program can adapt the model parameters (in number and value)
to the 90 - 95 % of the reflections, while the same is not possible with the ‘free’ reflections that are
basically hidden from it. Nevertheless a properly parameterized model after fitting also has to
properly predict the ‘free’ reflections. If after fitting the ‘free’ reflections are less well described by
the model this indicates overfitting. Therefore, the Rfree is a more unbiased estimate of the model
improvement during refinement and has to ideally decrease in the same manner as the Rwork. In the
final model eventually the Rwork and Rfree values should ideally not deviate more than 5 %.
To refine the parameters listed above in reciprocal space, different parameterization
methods such as rigid body refinement, simulated annealing, individual coordinate refinement,
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occupancy refinement and TLS (translation, libration screw) refinement are commonly employed.
During rigid body refinement proteins are viewed as entities that are slightly misplaced in
orientation and position. The rigid body refinement step essentially rotates and translates this entity
and thereby moves the model of the protein from its slightly misplaced to its correct position.
Simulated annealing is a mathematical procedure that consists of two steps. In the first step the
kinetic energy of the molecules that constitute the refinement model is significantly increased. This
allows the molecules or parts of them (e. g. the side chains of a protein or protein loops) to
significantly alter their positions and therefore to overcome the energy barriers of the local energy
minima they might be trapped in. When the kinetic energy is then reduced during the second step
of the simulated annealing procedure there will be an increased chance for the molecules to assume
their native conformations, i. e. the conformations with the lowest global energy128. The individual
coordinate refinement is different from the rigid body refinement as here the positions of misplaced
individual atoms and not the entire protein are corrected. The occupancy refinement takes into
account that individual atoms do not necessarily occupy a defined space to 100 %. This can for
example happen when an amino acid side chain takes up two or more alternative conformations.
Consequently, the presence of the side chain at either position over time is less than 100 %. The
TLS refinement is a form of B-factor refinement. The B-factor (also called temperature factor)
describes the vibrations and oscillations (i. e. the thermal movement) of individual atoms around
their central position and therefore accounts for the internal flexibility of the protein. This atomic
movement can be described most precisely by assigning anisotropic B factors to each atom.
However, this leads to a huge increase in the number of parameters (six parameters per atom)
compared to the assignment of isotropic B factors for each atom (one parameter per atom).
Therefore only high resolution datasets (<1.5 Å) justify an anisotropic B factor refinement, as only
in these datasets the ratio of observables to parameters remains high enough for reliable fitting.
However one can simulate the anisotropic movement of individual atoms by TLS refinement,
which is not limited to a certain resolution. In TLS refinement segments of the proteins are treated
as rigid bodies undergoing TLS (translation, libration, screw) vibrational motion.
The output from reciprocal space refinement consists of a file containing the refined model
coordinates, from which Fobs-Fcalc and 2Fobs-Fcalc electron density maps can be calculated. In the
next step these model coordinates and electron density maps are visualized by Coot102, one of the
most common programs for real space model refinement. After manual model building in Coot, the
modified coordinates are saved in a new coordinate file that is subsequently used in the next round
of reciprocal space refinement. The overall refinement progress is monitored by Rwork and Rfree and
the model building finished when both R-factors have converged.
M a t e r i a l s a n d M e t h o d s
84 | P a g e
2.2.5.10 Glycan modeling.
After the structure of the UL16mon-MICBshort complex was solved, the GlyProt104 online server was
used to model hybrid and complex glycans linked to the seven Asn residues with observed NAG
electron density in order to produce a realistic estimate of size and distribution of the glycan moiety
of native UL16.113
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3.2 Expression and purification of
complex
Efforts to obtain soluble UL16 protein after its expression as
proteins in E.coli failed. In case of His
could not be refolded (data not shown).
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shown). Taken together, these initial results suggested that the glycosylation of UL16 is important
for its solubility and that due to the inability to
(such as glycosylation), E.coli is no
3.2.1 Expression of UL16 in CV
During the early stages of the project
expressed in CV-1 cells (see Section
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Figure 3-6. Glycosylation state of UL16 express
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3.2.2 Deglycosylation of UL16 produced in CV-1 cells
Since even small glycan heterogeneity (see Sections 3.3.2 and 3.3.3) can turn out to be a major
obstacle in the attempts to crystallize a glycoprotein, the strong heterogeneity observed for the
CV-1 cell produced UL16 (Figure 3-6) would make it basically impossible to crystallize UL16 in
its fully glycosylated state. A common strategy to reduce the glycan heterogeneity of a
glycoprotein, which in turn increases the chances to obtain well-diffracting glycoprotein crystals, is
the employment of glycosidases such as PNGase F and Endo H. In order to test these two enzymes
in terms of their capabilities to efficiently deglycosylate CV-1 cell produced UL16, the latter was
separately incubated with both enzymes and the two samples subsequently analyzed by SDS-
PAGE.
Lane 1 of the reducing SDS-gel in Figure 3-7 shows CV-1 cell produced UL16 after
cleavage with PNGase F, while lane 2 shows the same UL16 after cleavage with EndoH. In case of
PNGase F cleavage (Figure 3-7, lane 1) two bands are observed, one at 33 kDa and one at 17 kDa.
The 33 kDa band represents PNGase F, while the 17 kDa band represents the completely
deglycosylated UL16 protein. In case of Endo H cleavage (Figure 3-7, lane 2) four dominant bands
at 27, 25, 20 and 18 kDa are observed. The 27 kDa band represents Endo H, while the 18 kDa band
represents the almost completely deglycosylated UL16 since after Endo H cleavage single NAG
residues remain attached to the glycosylated asparagine residues of the protein. These NAG
residues are the reason why the lowest UL16 band (18 kDa) after Endo H cleavage (lane 2 in
Figure 3-7) has a slightly higher molecular weight compared to the UL16 band (17 kDa) after
PNGase F cleavage (lane 1 in Figure 3-7) where UL16 is completely stripped of all glycans. More
interesting, however, is the presence of the 20 and 25 kDa bands (UL16 glycosylation states) after
Endo H cleavage (lane 2 in Figure 3-7), which could indicate the presence of complex-type glycans
at some of the UL16 N-linked glycosylation sites that cannot be cleaved by Endo H (see Section
4.1.1).
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Figure 3-7. Deglycosylation of UL16 by
produced, purified, untagged UL16 after cleavage with PNGase F (lane 1) and
bands corresponding to PNGase F, Endo H
Molecular weight standards (lane M) are marked on the left in units of kDa.
3.2.3 Expression of UL16 in CHO Lec 3.2.8.1 cells
An alternative approach to the use of glycosidases in order to reduce
of the glycan shell of a given glycoprotein
cells (see Sections 2.1.6.2 and 2.2.2
combination of different lectin (Lec) phenotypes (3, 2, 8 and 1
Golgi glycosyltransferase and two Golgi
produce hybrid or complex glycans in
Lec1 mutant: Deficient in N-acetylglucosaminyltransferase 1 (GlcNAc
catalyses the first committed step from oligomannose to hybrid and complex
N-linked glycans in the
Lec2 mutant: Exhibits reduced activity of CMP
acid into the Golgi.
Lec3 mutant: Exhibits a similar phenotype as the Lec2 mutants. However, their defect is
unknown.
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Endo H and PNGase F. Reducing SDS-PAGE showing CV
Endo H (lane 2)
and distinct UL16 glycosylation states are labeled accordingly.
the amount and heterogeneity
is the use of specific cell lines such as CHO Lec 3.2.8.1
)105. CHO Lec 3.2.8.1 cells are adherent cells
). They are deficient in at least one
nucleotide-sugar transporters, and are therefore not able to
their Golgi compartments.
-T1), the
Golgi apparatus.
-sialic acid transporters that transport CMP
-1 cell
. Protein
that feature a
enzyme that
-sialic
Lec8 mutant: Exhibits a reduced activity of UDP
galactose reduced transport of UDP
However, these mutations do not affect high
plus an additional variable number of
Lec 3.2.8.1 cells reduce the amount and heterogeneity of the glycan moiety by not p
hybrid and complex type glycans, some heterogeneity remains due to the variable number of
mannose residues of the high
CHO Lec 3.2.8.1 cells, stably
as the CV-1 cells, were eventually employed to produce
species. Note that if CHO Lec 3.2.8.1 cells
of a protein, which can be evaluated
CV-1 cells (full glycosylation is possible) with the glycosylation state of the same protein produced
by CHO Lec 3.2.8.1 cells (missing complex and/or hybrid glycans),
presence of hybrid and/or complex glycans
and dimeric forms of UL16
in Figure 3-8 after performing a non
dimeric forms of UL16 (after Fc
obvious that CHO Lec 3.2.8.1 produced
SDS-gel, which indicates a severely
surface of UL16.
Figure 3-8. Glycosylation state of UL16 expressed by CHO Lec 3.2.8.1 cells.
showing purified, untagged UL16 monomer and dimer species as observed when UL16 is expressed in CHO
Lec 3.2.8.1 cells (compare Figure
of kDa.
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-galactose transporters that transport UDP
-galactose into the Golgi.
-mannose glycans, which consist of two
5 to 9 mannose residues. Consequently even though CHO
-mannose glycans.
transfected with the same UL16-Fc construct
a more homogeneous UL16
are observed to have an effect on the glycosylation state
by comparing the glycosylation state of
this
on the surface of the native protein
(after Fc-tag cleavage) produced by CHO Lec 3.2.8.1 cells
-reducing SDS-PAGE. When compared to
-tag cleavage) produced by CV-1 cells (
UL16 has narrower and less smeary
(hybrid and complex type) reduced
3-6). Molecular weight standards (lane M) are marked on the left in units
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-
NAG residues
roducing
(see Section 2.2.3.5.1)
glycoprotein
a protein produced in
strongly indicates the
105. The monomeric
are shown
the monomeric and
Figure 3-6), it becomes
protein bands on the
glycan moiety on the
Non-reducing SDS-PAGE
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3.2.4 Subcloning of UL16-Fc expressing CHO Lec 3.2.8.1 cells
As individual cells after transfection
protein expression, it is advisable to isolate individual clones and
levels (see Section 2.2.2.7). Usually this is done by ELISA
techniques, which allow for an exact
established Fc-ELISA was available in the laboratory at the time a
was performed (see Section 2.2.2.7.1
The outcome of such a pull-down assay can
expresses UL16-Fc, a protein band of about 60 kDa should be found on
conditions (Mw of glycosylated UL16
35 kDa; Mw of single chain Fc: 25 kDa)
isolated clones (and the polyclonal cells
cells) and therefore indicates a positive expression of UL16
band visible in each lane of the SDS
belongs to a protein of the serum containing cell culture supernatant that b
the Protein A/G beads (data not shown).
tested clones and the polyclonal cells. However, the
to UL16-Fc differed among the clones.
prominent UL16-Fc band it was used for
Figure 3-9. Subcloning of UL16-Fc expressing CHO Lec 3.2.8.1 cells.
result of a Protein A/G pull down of UL16
3.2.8.1 clones. The label on top of each lane corresponds to th
‘poly’ label refers to a polyclonal population of UL16
weight standards (lane M) are marked on the left in units of kDa.
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and initial selection can have different phenotypes in terms of
probe their protein
(enzyme-linked immunosorbent assay)
quantitative evaluation of the expression level.
Protein A/G pull
) to qualitatively determine the level of UL16-
then be easily evaluated by SDS-PAGE.
such a gel under reducing
mon from CHO Lec 3.2.8.1 cells based on SDS
. Indeed, Figure 3-9 shows a 60 kDa band
obtained after initial selection of the stably transfected
-Fc in each case. The second
-PAGE in Figure 3-9 is not related to UL16
inds non-
The intensity of the 70 kDa band was similar
intensity of the 60 kDa band that corresponds
Since clone 05 (lane 05 in Figure 3-9) showed the most
the subsequent expression rounds of UL16-
Reducing SDS-PAGE
-Fc from cell culture supernatants produced by distinct
e label of the individual clone analyzed. The
-Fc expressing CHO Lec 3.2.8.1 cells.
expression
Since no
-down assay
Fc expression.
If a clone
-PAGEs:
for each of the
70 kDa
-Fc and rather
specifically to
for all four
Fc.
showing the
CHO Lec
Molecular
3.2.5 UL16-Fc purification by
After UL16-Fc clone 05 had been
expression, its cell population was
scale protein production (see
culture supernatant had been
chromatography (see Section
Protein A-mediated UL16
containing cell culture supernatant
Äkta prime system and washed
absorbance at 280 nm (A
then eluted in one step with 100 %
collected during the entire elution period
chromatogram (Figure 3-
contained high amounts of relatively pure
concentrated sample was then
Fc-tag (see Section 2.2.3.5.3
Figure 3-10. AC purification of UL16
cells) purification by AC using a
samples eluted from the column
the running buffer. Fractions that were subsequently analyzed by SDS PAGE are highlighted in red.
through. (B) Reducing SDS-PAGE showing the highlighted fractions from panel A.
lane corresponds to the analyzed fraction number
left in units of kDa. The UL16
Irmgard Hähnlein-Schick.
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Protein A affinity chromatography
identified as the most promising clone
scaled up significantly in order to set up
Section 2.2.2.2). After about 5 - 10 liters of UL16
collected, UL16-Fc was purified via
2.2.3.5.3). Figure 3-10A shows a typical chromatographic run of
-Fc purification. After loading the Protein A
by means of a peristaltic pump, the column was transferred to an
extensively with Protein A binding buffer
280) reached baseline (Figure 3-10A). The column
Protein A elution solution (Table
, and those that corresponded to A
10A) were analyzed by SDS-PAGE (Figure
UL16-Fc and were pooled
filtered and subjected to thrombin cleavage in order to remove the
).
-Fc. (A) Chromatogram of the UL16-Fc (produced by
Protein A HP column. The solid black line shows the A
, while the green line indicates the percentage of Protein A elution
. Molecular weight standards (lane M) are marked on the
-Fc purification and the SDS PAGE shown in this figure w
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in terms of UL16-Fc
roller bottles for large
-Fc containing cell
Protein A affinity
a
column with UL16-Fc
(Table 2-16) until the
-bound UL16-Fc was
2-16). Fractions were
280 peaks in the
3-10B). Fractions 8-14
and concentrated. The
CHO Lec 3.2.8.1
280 absorption of
solution in
FT: flow
The label on top of each
ere performed by
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3.2.6 UL16 purification by Protein A
chromatography
After thrombin cleavage, the protein
protein, the cleaved Fc-tag, and thrombin. To remove the l
diluted in Protein A binding buffer (
directly followed by a benzamidine column.
run of this type. Fractions were collected during the entire run and those fractions that
corresponded to A280 peaks in the chromatogram (
(Figure 3-11B). As UL16 lacks an Fc
consequently found in the flow-through (
peak (corresponding to UL16) had
together from the Protein A HP and
3-11B) with 100 % Protein A elution
pooled, concentrated and filtered flow
strategy efficiently separates UL16 from the
and thrombin and is therefore suitable to obtain highly purified UL16
3-11B). The fact that a thrombin band
lane 2 (eluate sample) of Figure 3
thrombin used for UL16-Fc digestion
Figure 3-11. AC purification of UL16.
of CHO Lec 3.2.8.1 cell produced UL16
in combination with a Benzamidine FF
eluted from the columns, while the green line indicates the percentage of
running buffer. Fractions that were subsequently analyzed by SDS PAGE are highlighted in red. FT: flow
through. (B) Non-reducing SDS-PAGE of the pooled FT (lane 1) and eluate (lane 2) fractions highlighted in
panel A. UL16 containing FT samples were pooled, concentrated and filtered. Molecular weight standards
(lane M) are marked on the left in units of kDa.
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and benzamidine affinity
solution consisted of three components (Figure 2
atter two components, the
Table 2-16) and passed over a Protein A column
Figure 3-11A shows a representative chromatographic
Figure 3-11A) were analyzed by SDS
-tag it cannot bind to the Protein A HP column and was
see lane 1 in Figure 3-11B). Once the A280
again reached baseline, the Fc-tag and thrombin were eluted
Benzamidine FF columns in one step (see lane 2 in
solution (Table 2-16). A non-reducing SDS
-through and eluate samples shows that this
cleaved Fc-tag (compare lane 1 and 2 in
(shown in lane
(Mw of bovine thrombin protease: 37 kDa) is not visible
-11B is most likely due to the relatively small amounts of
.
(A) Chromatogram of the UL16 purification after thrombin cleavage
-Fc by affinity chromatography (AC) using a Protein A HP
column. The solid black line shows the A280 absorption of samples
Protein A elution
-7): the UL16
solution was
that was
-PAGE
flow-through
Figure
-PAGE of the
purification
Figure 3-11B)
1 in Figure
in
column
solution in the
3.2.7 Monomeric and dimer
As is readily visible from
UL16 produced in CHO Lec 3.2.8.1 cells
dimeric (UL16dim) protein
Interestingly, the dimer band completely disappears when the UL16 sample
reducing (i. e. β-ME containing) SDS sa
where lane 1 of the SDS-
reducing SDS sample buffer, while lane
and 60 kDa, respectively,
that the UL16 dimer only
dimer consists of two disulfide linked
the question if both UL16 species are active in terms of MICB
Figure 3-12. Monomeric and dimeric forms of
monomer and dimer mixture (UL16
containing SDS sample buffer
units of kDa.
3.2.8 The monomer represents the active form of UL16
To determine which UL16 species is active
mixture of UL16mon and UL16
analyzed by separately applying
connected to a SMART FPLC system. The chromatographic runs
R e s u l t s
ic forms of UL16
lane 1 of the non-reducing SDS-gel shown in
consists to equal parts of a monomeric
species that exhibit molecular weights of 35 and
mple buffer. This observation is also shown
gel shows one UL16 band (UL16mon) at 35 kDa
2 shows two UL16 bands (UL16
after incubation with non-reducing SDS sample buffer. The
exists under non-reducing conditions strongly suggests that the
UL16 monomers. These observations
binding.
UL16. SDS-PAGE gel showing the same
mon/dim) after incubation with (lane 1) and without (
(Table 2-21). Molecular weight standards (lane M) are marked on the left in
in terms of MICB binding, samples
dim, (ii) MICBlong and (iii) a mixture of all
each of the three samples to a Superdex 75
and corresponding non
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Figure 3-11B, purified
(UL16mon) and
60 kDa, respectively.
is incubated with
in Figure 3-12,
after incubation with
mon and UL16dim) at 35
observation
UL16
, of course, give rise to
sample of a UL16
lane 2) β-ME 
comprising (i) a
three proteins were
PC 3.2/30 SEC column
-reducing
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SDS-gels are shown in Figure 3-13. The chromatogram of the UL16mon/dim sample (black color code
in Figure 3-13) shows two peaks with maxima at 102 min (see also fractions 30 and 31in panel A)
and 108 min (see also fractions 34 and 35 in panel A). The peak at 102 min corresponds to UL16dim
while the peak at 108 min corresponds to UL16mon. Although the theoretical size of MICBlong (Mw:
32.7 kDa) equals the size of the glycosylated UL16 monomer produced in CHO Lec 3.2.8.1 cells
(Mw: 35 kDa; Figure 3-13), MICBlong elutes (red color code in Figure 3-13) at 120 min (see also
fractions 40 and 41 in panel C) and therefore much later than UL16mon (t=108 min). A possible
explanation for this observation could be that MICBlong has a shape that, compared to glycosylated
UL16mon, allows it to better access the pores of the SEC matrix, which in turn would lead to
MICBlong being retained longer on its way through the column. Alternatively it is also possible that
MICBlong interacts non-specifically with the column matrix, which would also result in elevated
elution times. However, when MICBlong was incubated together with a mixture of both UL16
species (green color code in Figure 3-13) the MICBlong peak at 120 min disappeared (compare red
and green chromatograms in Figure 3-13). Instead, MICBlong was now found in fractions 31-34
(panel D in Figure 3-13), which correspond to an elution time of about 105 min that lies between
the elution times of UL16mon (t=108) and UL16dim (t=102). These results strongly indicate that
MICBlong only bound the UL16 monomer as otherwise a more significant shift of the complex peak
(green chromatogram in Figure 3-13) and MICBlong itself (panel D in Figure 3-13) to shorter elution
times should have been observed. Therefore, one can conclude that only the UL16 monomer is
active in terms of MICBlong binding. However, the questions remain what causes the dimerization
of the UL16 monomers and why the dimer is unable to bind NKG2D ligands such as MICB.
Figure 3-13. UL16mon-MICB
comprised of (i) UL16mon-MICB
(iii) MICBlong (red curve) when analyzed by analytical
connected to a SMART FPLC system
from the column. The inlay shows an enlarged area of the
fractions of the chromatograms
colored according to the color code of the chromatograms shown in panel A.
corresponds to the analyzed fraction number.
units of kDa.
3.2.9 Standard methods fail to separate the UL16 monomer from the dimer
In order to crystallize a protein species (i. e. a
homogeneous as possible
presence of significant amounts of
UL16mon-MICBlong complex
R e s u l t s
long complex formation monitored by SEC. (A) Chromatogram
long complex plus UL16dim (green curve), (ii) UL16
SEC using a Superdex
. In each case, the curves show the A280 absorption of
presented chromatograms. (B
shown in panel A, analyzed by non-reducing SDS-
The label on top of each lane
Molecular weight standards (lane M) are marked on the left in
single protein or a protein complex)
to facilitate crystal growth and proper crystal packing
inactive UL16 dimers in a
sample would most likely hamper the formation of well
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s of samples
mon/dim (black curve) and
75 PC 3.2/30 column
samples eluted
-D) A280 peak
PAGE. The gel frames are
it should be as
. It follows that the
UL16 monomer or a
-diffracting
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crystals. Therefore it was tried with different methods to separate the inactive UL16 dimer from the
active UL16 monomer. As described in the previous section, Figure 3-13 shows a SEC run using a
Superdex 75 PC 3.2/30 column connected to a SMART FPLC system. As the flow rate was set to
10 µl/min this setup represented the highest analytical SEC resolution that could be reached in our
laboratory at the time of the experiment. The red curve represented the chromatogram of MICBlong,
while the black and green curves represented the chromatograms of a UL16mon/dim sample and a
UL16mon/dim sample incubated with MICBlong (Figure 3-13), respectively. One can easily see that,
even when an analytical high resolution SEC column in combination with an extremely low flow
rate was used, UL16 monomer and dimer (black chromatogram in Figure 3-13) could not be
completely separated. Therefore, it is more than likely that a preparative SEC to separate the UL16
monomer from the dimer will not be very successful. Indeed, when this was tried by means of a
preparative Superdex 75 10/300 GL SEC column only one peak, comprised of two overlapping
peaks from the UL16 monomer and dimer, was obtained (data not shown). Since UL16 monomer
and dimer are not directly separable in this way, one could envision a SEC that would separate the
UL16mon-MICBlong complex from UL16dim after incubation of the UL16mon/dim mixture with
MICBlong. However, as can be seen from the single peak of the green chromatogram in Figure 3-13,
which corresponds to a mixture of UL16mon-MICBlong complex and UL16dim, also this attempt fails
as the UL16 dimer and the UL16mon-MICBlong complex are too similar in size and therefore elute
from the SEC column at the same time. A similar result was obtained with the UL16mon-MICBshort
complex (Figure 3-14). Therefore one can conclude that SEC is not a suitable method to separate
(i) UL16mon, (ii) the UL16mon-MICBlong complex or (iii) the UL16mon-MICBshort from the UL16
dimer.
In addition to SEC, also cation and anion exchange chromatography (IEX) failed to
separate the UL16 monomer from the dimer (data not shown). Further attempts aimed at reducing
the intermolecular disulfide bond between the UL16 dimer protomers with reducing agents such as
DTT, β-ME or 2-mercaptoethanolamine (2-MEA) were also not successful as under all reducing 
conditions that were tested not only the intermolecular disulfide bond of the UL16 dimer but also
the intramolecular disulfide bonds of the already existent and dimer-derived UL16 monomers were
apparently reduced (data not shown).
Figure 3-14. UL16mon-MICB
comprised of (i) UL16mon-MICB
(iii) MICBshort (red curve) when analyzed by analytical SEC using a
connected to a SMART FPLC system. In each case the curves show the A
from the column.
3.2.10 Ni-NTA purification of the UL16
Chromatographic methods
UL16 monomer or from
Therefore, a new strategy was devise
complex based on the ability of MICB
fused His6-tag (see Section
with an excess amount of purified MICB
component solution comprised of
(‘free MICBlong’), and (iii)
buffer (Table 2-15) and then passed over
UL16dim does not have a His
UL16dim was found in the
lane 1 in Figure 3-15C). This was not the case for
amounts of free His-tagged MICB
column via the His6-tag provided by MICB
NTA) HP column with elevated
Figure 3-15B and lane 2 in
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short complex formation monitored by SEC. (A) Chromatograms of samples
short complex plus UL16dim (green curve), (ii) UL16
Superdex 75
280 absorption of samples el
mon-MICBlong complex
such as SEC and IEX had failed to separate the UL16
the UL16mon-MICBlong complex, respectivel
d to separate the UL16 dimer from the UL16
long to bind to a Ni-NTA column by means of its N
2.2.3.5.4 and Figure 2-6). Briefly, UL16mon/dim
long (see Sections 2.2.3.4 and 3.1), which r
(i) UL16mon-MICBlong complex, (ii) non
UL16dim (see Figure 2-6). This solution was diluted in Ni
a HisTrap (Ni-NTA) HP column
-tag that would allow it to bind to the HisTrap (
flow-through accordingly (Figure 3-15A, lane 13 in
the UL16mon-MICBlong
long, both of which bound tightly to the
long and which had to be eluted
concentrations of imidazole (Figure 3-15
Figure 3-15C). It was also observed that the protein
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mon/dim (black curve) and
PC 3.2/30 column
uted
dimer from the
y (see Section 3.2.9).
mon-MICBlong
-terminally
mixture was incubated
esulted in a three
-UL16-bound MICBlong
-NTA binding
(Figure 3-15A). Since
Ni-NTA) HP column,
Figure 3-15B and
complex and the excess
HisTrap (Ni-NTA) HP
from the HisTrap (Ni-
A, lanes 43, 45, 47 in
band on the SDS-
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gel corresponding to UL16mon was rather faint
SDS sample buffer while the band was
reducing SDS sample buffer (compare lanes 43, 45, 47 in
3-15C).
Figure 3-15. IMAC purification of the UL16
UL16mon-MICBlong purification by IMAC using a
the A280 absorption of samples eluted from th
imidazole in the running buffer. Fractions that we
red with the corresponding fraction numbers
in panel A. The label on top of each lane corresponds to the analyzed fraction number
SDS-PAGE of the same samples shown in
containing fractions 39 - 50 were pooled
on the left in units of kDa.
3.2.11 SEC purification of the glycosylated UL16
To separate the excess amount of free MICB
SEC step using a Superdex 75 10/300 GL
shown in Figure 3-16A and shows two almost completely separated peaks at
32.5 min (Peak-2). Fractions were collected during the entire run.
and non-reducing gels shown in Figure
complex, while Peak-2 corresponded to free MICB
band is poorly visible under non-reducing conditio
R e s u l t s
when samples had been incubated with non
better defined when samples had been incubated with non
Figure 3-15B with lane 2 in
mon-MICBlong complex. (A) Chromatogram of the
HisTrap (Ni-NTA) HP column. The solid black line shows
e column, while the green line indicates the increase of
re subsequently analyzed by SDS-PAGE are highlighted
labeled. (B) Reducing SDS-PAGE of the fractions
. (C)
panel B (indicated by green arrows). UL16mon-MIC
and concentrated. Molecular weight standards (lane M) are marked
mon-MICBlong complex
long from the UL16mon-MICBlong complex
column was employed. The resulting chromatogram
29.5 min (Peak
As can be seen from the red
3-16B, Peak-1 corresponded to the UL16
long. It was also observed again that the UL16
ns (left gel in Figure 3-16B), while it
-reducing
-
Figure
in
highlighted
Non-reducing
long complex
, an additional
is
-1) and
ucing
mon-MICBlong
mon
was clearly
visible under reducing conditions (
samples were pooled, concentrated and filtered before they were used for
samples were treated similar
4 °C and later used in a new
Figure 3-16. SEC purification of the UL16
UL16mon-MICBlong complex purification by SEC using a
line shows the A280 absorption of samples eluted from the column. Fractions of the chromatogram that were
subsequently analyzed by SDS
labeled. (B) Non-reducing (left) and reducing (right) SDS
label on top of each lane corresponds to the analyzed fraction number
containing fractions are indicated below the gels. Molecular weight standards (lane M) are marked on the left
in units of kDa.
Figure 3-17A shows an analytical
3-16) performed with a Superdex
SEC run resulted in a single symmetric
were analyzed by reducing SDS
MICBlong complex (Figure
to purify the UL16mon-MICB
75 column was successful.
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right gel in Figure 3-16B). The UL16
ly but instead of being used for crystallization trials
round of UL16mon-MICBlong complex formation
mon-MICBlong complex. (A)
Superdex 75 10/300 GL
-PAGE are highlighted in red with the corresponding fraction numbers
-PAGE of the highlighted fractions in panel A. The
. UL16
SEC run of the purified UL16mon-MICB
200 PC 3.2/30 column connected to a SMART
A280 peak at 30.5 min (Figure 3-17A
-PAGE and found to contain pure, homogeneous UL16
3-17B). This proved that the abovementioned chromatographic
long complex by means of a Ni-NTA column followed by a
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mon-MICBlong complex
crystal setups. MICBlong
they were stored at
and purification.
Chromatogram of the
column. The solid black
mon-MICBlong complex
long complex (Figure
FPLC system. The
). Fractions of the peak
mon-
strategy
Superdex
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Figure 3-17. Analytical SEC of the UL16
complex sample that was purified using the strategy
SEC using a Superdex 200 PC 3.2/30
chromatogram that were subsequently analyzed by SDS
fraction numbers labeled. (B) Non-reducing SDS
top of each lane corresponds to the analyzed fraction number
fractions are indicated below the gel. Molecular weight standards (lane M) are marked on the left in units of
kDa.
3.2.12 Ni-NTA purification of the UL16
As described in detail in Section 3.3.1
(purification see previous section
UL16-MICB complex crystals comprised
domain of MICB (termed MICBα1α2
crystals, a new MICB construct, MICB
was consisted only of the MHC class I
Expression and purification protocols that had been developed for MICB
work also perfectly for MICBshort, which is not surprising if the high similarity of both constructs is
considered. However, attempts to purify the UL16
devised for UL16mon-MICBlong were surprisingly not successful as the Ni
chromatography failed completely (
had been incubated to form the
UL16mon-MICBshort and (iii) free, non
Ni-NTA column, a large peak was observed in the flow through, while only a small peak was
observed when the column was elut
complete opposite of what was observed during the UL16
(compare chromatograms in Figures
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mon-MICBlong complex. (A) Chromatogram of a UL16
presented in Figure 3-16 when analyzed by analytical
column connected to a SMART FPLC system. Fractions of the
-PAGE are highlighted in red with the corresponding
-PAGE of the highlighted fractions in panel A
. UL16mon-MICBlong complex containing
mon-MICBshort complex
, crystallization trials with the UL16mon-MICB
) revealed that it was in principle possible to
of UL16mon and the MHC class I-like α1α2 platform
). To reproduce the coincidentally obtained UL16
short (see Section 2.2.3.4.1 and Figure 2-1), was designed
-like α1α2 platform-domain.  
long
mon-MICBshort complex with the same
-
Figure 3-18A). UL16mon/dim and an excess amount of MICB
three component solution consisting of (i) UL16
-UL16-bound MICB. When this solution was passed over
ed with an imidazole gradient (Figure 3-18A
mon-MICBlong Ni-NTA purification step
3-15A and 3-18A). As can be seen from the reducing SDS
mon-MICBlong
. The label on
long complex
produce
-
mon-MICBα1α2
that
turned out to
strategy as
NTA affinity
short
dim, (ii)
the
). This is the
-gel
in Figure 3-18B the flow
MICBshort proteins, while the elution peak contained
MICBshort. The most likely explanation
proteins that were found alongside UL16
UL16mon-MICBshort complex
Figure 3-18. IMAC purification of the UL16
UL16mon-MICBshort purification by IMAC using a
the A280 absorption of samples eluted from the column
imidazole in the running buffer. Fractions that we
red with fraction numbers indicated. (B) Non
The label on top of each lane corresponds to the analyzed fraction number
UL16mon-MICBshort complex and UL16
Molecular weight standards (lane M) are marked on the left in units of kDa.
3.2.13 HIC purification
The strategy that finally allowed for the separation of the
UL16 dimer involved the use of
2.2.3.5.6). Figure 3-19A shows a representative purification of the UL16 monomer using this type
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-through peak contained not only the UL16dim
a small amount of
of the observed results was that the UL16
dim in the flow-through actually represented
, which was for some reason unable to bind to the Ni
mon-MICBshort complex. (A) Chromatogram of the
HisTrap (Ni-NTA) HP column. The solid black line shows
, while the green line indicates the increase of
re subsequently analyzed by SDS
-reducing SDS-PAGE of the fractions highlighted in panel A.
. Fractions containing a mixture of
dim and those containing only MICBlong are indicated below the ge
of the UL16 monomer
active UL16 monomer from the
Phenyl-HP hydrophobic interaction columns (HIC
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but also UL16mon and
free non UL16-bound
mon and MICBshort
the
-NTA column.
-PAGE are highlighted in
l.
inactive
; see Section
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of chromatography that is based on the so
2.2.3.5.6 for details). The UL16 dimer species did not bind to the phenyl matrix and was found in
the flow-through (see lane 1 in Figure
bound tightly and was eluted in one step with 100 % of HIC elution buffer (
in Figure 3-19B).
Figure 3-19. HIC purification of the UL16 monomer.
separation from the dimer (UL16dim) by HIC using a
absorption of samples eluted from the column
buffer in the running buffer. The pink arrows mark the
eluate fractions (see labels on top of the
PAGE are highlighted in red. (B) Non
fractions highlighted in panel A. The label on top of each lane corresponds to the analyzed fraction number
(see panel A). Molecular weight standards (lane M) are marked on the left in units of kDa.
3.2.14 SEC purification of glycosylated UL16
To obtain the UL16mon-MICBshort complex,
with an excess amount of MICBshort
SEC (see Section 2.2.3.6). Figure 3-
complex purification. Two protein peaks
other. The non-reducing gel in Figure
the chromatogram represents the UL16
represents MICBshort. The UL16mon band is observed at 3
is running at about 25 kDa. Additional
band in lane 1 of Figure 3-20B were most likely caused by a gel
(Peak-1) were pooled, concentrated
trials (see Section 3.3.2). The samples containing free MICB
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-called ‘salting-out effect’ of proteins (see
3-19B). On the other hand, the UL16 monomer species
Table 2
(A) Chromatogram of the UL16 monomer (UL16
Phenyl HP column. The solid black line shows the
, while the green line indicates the percentage of
path of the conductivity curve. Flow-through (FT) and
chromatogram) that were pooled and subsequently analyzed by
-reducing SDS-PAGE of the pooled FT (lane 1) and eluate (
mon-MICBshort complex
purified UL16 monomer was first mixed and incubated
and the complex then separated from unbound
20A shows a representative SEC run of the UL16
are clearly visible and almost entirely separated from each
3-20B shows that the early protein peak (Peak
mon-MICBshort complex, while the late peak (Peak
2 kDa on the gel, while the MICB
bands above or below the UL16mon and MICB
artifact. The complex samples
to 15 mg/ml and after 0.2 µm filtration used for crystallization
short (Peak-2), were also pooled and
Section
-18; see lane 2
mon)
A280
HIC elution
SDS-
lane 2)
MICBshort by
mon-MICBshort
-1: 31 min) in
-2: 36 min)
short band
short protein
concentrated and the obtained pure
complex formation and purification.
Figure 3-20. Purification of
UL16mon-MICBshort complex purification by SEC using a
line shows the A280 absorption of samples eluted from the column.
were pooled and subsequently analyzed by
fractions highlighted in panel A.
weight standards (lane M) are marked on the left in units of kDa.
3.2.15 SEC purification of deglycosylated
To obtain the deglycosylated
and incubated with an excess amount of
(see Section 2.2.3.7). The deglycosylated
SEC of which a representative run is
Figure 3-21B, the main peak in
UL16mon-MICBshort complex, while the shoulder that elutes after th
MICBshort excess. The protein
be clearly identified. The
were pooled, concentrated
For details about the crystallization of the deglycosylated UL16
3.3.3.
R e s u l t s
MICBshort used in subsequent cycles of UL16
glycosylated UL16mon-MICBshort complex. (A)
Superdex 75 10/300 GL
The red highlighted
SDS-PAGE. (B) Non-reducing SDS-
Peak-1 and Peak-2 were analyzed in lanes 1 and
UL16mon-MICBshort
UL16mon-MICBshort complex, purified UL16 monomer was first mixed
MICBshort, followed by its deglycosylation with
complex was then separated from excess MICB
shown in Figure 3-21A. As shown on the non
the chromatogram (Figure 3-21A) represents the deglycosylated
e main peak represents
band that corresponds to the left shoulder of the main peak
deglycosylated UL16mon-MICBshort complex samples
to 15 mg/ml and, after 0.2 µm filtration, used for crystallization trials.
mon-MICBshort
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mon-MICBshort
Chromatogram of the
column. The solid black
fractions of each peak
PAGE of the pooled peak
2, respectively. Molecular
complex
Endo H
short by
-reducing gel in
unbound
could not
(fractions 32-38)
complex see Section
108 | P a g e
Figure 3-21. Purification of Endo H deglycosylated UL16
Endo H deglycosylated UL16mon-MICB
column. The solid black line shows the A
were subsequently analyzed by SDS-PAGE are highlighted in
highlighted in panel A. The label on top of each lane corresponds to the analyzed fraction number
weight standards (lane M) are marked on the left in units of kDa.
3.3 Crystallization of the UL16
3.3.1 Glycosylated UL16mon
Initial crystals of the glycosylated UL16
by mixing a 15 mg/ml complex solution 1:1 with crystallization solution
Light Screen (conditions 15 and 28
hanging drop vapor diffusion method (i. e. crystal drops were pipetted by hand).
comprised 0.2 M ammonium sulphate
PEG 8000, while condition 28 comprise
cacodylate trihydrate pH 6.5 and 15
R e s u l t s
mon-MICBshort complex. (A) Chromatogram of the
short complex purification by SEC using a Superdex 75 10/300 GL
280 absorption of samples eluted from the column
red. (B) Non-reducing SDS-PAGE of fractions
-MICB complex
-MICBlong complex
mon-MICBlong complex (see Section 3.2.11)
s provided by the
). Crystals grew at 20 °C over a period of 1 month using the
, 0.1 M sodium cacodylate trihydrate pH 6.5 and 15 % (w/v)
d 0.2 M sodium acetate trihydrate, 0.1 M sodium
% (w/v) PEG 8000. Glycosylated UL16mon-MICB
. Fractions that
. Molecular
were obtained
Hampton
Condition 15
long complex
crystals were fished, soaked in reservoir solution enriched with 25 %
frozen in liquid nitrogen prior to
tested at our X-ray home source
Therefore, to make sure
large crystal, which during handling broke into pieces (
mother liquor, diluted in reducing SDS sample buffer
Figure 3-22. Crystal obtained
In total, three samples were
purified UL16mon/dim sample of glycosylated UL16 produced in CHO Lec 3.2.8.1 cells (
purified MICBlong sample (lane
complex (lane 2). Since only tiny amounts of protein are usually present in a crystal, instead of a
standard Coomassie staining a silver staining (see Section
3-23 was performed. The protein bands
did indeed contain protein. By c
shown in lanes 1 (UL16mon
was present in the crystal,
bands (purple labels) at 50 (labeled MS
unrelated to the UL16mon
determine which proteins
cut out of the gel and sent for mass spec
(TOPLAB GmbH, Martinsried)
band failed, the protein that corresponded to the MS
R e s u l t s
glycerol
their X-ray exposure (see Section 2.2.5.4
, neither a protein nor a salt diffraction pattern c
the obtained crystals really consisted of UL16mon
Figure 3-22), was extensively washed with
, and finally analyzed by
from a protein solution containing UL16mon-MICBlong
analyzed by SDS-PAGE under reducing conditions
3) and the dissolved crystal of the glycosylated UL16
2.1.5.5) of the SDS
visible in lane 2 (Crystal) proved that the obtained crystals
omparing the protein bands from lane 2 with the positive controls
) and 3 (MICBlong) it became obvious however, that only UL16
while a band of MICBlong (32 kDa) was missing. Instead two additional
-1) and 20 kDa (labeled MS-2) were found that seemed
and MICBlong proteins used for setting up the crystals. In order to
were represented by the two additional protein bands, both bands were
trometric analysis. The latter was performed externally
. While the identification of the protein corresponding to the
-2 band was successfully identified as the
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, and then flash
). Unfortunately, when
ould be observed.
-MICBlong complex a
SDS-PAGE.
complex.
(Figure 3-23): A
lane 1), a
mon-MICBshort
-gel shown in Figure
(35 kDa)
MS-1
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MICB α1α2 platform-domain (Figure
expected UL16mon-MICBlong complex but a complex consisting of UL16
been deprived of its α3-domain (Figure
Figure 3-23. Crystal composition of the potential
samples comprised of (i) a mixture of
apparent UL16mon-MICBlong crystal (lane 2
and MS-2 were analyzed by mass spectrometry
in units of kDa. The gel was silver stained (see Section
3.3.2 Glycosylated UL16mon
Crystals of the (glycosylated) UL16
mixing a 15 mg/ml complex solution 1:1 with crystallization solutions provided by the
Crystal Screens 1 (condition 15) &
and 28). Crystals grew at 20 °C over a period of 1 month using the sitting drop vapor diffusion
method (i. e. crystal drops were pipetted by
conditions were extremely similar to those
results, conditions were further refined
essentially comprised 0.1 M of buffer at pH 6.5 (either sodium cacodylate or ME
0.2 M of salt (either ammonium sulphate
8000 or PEG monomethylether 5000
fished, soaked in reservoir solution enriched with
then flash frozen in liquid nitrogen prior to data collection (see
R e s u l t s
2-1). This means, that what had crystallized was not the
mon and a MICB
2-1).
UL16mon-MICBlong crystal. (A) Reducing SDS
purified UL16 monomer and dimer (lane 1), (ii) fragments of the
) and (iii) purified MICBlong (lane 3). Protein bands labeled MS
. Molecular weight standards (lane M) are marked on the left
2.2.3.2).
-MICBshort complex
mon-MICBshort complex (see Section 3.2.14) were obtained by
2 (condition 26) and the Hampton Light Screen (
crystallization robot). As expected, all
initially identified in Section 3.3.1. Based on these
with self-made fine screens. All identified
S monohydrate),
or sodium acetate) and 15 - 30 % of precipitant (PEG
). Glycosylated UL16mon-MICBshort complex c
cryoprotectant (various types were tested)
Section 2.2.5.4). A picture of the
that had
-PAGE of
-1
Hampton
conditions 15
identified
conditions
rystals were
, and
obtained crystals is shown in
10 Å, a resolution that could not be increased e
synchrotron radiation. Attempts to
essentially as described in
Figure 3-24. Crystals of the
UL16mon-MICBshort complex protein solution.
3.3.3 Deglycosylated
A pivotal step in obtaining well
deglycosylation of UL16mon
deglycosylated UL16mon-MICB
described in Section 3.3.2
mg/ml deglycosylated complex
ammonium sulphate, 0.1
UL16mon-MICBshort crystals grew at 4
vapor diffusion method (i.
fished, soaked in reservoir solution enriched with 15 % ethylene glycol, and then fl
liquid nitrogen prior to data collection (see
crystals diffracted to 1.8 Å
UL16mon-MICBshort crystals were obtained at 20 °C.
R e s u l t s
Figure 3-24. Crystals diffracted at our X-ray home source to about
ven when crystals were exposed
improve the resolution by dehydrating the crystals
Ref.129) were not successful.
UL16mon-MICBshort complex. The crystal shown was grown from a
UL16mon-MICBshort complex
-diffracting UL16mon-MICBshort complex crystals was the
, performed after complex formation with M
short complex were obtained under essentially the same
. The best diffracting UL16mon-MICBshort crystals
solution 1:1 with a crystallization solution containing 0.2
M sodium cacodylate pH 6.5, and 25 % PEG
°C over a time period of 4 months using the sitting drop
e. crystal drops were pipetted by crystallization
Section 2.2.5.4). Deglycosylated UL16
using synchrotron radiation. However,
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8 -
to high intensity
(performed
ICBshort. Crystals of the
conditions as
grew after mixing 15
M
8000. Deglycosylated
robot). They were
ash frozen in
mon-MICBshort
no deglycosylated
R e s u l t s
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3.4 SPR measurements of UL16-NKG2D ligand interactions
SPR experiments were performed to obtain the kinetic and steady-state binding parameters for
different UL16mon-NKG2D ligand interactions (Table 3-1). These experiments revealed an average
dissociation constant (KD) for the UL16mon-MICBlong complex of 67 nM (Figure 3-25A and C),
while the average KD value for the UL16mon-MICBshort complex was determined to be 66 nM
(Figure 3-25B and D), respectively. These KD values are virtually identical and therefore indicate
that the α3-domain of MICB is not involved in the binding to UL16. Furthermore, also various 
ULBP molecules were tested for their interaction with the UL16 monomer. The average affinities
for the UL16mon-ULBP1 (Figure 3-26B) and UL16mon-ULBP2 (Figure 3-26A and C) complexes
were shown to be 12 and 43 nM, respectively, whereas no interaction was observed between the
UL16 monomer and NKG2D ligands ULBP3, ULBP4 or ULBP5. The highest UL16 monomer
(analyte) concentration tested was 100 µM. One may wonder at this point why no steady-state
analysis was performed for the interaction between UL16 monomer and ULBP1 (Table 3-1 and
Figure 3-26B). This is because the low UL16 monomer concentrations did not reach the chemical
equilibrium during association, which is an important requirement to obtain reliable steady-state KD
values that can be subsequently compared to the KD values obtained from kinetic SPR experiments.
Table 3-1. Kinetic and affinity data determined by SPR113
Experimental setup Steady-State-Analysis Kinetic Analysis Average Affinity
Immobilized
(ligand)
in solution
(analyte) KD [M] KD [M] kon [M
-1s-1] koff [s-1] KD [M]
MICBshort (α1-2) 
UL16
66∙10-9 66∙10-9 0.82∙106 0.054 66∙10-9
MICBlong (α1-3) 68∙10-9 66∙10-9 0.68∙106 0.045 67∙10-9
ULBP1-Fc n.d. 12∙10-9 1.31∙106 0.016 12∙10-9
ULBP2-Fc 43∙10-9 42∙10-9 1.71∙106 0.072 43∙10-9
ULBP3-Fc
No SPR response was observed upon injection of 100 µM UL16ULBP4-Fc
ULBP5-Fc
Figure 3-25. ‘Kinetic and equilibrium SPR
of UL16 binding to covalently immobilized MICB proteins comprising domains
(A), and domains α1, α2 and
and data are representative of at least two separate experiments with similar results. Double
sensorgrams (shown in color) are overlaid with fits of a ‘
Corresponding residual plots below the sensorgrams show the kinetic
data points from curve fit values.
data used to determine averaged (AVG) equilibrium (Eq) response values (Eq
equilibrium analysis. (C,D) Equilibrium analysis of UL16 binding to
Averaged equilibrium response values (red squares) are plotted against inject
fitted to a ‘1:1 Langmuir isotherm
about setup details (black font) and measured parameters from kinetic (blue font) and equilibrium analysis
(red font).’113
R e s u l t s
analyses of UL16 interactions with MICB.
α
α3 (MICBlong). (B), Each individual analyte concentration was
1:1 binding with mass transfer
-fit range and absolute deviation (
The red arrow and the red highlighted area of the sensorgram series indicate
MICBshort
ed UL16 concentrations and
’ model (black line). The shaded boxes contain additional information
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(A,B) Kinetic analyses
1 and α2 only (MICBshort)
injected twice
-referenced
’ model (black lines).
∆) of 
-Response AVG) for
(C) and MICBlong (D).
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Figure 3-26. ‘Kinetic and equilibrium SPR
Kinetic analyses of UL16 binding to Protein A
Each individual analyte concentration was injected twice and data are representative of at least two separate
experiments with similar results. Double
‘1:1 binding with mass transfer’ model (black lines). Corresponding residual plots below the sensorgrams
show the kinetic-fit range and absolute deviation (
the red highlighted area of the sensorgram series indicate data used to dete
equilibrium (Eq) response values (Eq-Response AVG) for equilibrium analysis
UL16 binding to the ULBP2-Fc ectodomain
against injected UL16 concentrations and fitted to a ‘
boxes contain additional information about setup details (black font) and results from kinetic (blue font) and
equilibrium analysis (red font).’113
3.5 Structure determination of the UL16
3.5.1 Data collection
The data used for solving the crystal structure of the
were collected at the Swiss Light Source (SLS) in
X06SA) beamline and the PILATUS
R e s u l t s
analyses of UL16 interactions with ULBP1 and ULBP2.
-G captured (A) ULBP2-Fc and (B) ULBP1-Fc ectodomains
-referenced sensorgrams (shown in color) are overlaid with fits of a
∆) of data points from curve fit values. The red arrow and
rmine averaged (AVG)
. (C), Equilibrium analysis of
. Averaged equilibrium response values (red squares) are plotted
1:1 Langmuir isotherm’ model (black line). The shaded
-MICB complex
deglycosylated UL16mon-MICB
Villigen-Switzerland using the PX (also
6M detector. Setup details are shown in Table 3
(A, B)
.
short complex
called
-2.
Table 3-2. Data collection parameters
Parameter
Crystal to detector distance
Wavelength
Oscillation angle
Beam intensity
Frames per set
Number of data sets1)
Number of crystals used
1) Each data set was recorded from a different part of the crystal
3.5.2 Data processing
The three subsets of data
indexed and integrated with XDS
number of Bravais lattice types
spots (marked with an asterisk in
Table 3-3. Bravais lattice types consistent with observed reflections
Further analytic cycles with XDS
19 (i. e. space group P2121
P212121 were indeed not found (or had negligible intensities) among the observed reflections
CORRECT.LP output in Table
files (one from each data set) were scaled together using XSCALE
R e s u l t s
Value
325 mm
1.0013 Å
0.25 °
55 %
360 frames
3 sets
1 crystal
collected from the single UL16mon-MICBshort
123 (X-ray Detector Software). In each cas
that were consistent with the observed locations of the diffraction
Table 3-3).
123 favored a primitive orthorhombic lattice (oP) and space group
21), as the reflections that should be systematically absent in space group
3-4). Under this latter assumption the three XDS
123.
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crystal were separately
e, XDS suggested a
(see
123 data-output hkl-
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Table 3-4. Systematic absences.
Table 3-5 shows an excerpt of the
redundancy (based on number of observed
observed R-factor and the I/σI for each resolution shell and the complete data set
critical evaluation of these factors the resolution limit of the dataset was set to 1.8
R e s u l t s
overall statistical output from XSCALE123, revealing
and possible unique reflections), the completeness,
.
Å.
the
the
Based on the
Table 3-5. XSCALE output.
A summary of the data collection statistics from
XSCALE-refined unit cell parameters is shown in
Table 3-6. Data collection statistics
Statistic
Space group
No. of complexes in asymmetric unit
Unit cell dimension
a,b,c (Å)
α, β, γ (°) 
Resolution (Å)
Rmerge
I/σI 
Completeness (%)
Redundancy
Wilson Factor [Å2]
1) Highest resolution shell is shown in parenthesis
Based on the XSCALE statistical
by Dr. Georg Zocher) that (i)
and (ii) returned an overall B
XSCALE was also used to define 5 % of the
the calculation of the Rfree
Section 2.2.5.9). Finally, the XCALE data
programs XDSCONV and f2mtz.
R e s u l t s
Table 3-5, including the spa
Table 3-6.
113
Value
P212121
2
58.1, 104.2, 146.8
90, 90, 90
50-1.8
7.2 (49.4)1)
16.9 (3.4)
98.7 (97.5)
8.9 (6.9)
24.1
output also a Wilson plot (Figure 3-27) was generated
supported the resolution cutoff at about 1.8 Å
-factor of 25.4 Å2 (Figure 3-27)125.
total number of reflections in the data set for
factor that is used as a quality control during structure refinement (see
-output hkl-file was converted to an mtz
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ce group and the
(performed
(see Section 2.2.5.7.3)
-file using the
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Figure 3-27. Wilson plot of the UL16
generated by Dr. Georg Zocher (using the XSCALE output and a self
average intensities (y-axis) of reflections recorded at various defined resolutions (x
3.5.3 Matthews coefficient a
The use of (i) the Matthews probability calculator (see
3-6 (unit cell parameters and space group) and
protomers (Mw: 44,000 Da) allowed for the calcul
number of protomers (z) in the asymmetric unit (ASU)
UL16mon-MICBshort molecules share
was calculated to be 2.7 Å3/Da, which corresponds to a
3.5.4 Structure determination
The structure was solved by molecular replacement
unliganded MICB structure64 (PDB code
PHASER100 are listed in Table 3-7.
Table 3-7. PHASER input parameters
Parameter
Resolution for search
Number of (MICB) copies to search for
Mass of protomer (UL16mon-MICBshort)
R e s u l t s
mon-MICBshort dataset. The Wilson plot shown in this figure was
-written program)
-axis).
nd solvent content
Section 2.1.2.6), (ii) the data shown in
(iii) the molecular weight of the UL16
ation (see Section 2.2.5.7.5) of the
. The calculation indicated
one ASU. With two protomers/ASU, the Matthews coefficient
crystal solvent content of 54 %.
(MR) as implemented in PHASER
: 1je6) as search model. The search parameters used in
Value
50 - 2.5
2
44,000
and shows the
Table
mon-MICBshort
most likely
that two
100 using the
In total, PHASER100 found two solutions with
as listed in Table 3-8.
Table 3-8. PHASER solutions
Parameter
LLG
RF Z-core
TF T-score
In addition to statistical parameters, t
that contained the positions
in the ASU. Together with the mtz
initial electron density map could be displayed in Coot
Figure 3-28. Starting model of the UL16
MICBshort (yellow sticks) molecules present in the ASU overlaid with the corresponding 2F
mesh) and Fobs-Fcalc (green and red mesh) electron density maps at co
respectively. Also shown are the models of two MICB
positive electron density (green mesh,
UL16mon. Residual electron density is observed for other areas surrounding the yellow colored MICB
molecule. The figure was created
The initial density map (Figure
UL16 molecules as positive
also revealed that both UL16
noncrystallographic symmetry (NCS). After
averaging using RESOLVE
R e s u l t s
satisfactory LLG, RF Z-score and TF Z
Solution 1 Solution 1 + Solution
214 671
6.3 5.7
14.9 25.4
he PHASER100 output also consisted of a coordinate pdb
(and therefore the phases) of the two correctly placed
-file obtained after XDSCONV/cad/f2mtz (see
102.
mon-MICBshort complex after PHASER
100
ntour levels of
short symmetry mates (orange sticks). The large patch of
see highlighted area) on top of MICBshort
with Coot102.
3-28) already clearly showed the approximate location of the
electron density in areas adjacent to the UL16mon
mon-MICBshort protomers in the ASU are related by a two
phases were improved by solvent flattening and NCS
130 (performed by Dr. Georg Zocher), the Cα
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-score values
2
-file
MICB molecules
Section 3.5.2), an
. Model of one out of two
obs-Fcalc (blue
about 1.5 and 3.5 σ, 
indicates the position of
short
two
-MICBshort interface. It
-fold
chains of the two UL16
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molecules in close proximity to the UL16
3-29) to start building short stretches
Figure 3-29. Starting model of the UL16
MICBshort (yellow sticks) molecules present in the ASU overlaid with the corresponding 2F
mesh) and Fobs-Fcalc (green and red mesh) electron density maps at contour levels of
respectively. Also shown are the models of two
unoccupied electron density (blue mesh,
UL16mon. Almost no electron density
colored MICBshort molecule. The figure
After one round of refinement with Refmac,
(glycine) model building and refinement
produced by ArpWrp131 is shown in
and refinement using Coot102 and PHENIX
glycine residues were extended, and the glycines
residues as defined by the UL16 primary sequence
R e s u l t s
mon-MICBshort interface were defined well enough
of glycine residues (performed by Dr. Georg Zocher
mon-MICBshort complex after RESOLVE130. Model of one out of two
about
MICBshort symmetry mates (orange sticks). The
see highlighted area) on top of MICBshort indicates the position of
(black regions) is observed for other areas surrounding the
was created with Coot102.
ArpWrp131 (Version 7.0) was used for automated
(performed by Dr. Georg Zocher). The
Figure 3-30. In subsequent rounds of manual model build
101, respectively (see Section 3.5.5), the stretches of
were exchanged against the correc
(Figure 3-31).
(Figure
).
obs-Fcalc (blue
1.5 and 3.5 σ, 
large patch of
yellow
glycine model
ing
t amino acid
Figure 3-30. Glycine model of UL16
right corner) built by ArpWrp overlaid with the corresponding 2F
red mesh) electron density maps at contour levels of
model of MICBshort in the bottom left corner. The figure was created with Coot
Figure 3-31. Details of the initial UL16
UL16 glycine model (see Figure
(green and red mesh) electron density maps
built glycine residues, missing amino acid residues and missing amino acid side chains (e. g. of a tyrosine
residue) are marked with red arrows. The figure was created with Coot
R e s u l t s
mon obtained with ArpWrp131. Model of the UL16
obs-Fcalc (blue mesh) and F
about 1.5 and 3.5 σ, respectively. Also shown is the 
102.
mon glycine model obtained with ArpWrp131
3-30) overlaid with the corresponding 2Fobs-Fcalc
 at contour levels of 1 and 3 σ, respectively
102.
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mon glycine chain (top
obs-Fcalc (green and
. Magnified portion of the
(blue mesh) and Fobs-Fcalc
. Stretches of already
R e s u l t s
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3.5.5 Structural refinement
Reciprocal space refinement was performed with PHENIX101, and included rigid body refinement,
simulated annealing, individual coordinate refinement, occupancy refinement, and TLS refinement
of 26 TLS groups assigned by the TLSMD Server132. Real space refinement (i. e. model building)
was done with Coot102. The refinement progress was monitored throughout by the decrease of Rwork
and Rfree and by ensuring that the deviation between both R-factors would not exceed 5 %. The
final model had Rwork and Rfree values of 17.7 % and 21.3 %, respectively, and was validated using
PROCHECK100 and WHAT_IF133. Secondary structure elements were assigned with DSSP134.
Ramachandran statistics were obtained with Coot102 version 0.5. Structural figures were created
with PyMOL103. The complete refinement statistics are shown in Table 3-9.
Table 3-9. Refinement statistics113
Statistic Value
Resolution (Å) 50-1.8
No. reflections
measured 733339
unique 82272
Rwork 17.7
Rfree (test set of 5%) 21.3
No. of non-H atoms 5980
Protein 5084
Carbohydrates (NAGs) 196
PEG8000 49
Acetate 12
Water 639
Average isotropic B factor (Å2)
Protein main chain 28.0
Protein side chain 34.1
Carbohydrates (NAGs) 41.5
PEG8000 55.6
Acetate 65.0
Water 39.1
R.m.s deviations
Bond lengths (Å) 0.006
Bond angles (°) 1.057
Ramachandran regions 1)
most favorable (%) 97.4
allowed 2.6
outliers 0
1) Determined with Coot102 version 0.5
R e s u l t s
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3.6 The crystal structure of UL16
‘The UL16 ectodomain folds into a modified version of the immunoglobulin (Ig)-like domain
(Figure 3-32A). The presence of nine β-strands, arranged in two antiparallel β-sheets (formed by 
β-strands A, G, F, C, C’, C’’ and β-strands D, E, B, respectively) and a central disulfide bond 
linking β-strands B and F clearly classifies it as a variable (V-type) Ig-like domain32, 33, 35. In
contrast to classical V-type Ig domains, however, UL16 also has an additional N-terminal ‘plug’
(amino acids 27-50), formed by a two-stranded antiparallel β-sheet (β-strands X1 and X2) and a 
short 310-helix (Figure 3-32A). The plug covers the concave side of the AGFCC'C'' β-sheet and is 
covalently linked to the Ig-like core with a disulfide bond between β-strands X2 and F. The 
UL16mon-MICBshort complex was partially deglycosylated prior to crystallization, leaving only
single NAG molecules attached to glycosylation sites. While there is no evidence for O-linked
glycosylation, the electron density maps provide clear evidence for the presence of NAGs at seven
out of eight putative N-glycosylation sites (asparagines 35, 41, 68, 84, 95, 101 and 132). Six of
these seven asparagine residues (Asn41, 68, 84, 95, 101, 132) carry NAG residues that are clearly
defined by electron density (Figure 3-32A). While extra density is present at the seventh residue,
Asn35, this density is not well defined, and consequently no NAG residue was built at this location.
No extra electron density is observed in the vicinity of the eighth asparagine, Asn145, and thus this
residue is either not glycosylated or carries an especially flexible glycan moiety. Modeling
experiments show that native glycosylation would effectively shield much of the UL16 surface
from solvent (Figure 3-32B). In particular, the outward-facing AGFCC'C'' β-sheet and the 
N-terminal plug are expected to be mostly covered with glycans in the fully glycosylated protein.
By contrast, the solvent-exposed face of the DEB β-sheet is devoid of glycans and available for 
interactions with other proteins.’113
124 | P a g e
Figure 3-32. ‘Structure of UL16 in complex with MICB
The portions of UL16 belonging to the V
respectively35. Glycosylated asparagines (nitrogen atoms dark blue, oxygen atoms red) and attached
residues (yellow) are shown as ball-and
temperature factors and was therefore not included in the refinem
Structure of the UL16mon-MICBshort complex. UL16 is colored as in
order to visualize the native glycosylation of UL16, modeled glycans are shown in yellow as ball
models with a semitransparent surface.’
3.7 The crystal structure of MICB
‘The extracellular region of MICB consists of two structural domains, the
(MICBshort) and the C-type Ig-like α
members of NKG2D ligands, but not among members of the ULBP family
previously reported for the unliganded MICB
resembles MHC class I molecules, with two long parallel α
α2, arranged above an eight-stranded antiparallel
domains and secondary structure elements see
structure of the unliganded MICB ectodomain
unchanged upon engagement of UL16 (root
atoms). Although minor differences are seen within three surface
N-terminal helix (α0), the residues in these regions have elevated 
contact UL16.’113
R e s u l t s
short. (A), Ribbon tracing of the structure of UL16.
-type IgSF fold the N-terminal ‘plug’ are colored
-stick models. The grey NAG residue attached to Asn35 has high
ent. Disulfide bonds are shown in green. (B)
panel A, MICBshort is shown in orange. In
113
short
α1α2-platform domain
3-domain64. The α3-domain is present only in the MIC family
19, 20, 61, 63, 64
64, MICBshort folds into a structure that closely
-helices, contributed by domains α1 and 
β-sheet (Figure 3-32B; for nomenclature of
Figure 3-33). Comparison of MICB
64 shows that the platform domain remains essentially
-mean-square deviation of 1.4 Å for 172 common C
-exposed loops and a
temperature factors and do not
blue and red,
NAG
-and-stick
. As
short with the
α 
short
3.8 The UL16-MICB
‘UL16 primarily engages MICB
surface comprised of its DEB
provided by the DE-loop (connecting
C-terminus (Figure 3-33B and
Figure 3-33. ‘Amino acid sequences of NKG2D ligands, NKG2D, and UL16.
NKG2D ligands. Sequences of the
ULBP1, ULBP2, ULBP3, ULBP4, ULBP5 and ULBP6 are included in the alignment.
nomenclature of ULBP proteins is indicated. Secondary structure elements as observed in the structure of
MICB in complex with UL16 were assigned by DSSP
arrows (β-strands) below the
UL16 in the UL16mon-MICB
monomer (see Discussion and
structures20, 61. Residues shaded in green contact the green NKG2D m
MICA-NKG2D and ULBP3
substitutions between MICA and MICB in regions that contact UL16 in the
ULBP5 residue boxed in cyan was recently shown to be the major determinant for diminished binding
R e s u l t s
short interface
short via a predominantly hydrophobic, glycan
β-sheet and the adjacent β-strand A, with additional contacts
β-strands D and E) and four amino acids (aa 160
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NKG2D and UL16135. Disulfide bridges and corresponding cysteines are represented with magenta lines.
Gaps are indicated by (-). (B) Structural mimicry of UL16. Shown are relevant portions of the sequences of
the green human NKG2D monomer20, 61 (Figure 4-4A and B) and UL16. Secondary structure elements as
observed in the structure of MICB in complex with UL16 and MICA in complex with NKG2D20,
respectively, were assigned and represented as described in panel A. The five residues marked with
numbered black boxes below the sequence define the central binding motif that engages MICB or, in the case
of NKG2D, MICA20, in a similar manner (Figure 4-4C). Residues with the same number superimpose in
space, although they are located in different regions in the protein sequences. Residues shaded in yellow and
orange form contacts with MICA in the case of NKG2D20 and with MICB in the case of UL16, respectively.
NKG2D residues in red contact ULBP3 in the ULBP3-NKG2D complex61. Residues that augment the central
binding motif, performing similar functions in the UL16-MICB and NKG2D-MICA complexes are marked
with filled light red boxes below the sequence. An example is shown in Figure 4-4C. Disulfide bridges are
represented with magenta lines. Hexagons mark the seven UL16 asparagine residues linked with glycans as
observed in the UL16mon-MICBshort complex.’113
‘This surface interacts with the two long parallel helices at the top of the MICB α1α2 platform-
domain and the β5β6-loop connecting β-strands β5 and β6 of MICB (Figure 3-33A and Figure 
3-34), shielding an area of 2194 Å2 from solvent. With the exception of the MICB region that
corresponds to the peptide-binding groove in MHC class I proteins, the contact area contains few
interfacial solvent-filled cavities. The complex features good surface complementarity (Sc = 0.77)
and is highly curved (planarity = 4.0)136, 137. Its overall organization resembles a saddle with two
stirrups (UL16) that is mounted on horseback (MICB) (Figure 3-34A, see also Figure 3-32B). The
saddle is formed by the DEB β-sheet, whereas the stirrups are contributed by the DE-loop and the 
C-terminus on either side of the sheet. To facilitate discussion of interactions, the three regions of
the UL16-MICB interface were divided into three regions (A, B and C, Figure 3-34). Contact
region A, which is located at the center of the complex and mostly hydrophobic in nature,
contributes 54 % of the total contact area. Interactions predominantly involve residues within the
DEB β-sheet and β-strand A of UL16. Eight UL16 residues (Trp54, Leu56, Met59, Ile61, Ile63, 
Tyr125, Leu110 and Leu114) define a compact hydrophobic face that interacts with non-polar
regions of MICB residues in its central α3-helix. These interactions are augmented with a salt 
bridge between UL16 Asp112 and MICB Lys152 and a number of mostly water-mediated
hydrogen bonds (Figure 3-34B). Contact region B, with 23 % of the total contact area, is located
at one end of the DEB β-sheet and within the DE-loop of UL16. UL16 residues in this region 
contact several acidic residues (Glu64, Asp65 and Glu68) in the α1-helix of MICB, mostly via 
polar interactions (Figure 3-34C). Contact region C, which contributes 23 % to the total contact
area, is located on the other side of the UL16 saddle. Here, the C-terminus of the UL16 ectodomain
interacts with the β5β6-loop and the N-terminus of MICBshort via a mixture of hydrophilic and
hydrophobic contacts (Figure 3-34D). The overall architecture of the complex, with its large
contact area and substantial number of interactions between contacting residues, indicates tight
binding, which is in agreement with the obtained SPR data that place the affinity of
monomer for MICBshort at 66
Figure 3-34. ‘Interaction between UL16 and MICB.
from Figure 3-32. Also shown in the lower right corner of panel A is a schematic representation of the
‘saddle on horseback’ arrangement between UL16 and MICB. (B
and C of the complex. Nitrogen, oxygen and sulfur atoms are colored blue, red, and yellow, respectively.
Hydrogen bonds and salt bridges are represented with dashed green and red lines, respectively, and
hydrophobic contacts (distance
π-π interactions of two arginine guanidinium groups. Water molecules are shown as red spheres.
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4. Discussion
4.1 The UL16-MICB complex - purification and crystallization
obstacles
4.1.1 CV-1 cell produced UL16 is not suitable for crystallization
Deglycosylation is often a pivotal step in the process of obtaining high quality crystals of
glycoproteins. This is due to the observation that the glycans (as shown in Figure 3-6) are usually
extremely heterogeneous. Glycan heterogeneity means that the very same asparagine (Asn) residue
of a defined N-glycosylation recognition sequence (Asn-X-Ser/Thr) in the glycoprotein’s primary
sequence can carry glycan trees that vary for instance in (i) the glycan type (high-mannose, hybrid
or complex glycans), (ii) the presence of a core fucose and (iii) the number and length of the
polysaccharide branches.
A heterogeneous glycoprotein mixture (which is usually obtained after purification) can be
imagined as consisting of a common invariable core (the protein) and a highly variable shell (the
heterogeneous glycans). In order for a protein or glycoprotein to lead to the formation of high
quality, i. e. well-diffracting crystals, the individual molecules have to be regularly packed against
each other. Regular packing however is only possible if the surfaces of the molecules that are to be
crystallized are very similar and therefore allow for the regular formation of stable crystal contacts
when the individual molecules are arranged in the three-dimensional crystal lattice. It follows that
this regular packing and the formation of regular and stable crystal contacts will not be possible for
glycoproteins with their highly heterogeneous glycan shells. This can be a possible reason when
only poorly diffracting crystals (if any crystals at all) of glycoproteins are obtained. To remove the
heterogeneity, glycosidases are usually employed. Two of the most common glycosidases are
Endo H (Mw: 29 kDa) and PNGase F (Mw: 36 kDa). PNGase F virtually removes all N-linked
oligosaccharides (high mannose, complex and hybrid glycans) from glycoproteins, whereas
Endo H only removes high-mannose and hybrid N-linked glycans. Therefore the pattern of protein
bands that is visualized on a SDS-gel after a glycosylated protein has been cleaved with both
glycosidases under denaturing conditions can give valuable information about the presence of
complex type N-linked glycans. This kind of assay was performed with UL16 produced in CV-1
cells (Figure 3-6). As CV-1 cells were derived from monkeys, i. e. from close relatives of humans,
one can assume that the UL16 produced in this cell type carries a similar set of glycans as one
would expect from a human cell infected with HCMV.
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Although the UL16 heterogeneity can be reduced by Endo H (see lane 2 in Figure 3-6) at
least three UL16 glycoprotein species remain that will continue to make crystallization difficult and
would most likely require additional purification steps in order to isolate a single glycoform for
crystallization. The question arises now, why UL16 was not deglycosylated with PNGase F, as in
that case only one UL16 species (without any glycans at all) would have been obtained (see lane 1
in Figure 3-6).
This is because PNGase F hydrolyses the bond between the carbonyl group of the
asparagine side chain and the neighboring nitrogen atom that creates the glycosidic bond with the
first NAG residue of the glycan tree. Therefore the PNGase F enzymatic reaction always results in
the transformation of asparagine to aspartate residues when the glycans are cleaved off. Due to the
introduction of a negative charge by the aspartate, the structure of the protein may (locally or even
globally) change, which of course leads to the question of how much the protein core of a
PNGase F cleaved glycoprotein actually still resembles the native fold of the protein. Therefore,
Endo H is generally preferred for the deglycosylation of glycoproteins since after Endo H cleavage
one NAG residue remains attached to the N-linked asparagine residues of the protein, which not
only avoids possible structural changes in the protein but also allows for the direct identification of
asparagine sites that are actually glycosylated. In conclusion, due to the extreme and heterogeneous
glycosylation and the difficulties to effectively deglycosylate the protein with Endo H, CV-1 cells
are not very suitable to express UL16 protein that is supposed to be used for crystallization.
As a consequence and as outlined in Section 3.2.3, CHO Lec 3.2.8.1 cells, which are
deficient in a number of glycosyltransferases and Golgi nucleotide-sugar transporters, were
eventually employed to produce a more homogeneous UL16 glycoprotein species that was used
throughout in the attempts to crystallize the UL16-MICB complex105 (see Section 3.6, 3.7 and 3.8).
Note however, that the CHO Lec 3.2.8.1 produced UL16 monomer still exhibits a molecular weight
of 35 kDa (Mw of UL16 without glycans: 18.5 kDa), which shows that still about 50 % of the CHO
Lec 3.2.8.1 produced UL16 glycoprotein consists of glycans (Figure 3-8). These remaining glycans
are all of the high-mannose type as CHO Lec 3.2.8.1 cells only disable the synthesis of hybrid- and
complex type glycans (see Section 3.2.3). This and the results obtained from the deglycosylation
experiments of CV-1 produced UL16 (see above) suggest that when natively expressed in human
cells after viral infection, the UL16 protein is surrounded by a glycan layer consisting of high-
mannose type-, complex type- and likely also hybrid type glycans.
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4.1.2 The UL16 dimer is likely formed by locally misfolded UL16 monomers
After its purification (see Sections 3.2.5 and 3.2.6) CHO Lec 3.2.8.1 cell expressed UL16 consists
to equal parts of a monomeric (UL16mon) and a disulfide-linked dimeric (UL16dim) protein species
(see Section 3.2.7). Hence, the question was raised (see Section 3.2.8) what causes the dimerization
of the UL16 monomers. In order to provide an answer to this question, the UL16 structure, as
observed in the structure of the UL16mon-MICBshort complex, was analyzed in terms of cysteine
residues (Figure 4-1; see also Figure 3-33). As became apparent from the crystal structure of the
UL16mon-MICBshort complex (see Section 3.6), UL16 features a V-type Ig-like fold (Figure 4-1A),
which consists of two antiparallel β-sheets (the DEB-sheet and the AGFCC’C’’-sheet) that together 
form a β-sandwich. The surface exposed side of the DEB-sheet (Figures 4-1A and B) is comprised 
of a set of predominantly hydrophobic amino acid side chains and can therefore be considered as a
relatively large hydrophobic patch on the molecular surface of the UL16 monomer. Furthermore,
five cysteines are present in the Ig-like domain of the UL16 monomer, four of which contribute to
the formation of two disulfide bonds (green bonds in Figure 4-1B; see also Figure 3-33). It follows,
that the only cysteine residue that remains non-disulfide bonded in the UL16 monomer is Cys60,
which is located at the N-terminus of β-strand b that together with β-strands d and e comprises the
hydrophobic DEB-sheet (labeled in Figure 4-1). Cys60 is very well defined (i. e. does not show
multiple side chain conformers) in the electron density of the UL16mon-MICBshort crystal structure
(Figure 4-2A) and points with its free SH-group towards the hydrophobic core of the Ig-like fold
(Figures 4-1B and 4-2B). In other words, the SH-group of Cys60 is not surface exposed in natively
folded UL16 monomers but instead buried in the core of the Ig-like domain (Figure 4-2B). As a
consequence, Cys60 should not be able to participate in any disulfide bond formation that could
result in the disulfide-bridged UL16 dimer. It follows further that the disulfide bridge formation
between two UL16 monomers can only be explained if the SH-group of Cys60 becomes surface
exposed, i. e. if it becomes part of the outer surface of the DEB-sheet. This in turn would suggest
that the UL16 monomers (those that participate in the UL16 dimer formation) are locally misfolded
at or close to the Cys60 residues. Note that also the possibility remains that the Ig-like domain of
UL16 monomer is not only locally but globally misfolded. In the latter case also other cysteines
than Cys60 might be involved in the UL16 dimer formation. Assuming that the UL16 monomers
are only locally misfolded, a possible reason why the Cys60 residues become surface exposed can
again be given based on the obtained structure of the UL16mon-MICBshort complex. In the latter,
Cys60 is stabilized in the Ig-like core of UL16 by a very weak hydrogen bond (distance of 4 Å)
that is formed between the SH-group of Cys60 and the OH-group of Tyr-138 (Figure 4-2).
Otherwise Cys60 is mainly surrounded by the hydrophobic portions of the surrounding amino acid
residues Val-156, Tyr-138, Thr
speculate that the position of the rather hydrophilic
energetically not very favorable
UL16 monomers are locally misfolded around
on the surface exposed side of the DEB sheet, which then leads to the formation of the disulfide
linked UL16 dimers.
Figure 4-1. The role of Cys60
the DEB and AGFCC’C’’ β
Figure 3-32A). (B) Close-up view of the UL16 DEB sheet (see panel A) showing the predominantly
hydrophobic side chains that comprise this sheet as well as the position (red circle) and orientation of the
Cys60 side chain. The gray mesh represents the surface of the depicted side chains.
Figure 3-34.
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Figure 4-2. Environment of the Cys60
Tyr-138 (shown as sticks) as observed in the crystal structure of the UL16
with the corresponding 2Fobs-Fcalc (blue mesh) and F
contour levels of 1 and 3 σ, respectively. The dotted line represents a weak hydrogen bond with a distance of 
4 Å and unfavorable angle, formed between the SH
Oxygen and sulfur atoms are colored red and yellow, respectively.
AGFCC’C’’ β-sheet sandwich of UL16 with focus on the Ig
like domain that surround the Cys60 side chain of UL16. The hydrophobic parts of the UL16 core residues
and Cys60 are colored white. Nitrogen, oxygen and sulfur atoms are colored blue, red, and yellow,
respectively.
4.1.3 MICB binding sites are inaccessible in the UL16 dimer
Based on the results presented in Section
interact with MICBlong, whereas the UL16 dimer
arise if this specific binding behavior
MICBshort still engage the UL16 dimer?
with MICBshort and MICBlong (see Section
both MICBshort and MICBlong bind the
identical α1α2-platform domains, whereas
binding. Based on this identical binding mode
seems rather unlikely that MICBshort
the UL16 dimer, unless there was steric interference of the UL16
the α3-domain of MICBlong.
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A more fundamental question is, why the UL16 dimer is unable to bind NKG2D ligands
such as MICB in the first place (see Section 3.2.8). Again, possible answers to this question can be
presented in light of the UL16mon-MICBshort complex structure. UL16 mainly contacts MICBshort
(and MICBlong) via the predominantly hydrophobic residues on the surface exposed side of the
DEB-sheet (see contact region A in Figure 3-34). The Cys60 residue that likely is responsible for
the UL16 dimer formation (see previous section) lies within this DEB sheet and therefore in the
vicinity of the UL16 binding site of MICB. It follows that the formation of a disulfide bond
between the Cys60 residues of two UL16 monomers that form the dimer will most likely result in
the complete occlusion of the two monomer binding sites. This conclusion is not only supported by
structural evidence but also by distinct binding behavior of both UL16 species in terms of Phenyl
HP columns (discussed in Section 4.1.6).
When it was shown that the UL16 dimer is completely inactive in terms of MICBlong
binding (see Section 3.2.8), attempts were made to separate either the UL16 monomer or the
UL16mon-MICBlong complex from the inactive and therefore contaminating UL16 dimer. However,
standard chromatographic methods such as SEC or IEX failed to provide an efficient separation
strategy (see Section 3.2.9). It was also tried to reduce the disulfide-linked dimer to the monomer
by means of different reducing agents but also this approach remained unsuccessful (see Section
3.2.9). However, as outlined in the previous section, the intermolecular disulfide bond(s) are most
likely caused by either locally or globally misfolded UL16 monomers. Therefore it has to be
doubted that a successful reduction of the UL16 dimer would lead to natively folded UL16
monomers.
4.1.4 Purification and crystallization of the UL16mon-MICBlong complex
It was shown that purified UL16 in solution (see Sections 3.2.5 and 3.2.6), consists to equal
amounts of UL16 monomers and dimers (see Section 3.2.7). It was further shown that (i) the dimer
is comprised of two disulfide bridged UL16 monomers (see Section 3.2.7), that (ii) only the
monomer is active, while the dimer is not (see Section 3.2.8) and that (iii) standard
chromatographic methods fail to separate the UL16 dimer from the UL16 monomer as well as from
the UL16mon-MICBlong complex (Section 3.2.9).
Eventually, the only purification strategy that led to the efficient disposal of the UL16
dimer was the separation of the UL16 dimer from a mixture comprised of UL16mon-MICBlong
complex and excess amounts of MICBlong by means of IMAC AC (see Section 3.2.10). After
separation from excess MICBlong by SEC (see Section 3.2.11), the obtained UL16mon-MICBlong
complex was used in crystallization trials that successfully led to the growth of, unfortunately, non-
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diffracting crystals (see Section 3.3.1). However, when these crystals were analyzed by SDS-PAGE
it turned out that what had crystallized was not the expected UL16mon-MICBlong complex but a
complex comprised of UL16 monomer and the MHC class I-like α1α2 platform-domain of MICB 
(named MICBα1α2). In other words, MICBlong had been deprived of its α3-domain (see Section 
3.3.1) The most likely explanation of this totally unexpected result is a contamination of the
UL16mon-MICBlong complex with trypsin (a serine protease that is frequently used for various
applications in our laboratory) prior to the setup of the crystal drops. The analysis of the full length
amino acid sequence of MICB with the online tool PeptideCutter revealed two potential trypsin
cleavage sites at position 179 and position 180 of MICB, two residues at the very N-terminal end of
the MICB α2-domain (see Figure 3-33). Nevertheless, the coincidental cleavage of MICBlong
showed that it was in principle possible to crystallize a UL16mon-MICBα1α2 complex under the
conditions described in Section 3.3.1.
In order to reproduce these UL16mon-MICBα1α2 crystals, a shorter MICB construct,
MICBshort, was designed (see section 2.2.3.4) that consisted only of the MICB α1α2 
platform-domain followed by an N-terminal thrombin cleavage site and a His8-tag. This construct
was then successfully expressed and purified by following the protocols that had been devised for
the expression and purification of MICBlong (see Sections 3.1).
4.1.5 Separation of UL16dim from UL16mon-MICBshort complex by Ni-NTA AC
Unfortunately however, attempts to separate the UL16 dimer from the UL16mon-MICBshort complex
by means of IMAC AC repeatedly failed (see Section 3.2.12). This was very surprising since, as
described in Section 3.2.10, the same strategy had worked perfectly well for the separation of the
UL16 dimer from the UL16mon-MICBlong complex (see Section 3.2.10). Two possible reasons for
these observations may exist. The first explanation could be that the His8-tag of MICBshort was
cleaved of by thrombin protease. This clearly is a possibility since the Fc-tag of UL16-Fc is
cleaved by thrombin as part of the UL16 purification strategy (see Section 3.2.6). Although
benzamidine columns are specifically used in this strategy to trap the utilized thrombin, it cannot be
ruled out that some thrombin molecules pass through these columns and consequently contaminate
the obtained UL16mon/dim sample. It follows that by mixing these potentially contaminated
UL16mon/dim samples with MICBshort in order to set up the UL16mon-MICBshort complex, thrombin
gains access to the thrombin cleavage site of MICBshort. This explanation is supported by the fact
that differently from MICBshort, the His6-tag of MICBlong is not cleavable by thrombin (see Section
2.2.3.4.1 and Figure 2-1) and by the observation that the MICBshort which was eluted from the Ni-
NTA column with imidazole (lanes 69, 71 and 73 in Figure 3-18B) exhibited a slightly higher
molecular weight than the MICB
in Figure 3-18B). However, a second explanation could be that the His
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In conclusion, the inability to separate the UL16 dimer from the UL16mon-MICBshort complex with
the strategy that had been devised and successfully been used for the purification of the
UL16mon-MICBlong complex, marked a major setback in the project.
4.1.6 Purification of the UL16 monomer
The failure to separate the UL16 dimer from the UL16mon-MICBshort complex made it necessary to
refocus on the goal of finding a purification strategy that would reliably separate the UL16
monomers from the dimers. The strategy that was finally successful in this respect involved the use
of HIC columns, a column type that separates proteins according to their hydrophobic surface
properties (see Sections 2.2.3.3 and Section 3.2.13). When a mixture of UL16 monomer and UL16
dimer was passed over a Phenyl HP column, the monomer was retained, whereas the dimer passed
through the column and was accordingly found in the flow-through (see Section 3.2.13). Of course,
one may wonder what the reason behind this distinct binding behavior of the two UL16 species in
terms of the Phenyl HP column might be.
It was shown in Section 3.6 that the outward-facing AGFCC'C'' β-sheet and the N-terminal 
plug of the UL16 monomer are covalently linked to eight NAG residues that represent what is left
of the UL16 glycan trees after Endo H cleavage. In contrast, the solvent-exposed side of the DEB
β-sheet was shown to constitute an extensive hydrophobic face (Figure 4-1) on the surface of UL16 
(comprised of UL16 residues Trp54, Leu56, Met59, Ile61, Ile63, Tyr125, Leu110 and Leu114) that
is not only devoid of glycans but also represents the major binding site of MICB (54 % of the total
contact area). Its accessibility and its hydrophobic properties also make the outer side of this DEB
β-sheet especially well suited to mediate the contacts between the UL16 monomer and the 
hydrophobic Phenyl HP column matrix. It follows that any kind of effective shielding of this
hydrophobic UL16 surface region would not only lead to the inability of the UL16 molecules to
interact with the hydrophobic column matrix but also to their failure to contact MICB. However,
this could be exactly what happens when the UL16 dimer should indeed be formed by two locally
misfolded UL16 monomers via their exposed cysteine residues at position 60 (see Section 4.1.2).
The reason for this is that the Cys60 residues themselves are part of the DEB β-sheets of UL16 and 
that a disulfide bond between them would cause the UL16 dimer-forming monomers to mutually
shield their DEB β-sheets and in this way their binding site for both the Phenyl HP matrix and
MICB. It needs to be pointed out, however, that the formation of the UL16 dimer by two globally
misfolded UL16 monomers (as discussed in Section 4.1.2), could be an alternative explanation for
the abovementioned binding characteristics of the UL16 dimer as the global misfolding would most
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likely lead to severe alterations in the DEB β-sheet of UL16 that also could, even if the DEB 
β-sheet was surface exposed, lead to the inability of UL16 to bind the phenyl matrix or MICB.  
4.1.7 Surface plasmon resonance measurements
The HIC purification strategy that allowed to separate the UL16 monomer from the UL16 dimer in
a MICB independent fashion marked a major step forward on the way towards the crystal structure
of the UL16mon-MICBshort complex. Furthermore, the UL16 monomer could also now reliably be
used as the analyte (the soluble binding partner) in SPR experiments (see Section 3.4). Knowing
the exact concentration of the analyte is of pivotal importance in SPR experiments as the
concentration of the analyte directly influences the determination of the binding parameters. It is
therefore obvious that a mixture consisting of an unknown ratio of UL16 monomer and dimer is not
suitable for SPR applications because the concentration of the active UL16 monomer in this
mixture cannot be reliably determined with standard protein determination assays such as the
Bradford assay or the λ280 assay.
The SPR data obtained for the interactions between purified UL16 monomer and the two
MICB proteins, MICBlong and MICBshort, revealed affinity values of 67 and 66 nM, respectively,
which can be considered as being virtually identical (see Section 3.4Table 3-4 and Table 3-1).
However, the affinity is only an indirect measure for the stability of a complex. The direct
parameter that characterizes the complex stability is the off-rate constant kd, which can be obtained
by performing kinetic SPR experiments138, 139. The kd values determined for the UL16mon-MICBlong
and UL16mon-MICBshort interactions were 0.045 and 0.054 s-1 (see Section 3.4 and Table 3-1),
respectively. This high similarity can be interpreted in the way that the α3-domain of MICBlong is
not involved in binding to UL16, an information that was not available from the structure of the
UL16mon-MICBshort complex and that is in good agreement with a previous report published by
Spreu et al.88. Also the interactions of other NKG2D ligands such as ULBP1, ULBP2, ULBP3,
ULBP4 and ULBP5 with the UL16 monomer were tested (see Section 3.4 and Table 3-1). The
obtained data showed that MICA, ULBP3, ULBP4 and ULBP5 do not interact with the UL16
monomer, while ULBP1 and ULBP2 bind tightly. These results are in good agreement with the
current literature65, 84-90. In detail, the UL16mon-ULBP1 and UL16mon-ULBP2 complexes exhibit kd
values of 0.016 and 0.072 s-1, respectively. This places the complex stability of the UL16mon-
ULBP2 complex close to the one observed for the UL16mon-MICB interaction and also shows that
ULBP1 is the NKG2D ligand that forms the most stable complex with UL16 (see Section 3.4 and
Table 3-1). The reasons for the UL16 monomer failure to engage other NKG2D ligands such as
MICA or ULBP3 will be discussed in detail in Section 4.2.3.
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4.1.8 Purification and crystallization of the UL16mon-MICBshort complex
In addition to SPR studies, purified UL16 monomer was also used to obtain the UL16mon-MICBshort
complex for crystallization attempts. Briefly, UL16mon and MICBshort were mixed and incubated
and the formed complex purified by SEC. The crystallization attempts that followed were
eventually successful (see Section 3.3.2) and resulted in crystals that were similar to those that had
been obtained coincidentally during crystallization experiments with the UL16mon-MICBlong
complex (see Section 3.3.1). Also the crystallization conditions were quite similar (see Sections
3.3.1 and 3.3.2), which is likely attributed to the high structural similarity between the
UL16mon-MICBshort and the UL16mon-MICBlong complexes. Unfortunately, crystals of the
UL16mon-MICBshort complex diffracted only to about 8 - 10 Å. A possible reason for this result
could be the remaining heterogeneity of the high-mannose glycan trees that still cover the surface
of the UL16 monomer after its expression by CHO Lec 3.2.8.1 cells. To test this hypothesis the
UL16mon-MICBshort complex was further deglycosylated enzymatically by use of the glycosidase
Endo H (see next section) and the crystallization attempts repeated with a deglycosylated
UL16mon-MICBshort complex. The reasons why Endo H and not PNGase F was used to
deglycosylate the UL16mon-MICBshort complex are described in Section 4.1.1.
4.1.9 Purification and crystallization of the deglycosylated
UL16mon-MICBshort complex
Attempts to crystallize the glycosylated UL16 monomer in its non-MICB-bound state never
returned any promising results. Furthermore, attempts to crystallize deglycosylated UL16 monomer
were hampered due to the observation that UL16 monomer, after its deglycosylation with Endo H,
started to precipitate. This indicates that the glycan shell of UL16, besides its other possible
functions (see Section 3.6), prevents UL16 from aggregating, possibly by increasing its overall
solubility. This would make also sense considering that the outer face of the DEB β-sheet, and 
therefore an extensive area of the overall UL16 surface, is extremely hydrophobic (Figure 4-1).
However, when deglycosylation of UL16 was performed in its MICB-bound state, no UL16
aggregation or complex aggregation was observed. Therefore, the strategy was adjusted in a way
that the deglycosylation step with Endo H followed after the formation of the UL16mon-MICBshort
complex (see Section 3.2.15). Briefly, purified UL16 monomer was first mixed and incubated with
MICBshort and the formed complex further purified by SEC (see Section 3.2.14). Then, in a second
step, the UL16mon-MICBshort complex was deglycosylated with Endo H and, again, further purified
by SEC (see Section 3.2.15).
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Crystallization trials with the purified, deglycosylated UL16mon-MICBshort complex showed
that this deglycosylated complex could be successfully crystallized under the exact same conditions
as the glycosylated UL16mon-MICBshort complex (see Section 3.3.3). The obtained crystals
diffracted to about 1.8 Å and a full crystallographic dataset was recorded, which was subsequently
used to solve and analyze the crystal structure of the deglycosylated UL16mon-MICBshort complex
(see Sections 3.5 - 3.8).
Taken together, these results clearly show how severely the resolution of X-ray diffraction
data can depend on the glycosylation state of the crystallized proteins (see Sections 3.3.2 and
3.3.3). When CHO Lec 3.2.8.1 cell produced UL16 was used (where each N-glycosylation site was
most likely connected to a glycan tree of 7 - 11 sugar residues), the resolution of the
UL16mon-MICBshort complex was in the range between 8 - 9 Å, whereas when UL16 was further
deglycosylated with Endo H (where each N-glycosylation site is only connected to a single NAG
residue), the resolution of the UL16mon-MICBshort complex was dramatically increased to 1.8 Å.
The 1.8 Å dataset was eventually used to solve the structure of the UL16mon-MICBshort
complex, which to the best of the author’s knowledge is the first structure of a viral immunoevasin
in complex with a stimulatory NK cell receptor ligand. The results of the structural analyses of the
complex were presented in Sections 3.6 (UL16mon), 3.7 (MICBshort) and 3.8 (UL16mon-MICBshort
interface). The structural insights gained from the UL16mon-MICBshort structure will be discussed in
the subsequent sections, starting with the comparison between the UL16mon-MICBshort complex and
the NKG2D-MICA complex.
4.2 The UL16-MICB complex - structural insights into NKG2D
ligand binding by UL16 and NKG2D
4.2.1 Comparison between the UL16-MICB and the NKG2D-MICA complex
‘A crystal structure of the NKG2D homodimer bound to MICB is unavailable. However, the
NKG2D structure in complex with the highly homologous MICA protein shows that both NKG2D
monomers make extensive contacts with the long helices at the top of the MICA α1α2-platform 
domain. The NKG2D-MICA complex buries a surface area of 2170 Å2, which is almost exactly the
same area buried in the UL16mon-MICBshort complex. A superimposition of the two complexes
demonstrates that contacts formed by UL16 overlap substantially with those made by one NKG2D
monomer (Figure 4-4A and B). One could therefore envision a scenario in which UL16 acts as a
direct competitor for NKG2D65, perhaps even displacing it from its ligands. While the higher
affinity of UL16 for MICBshort and ULBP1 (KD values of 66 and 12 nM, respectively) (Figures 3-25
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and 3-26 and Table 3-1) compared with the respective affinities of NKG2D for the same ligands
(KD values of 0.8 and 1 µM, respectively)
indicate that UL16 acts inside the cell and is therefore unlikely to compete with NKG2D for ligand
binding14, 19, 85, 86.’113
Figure 4-4. ‘Comparison of the UL16mon
two NKG2D monomers are shown in salmon and green, whereas UL16 and
orange, respectively. (A) Superposition of the UL16
complex20. MICA, which is very similar to MICB, is not shown for clarity.
α1α2-platform domains of MICA (left side, yellow) and MICB (right side, orange), wi
surfaces outlined in grey. Surface-exposed areas of residues that are buried upon complex formation with
NKG2D and UL16, respectively, are colored using the color scheme of panel (A). MICB/MICA residues
155, 158, 159, 162 and 163, which contact both UL16
green and blue shading, respectively. (C) Structural mimicry of UL16. Close
the structures shown in panel (A) with UL16 residues Ile63, Lys123, Tyr125, Leu110
superimpose with chemically equivalent NKG2D residues Ile182, Lys197, Tyr199, Met184 and Tyr152. Side
chain atoms, UL16-MICB contacts, and water molecules are colored as described in the legend to
3-34.’113
‘The detailed comparison of the central contact regions in each case reveals that, despite having
entirely different folds, NKG2D and UL16 use an almost identical pattern of amino acid side
chains to engage their ligands (Figure
pattern includes the MICB-contacting residues Ile63, Lys123 and Tyr125, while NKG2D uses an
identical pattern of residues, Ile182, Lys197, and Tyr199, to form very similar contacts with
MICA. Remarkably, although the three side chains are contributed by different structural element
in each case, their position in space overlaps closely (
additional UL16 residues, Leu110 and Leu114, which a
chemically related NKG2D residues Met184 and Tyr152 (
constitute a predominantly hydrophobic binding motif that is common to NKG2D and UL16
(Figure 4-4B, C), and that forms the center of the interaction with the MIC mol
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60 would support this scenario, most reports to date
-MICBshort and NKG2D-MICA complex structures. In all panels, the
MICB are colored blue and
mon-MICBshort complex onto the MICA
(B) Ribbon drawings of the
th their molecular
and NKG2D in a similar manner are shown in darker
-up view of the core region of
4-4C, see also Figure 3-33 and Figure 4-6). In
Figure 4-4C). This is also
re hydrophobic in nature and overlap with
Figure 4-4C). Together, the five residues
ecules. This central
-NKG2D
, Leu114 that
Figure
UL16, this
s
true for two
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binding motif is augmented by additional contacts, such as those mediated by UL16 residue Tyr65
and NKG2D residue Ser195, that perform similar functions in the UL16mon-MICBshort and
NKG2D-MICA20 complexes (see Figure 3-33B and Figure 4-4C). Since all MICA and MICB
residues contacted by this central binding motif are identical, and since the structures of MICA and
MICB superimpose well in this region, one can conclude that UL16 mimics a key structural motif
of NKG2D with an entirely different fold in order to engage MICB. Furthermore, it can be
considered likely that the central binding motif of the UL16 monomer also plays an important role
in the recognition of other NKG2D ligands, for which structures of complexes with UL16 are not
yet available.’113
4.2.2 The promiscuous binding mode of UL16
‘Bacterial and viral pathogens often interfere with cellular activities and immunosurveillance
processes to enhance their survival and effectiveness140. This is typically achieved by virulence
factors, which imitate the function of a host protein by mimicking its key structural features. In the
majority of such cases, pathogens first hijack and then manipulate host genes to produce
structurally homologous versions of host proteins82, 140-143. Thus, virulence factors and host proteins
are derived from the same origin and arise from divergent evolution. However, structural mimics
can also be generated through convergent evolution. Although differing in evolutionary origin and
three-dimensional structure, the virulence factors have in this case evolved to mimic key structural
features of cellular proteins. Examples for the latter strategy, which can only be revealed through
structural analyses, are still exceedingly rare and are limited to a small number of virulence
factors140, 144, 145. The comparison of HCMV UL16 with human NKG2D, reveals a striking example
of convergent evolution140. A set of five predominantly hydrophobic core residues on the UL16
surface precisely mimics a set of five equivalent residues in the central region of the interface used
by the structurally unrelated immunoreceptor NKG2D to interact with its ligands.’113
‘As this central binding motif represents only a portion of the total interface between
NKG2D and its ligands (Figure 4-4), one may wonder why UL16 mimics just this particular
structural motif of NKG2D. McFarland et al. reported that residues constituting this motif (Tyr152,
Met184 and Tyr199) form the basis for the highly degenerate ligand recognition mode of
NKG2D59, 60. They proposed a ‘rigid adaptation’ mechanism, in which a rigid binding site on
NKG2D uses the same set of predominantly hydrophobic core residues to make diverse
interactions with a series of chemically and structurally distinct ligand residues. As an example,
Tyr199 and Tyr152 of NKG2D can accommodate residues as diverse as Ala, Met or Phe at ligand
position 15960 (Figure 3-33A and Figure 4-6). Mimicry of these core residues likely enables UL16
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to employ this binding mechanism of NKG2D to contact a similar set of ligands. The ‘rigid
adaptation’ concept is furthermore supported by the finding that UL16 engages its ligands via a
rigid β-sheet, which does not allow for much conformational flexibility. The ligand residues 
contacted by NKG2D and UL16 in MICA and MICB, respectively, are Asp65, Thr155, Ala159,
Ala162, Asp163 and the hydrophobic portions of the Arg/His158 side chain (Figure 3-33A, Figure
4-4C, and Figure 4-6)20, 59, 60. Since NKG2D and UL16 both evolved the same central binding motif
in order to contact this specific set of ligand residues, the latter likely represent binding hot spots in
MICA and MICB59. Furthermore, these residues probably are also of major importance for
interactions with ULBP molecules (Figure 3-33A and Figure 4-6). Note for instance that (i) based
on the ‘rigid adaptation’ concept the amino acid at ligand position 159 can be quite variable in size
and chemical nature, (ii) Asp163 is conserved in all NKG2D ligands, and (iii) alanine and glycine
dominate at position 162.’113
4.2.3 Key determinants of NKG2D-ligand binding to UL16
‘Unlike NKG2D, UL16 engages only MICB, ULBP1, ULBP2 and ULBP6, but not MICA, ULBP3,
ULBP4 and ULBP565, 86-88, 90, 135. The SPR measurements show that UL16 binds MICB with high
affinity, whereas the affinity of UL16 for MICA is negligible (Table 3-1), in line with earlier
studies14, 85, 88. Given the high degree of similarity between MICA and MICB at the sequence and
structural level, the inability of UL16 to engage MICA is puzzling. In order to better understand the
structural parameters that guide UL16 binding to MICB vs. MICA, Spreu et al.88 assayed binding
of soluble UL16-Fc to MICB chimeras in which they had exchanged domains, subdomains and
single amino acids of MICB against equivalent regions of MICA. These experiments clearly
demonstrated that recognition by UL16 is linked to residues projecting from the helical structures
in the MICB α2-domain. However, the molecular mechanism by which these residues confer 
selectivity remained unclear.’113
‘The crystal structure of the UL16mon-MICBshort complex now allows us to identify the key
determinants of NKG2D-ligand binding to UL16. The performed structural alignment of MICA
and MICB identifies only seven MICB residues that contact UL16 in the complex and that are
replaced by other amino acids in MICA (Figure 3-33). Residues at positions 64, 71, 75, 102 and
158 can assume alternate conformations that would not interfere with binding, and could in some
cases even mediate favorable contacts with UL16. Therefore, their effect on UL16 binding is likely
to be negligible (see also Spreu et al.88). Replacement of α1-domain Glu68 with glycine (Figure 
3-34C) in MICA would eliminate several hydrophobic contacts and three hydrogen bonds with
UL16 residues 117 and 118, and could therefore conceivably have a negative effect on UL16
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binding. However, as complete replacement of the α1-domain of MICB by MICA (including 
residue Glu68) did not significantly affect UL16 binding88, residue 68 is probably not a key
determinant of UL16 binding.’113
‘On the other hand, however, Gln169 in the α2-domain of MICB is likely to be critical. 
The UL16-MICB structure shows that substitution of Gln169 with arginine, which is present at this
position in MICA, would lead to steric clashes with UL16 residues Met59 and Leu161 (Figure
4-5A) that would prevent binding. This is in perfect agreement with previous experiments
demonstrating that MICB carrying a Gln169Arg substitution no longer bound UL1688. Based on
the following reasons, it is in fact likely that the side chain at position 169 is not only the key
determinant of selective UL16 binding to the MIC molecules but all NKG2D ligands. (i) All
NKG2D ligands that carry a glutamine or glutamate at position 169, i. e. MICB, ULBP1, ULBP2
and ULBP6, bind UL16, while all ligands that have an arginine at this position, i. e. MICA, ULBP3
and ULBP4, do not bind UL16 (Figure 3-33). Although ULBP5 also carries a glutamate at position
169 and should therefore bind UL16, Wittenbrink et al. demonstrated by mutational studies that a
substitution in the α2-domain, which is unique among all NKG2D ligands (Figure 3-33), prevents 
binding of ULBP5 to UL16135. (ii) Arg169 has a similar conformation, stabilized by contacts with
surrounding hydrophobic residues, in the unliganded63 and liganded20 MICA structures (Figure
4-5A). In this orientation, however, the Arg169 side chain would clash with UL16 residues.
Modeling suggests that the arginine side chain could adopt only a single rotamer conformation,
sandwiched between the hydrophobic side chain regions of Leu172 and Lys173, that would not
result in steric clashes with UL16 (Figure 4-5A). However, such a rotamer is only seen in 2 % of
all observed arginines102. (iii) The conformation of Arg169 in the ULBP3 structure61, which is held
in place by a salt bridge to Asp170, would also clash with UL16 (Figure 4-5A). A similar
arrangement of Arg169 can be expected for ULBP4, where Asp170 is replaced with glutamate
(Figure 3-33). It is also important to note that Arg169 is not located near the NKG2D binding site
and therefore does not play a role in the interaction of either MICA or ULBP3 with NKG2D.’113
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Figure 4-5. ‘Selectivity of NKG2D-ligand
bound MICA20 was superimposed onto
(magenta) are shown. The α1α2-domain of NKG2D
and only the ULBP3 side chains of Arg169 (green) and Asp170 (light green) are shown. Cages surrounding
the two arginines of MICA and ULBP3 at position 169 depict the area that these side chains would require
a space-filling model. In both cases, the arginine side chains would clash with UL16 residues. (B) The
α1α2-platform domain of NKG2D-bound MICA
superimposed onto MICBshort (orange). The side chains of alanine (present in
(present in ULBP3) at position 162 are shown. Also shown are the Met184 side chains of both the MICA
bound (white) and ULBP3-bound (green) NKG2D monomers, both of which correspond to the green
NKG2D monomer in Figure 4-4A and
displaces Met184 and allows for the accommodation of Arg162 in ULBP3
rigid DEB sheet does not allow for a similar conformational adjustment, and ULBP3 residue Arg162 would
therefore clash with UL16 residues.’113
‘A second important requirement for binding of NKG2D ligands to UL16 is the presence of a small
hydrophobic side chain at position 162. In the UL16
Tyr125, a UL16 footprint residue (Figure
which has an arginine at this position, all other NKG2D ligands have either an alanine or a glycine
at position 162 (Figure 3-33A Figure
ULBP3 would clash with several UL16 residues (
UL16 to bind ULBP314, 19, 65, 85 (Table
the L2-loop of NKG2D in its MICA
undergoes a conformational adjustment in which the L2
sufficient space for the accommodation of Arg162 (
of UL16, which would not allow for such larger conformational
accommodate Arg162.’113
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binding by UL16. (A) The α1α2-platform domain of NKG2D
MICBshort, but only the MICA side chains Arg170 (pink) and Arg169
-bound ULBP361 was also superimposed onto MICB
20 (yellow) and ULBP361 (red), respectively, was
MICB and MICA) and arginine
B. Conformational changes of the L2-loop of MICA
-bound NKG2D. In UL16, the
mon-MICBshort complex, Ala162 faces towards
4-4C and Figure 4-5B). With the exception of ULBP3,
4-6). The long and positively charged Arg side chain of
Figure 4-5B), likely contributing to the failure of
3-1). Interestingly, Arg162 would also clash with
-liganded form. To allow for ULBP3 binding, NKG2D
-loop displaces Met184, resulting in
Figure 4-5B). However, the rigid DEB β
adjustments, is unlikely to
-
short,
in
-
-bound NKG2D
Met184 of
-sheet
Figure 4-6. ‘Schematic view of the structural mimicry of UL16.
NKG2D footprint residues participating in structural mimicry. UL16 residues are shown in white, the
corresponding NKG2D residues are shown in black
footprint are placed in yellow circles, at the approximate position of interaction. Also shown are the amino
acids at corresponding positions in ULBP1, ULBP5/6, ULBP2, ULBP3 and ULBP4. In ULBP3
the α3-helix starting at position 162 (
cases, the shifted ULBP3 residue that cor
following the ULBP3 one letter code. As an example, ULBP3 position Met168 and not Val169 corresponds
to MICB position Ala159. Also as a result of the helix kink, no ULPB3 residue corresponds in
MICB residue in position 155, indicated by (#). Interactions between residues are represented with arrows,
accompanied by green text for hydrogen bonds, red text for salt bridges, and magenta text for hydrophobic
contacts; the blue text indicates the clash of ULBP3 Arg162 (
of NKG2D as observed in the MICA/NKG2D complex structure
4.2.4 UL16 and the evolutionary
‘Taken together, these analyses suggest that some NKG2D ligands apparently bypass intracellular
retention by UL16 through alteration of a small number of key residues at strategic locations of
their potential UL16 binding interface.
by UL16 contributed to drive the diversification of NKG2D ligands, which eventually may have
led to the emergence of non
support for an HCMV-driven diversification of NKG2D ligands comes from studie
and colleagues showing that the HCMV immunoevasin UL142 targets most MICA allelic variants
except MICA*00814, 38, 91, 93
is by far the most frequent MICA variant in many populations
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. MICA and MICB residues that are contacted by the
Figure 4-5B) causes a one-residue shift towards the N
responds to the MICB residue is given by a superscript number
Figure 3-33A) with Leu100 of UL16 or Met184
20 (Figure 4-5B).’113
diversification of NKG2D ligands
It is therefore quite likely that the selective pressure exerted
-UL16 binding ligands such as MICA and ULBP3
. Intriguingly, MICA*008 contains a truncated cytoplasmic domain and
91, 93. As yet, no direct interaction of
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61, a kink in
-terminus. In these
space to the
14, 19, 38, 56, 65. Further
s by Cosman
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UL142 and MICA has been shown and the molecular mechanisms of MICA sequestration by
UL142 are unknown. In contrast to UL16, UL142 and MCMV-encoded immunoevasins m145,
m152, and m155 that suppress surface expression of mouse NKG2D ligands MULT-1, RAE-1, and
H60, respectively, are predicted to have an MHC class I-like fold14, 56, 91, 146-150. It will be of great
interest to determine the structural basis of NKG2D-ligand engagement by MHC class I-like
HCMV immunoevasins and to compare these interactions of two MHC class I-like molecules to
those of the NKG2D-like ligand binding mode of UL16.’113
‘NK receptors binding to MHC class I or class I-like molecules belong to two structurally
distinct families, the Ig superfamily and the C-type lectin superfamily151. While NKG2D belongs to
the latter group, the structural analysis presented here shows that UL16 assumes an Ig-like fold.
Therefore, one may ask whether UL16 is related to the Ig-like NK receptors that bind MHC class I
molecules, such as the leukocyte Ig-like receptors (LIRs) or the killer immunoglobulin-like
receptors (KIRs). Structures of LIR-1 in complex with HLA-A2151 and with the HCMV
MHC class I decoy UL1882 show that, in both cases, LIR-1 contacts β2-microglobulin and the 
α3-domain of the HLA-A2 and UL18 ligands via loops located at the interdomain hinge region of 
its two tandem Ig domains. In contrast KIRs, like UL16, engage the α-helical parts of the platform 
domain of MHC class I molecules, but, similar to LIRs, employ loops at the interdomain hinge
region of their Ig domains for this interaction151. Therefore, LIRs and KIRs exhibit an
MHC class I-binding mode that is distinct from that used by UL16. Since there is also no obvious
sequence homology between these Ig-like NK receptors and UL16, this supports the view that
UL16 evolved independently, mimicking a central binding motif of the structurally unrelated
NKG2D immunoreceptor.’113
4.2.5 Accession numbers
Atomic coordinates and structure factors of the UL16mon-MICBshort complex have been deposited
with the Protein Data Bank under accession code 2wy3.113
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5. Conclusions
The activating immunoreceptor NKG2D stimulates anti-viral and anti-tumor effector responses of
human cytotoxic lymphocytes such as natural killer (NK) cells, CD8 αβ T cells and γδ T cells. In 
contrast to many other immunoreceptors, NKG2D is fairly promiscuous in its ability to recognize a
diverse array of at least eight human MHC class I-related self-ligands. These NKG2D ligands are
upregulated in a cell stress-associated manner and thereby allow for immunorecognition of infected
or transformed cells. Several diverse and independent immune evasive strategies are employed by
HCMV to avert an NKG2D-mediated immunorecognition, underscoring the importance of this
particular surveillance system. One of the most well-known and extensively studied strategies of
HCMV to subvert NKG2D-mediated immune responses is mediated by the HCMV glycoprotein
UL16. UL16 counteracts NKG2D-mediated antiviral immune responses by intracellular retention
of the distantly related NKG2D ligands MICB, ULBP1, ULBP2 and ULBP6. However, other
NKG2D ligands such as the MICB-homolog MICA, the ULBP2-homolog RAET1G, and ULBPs
ULBP3 and ULBP4 are not targeted by UL16. These findings contributed to the hypothesis that
diversification of NKG2D ligands has been driven by viral immunoevasins rather than by
transformed cells.
The work presented in this thesis has led to the crystal structure determination of the HCMV
immunoevasin UL16 in complex with the NKG2D immunoreceptor ligand MICB at 1.8 Å
resolution. This is, to the best of the author’s knowledge, the first structure of a viral immunoevasin
in complex with a stimulatory NK cell receptor ligand. Furthermore, the affinities and kinetics of
the various UL16–NKG2D-ligand interactions were determined by surface plasmon resonance
(SPR). Major new findings based on the obtained structural and functional data are listed on the
subsequent two pages in respect to the aims formulated at the onset of this work.
C o n c l u s i o n s
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What is the three-dimensional structure of UL16?
 Determination of the crystal structure of UL16 in complex with MICB at 1.8 Å
resolution. UL16 adopts an immunoglobulin-like (Ig-like) fold and, similarly to the C-type lectin-
like receptor NKG2D, binds across the α-helices of the MICB α1α2-platform domain. Although Ig-
like proteins share a common structural fold, their sequence identities are often extremely low. This
explains why the Ig-like fold of UL16 could not be predicted from its primary sequence. Comparison
of the UL16-MICB complex with known crystal structures of MICA and ULBP3 in complex with
NKG2D allowed for an insightful comparative analyses of interaction modes by NKG2D and UL16,
respectively.
What are the structural features allowing UL16 to (partially) recapitulate the promiscuous
engagement of highly diverse ligands by NKG2D?
 In a rare example of structural mimicry (presumably due to convergent evolution)
Ig-like UL16 uses a set of residues at the center of its BDE β-sheet to mimic a central 
binding motif employed by the structurally unrelated lectin-like NKG2D
immunoreceptor to interact with its diverse MHC class I-related ligands. This result may
be also of more general interest because it strongly suggests that HCMV and humans have
independently evolved two structurally distinct receptors that nevertheless share the same central
ligand binding motif in order to achieve promiscuous binding to MIC and ULBP molecules. Whereas
the great majority of structurally defined virulence factors simply constitute structurally homologous
versions of host proteins that were acquired through hijacking of host genes, only two structurally
validated examples of viral proteins have been described that, similarly to UL16, likely are products
of convergent evolution.
What are the binding parameters (kinetic rate constants and affinities) of the individual UL16-
NKG2D ligand interactions?
 Surface plasmon resonance measurements showed that UL16 binds MICB, ULBP1,
and ULBP2 with similar affinities that lie in the nanomolar range (12 - 66 nM). The off-
rate constants, which represent a more direct measure of the complex stability, ranged between
0.016 s-1 for ULBP1 and 0.054 s-2 for MICBshort. No binding was observed between UL16 and
NKG2D ligands MICA, ULBP3, ULBP4 and ULBP5. ULBP6 was not tested.
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What is the structural basis for UL16 binding to a subset of diverse NKG2D ligands (MICB,
ULBP1 and ULBP2), and for its inability to bind the remaining NKG2D ligands (MICA, ULBP3
and RAET1G)?
 Comparison of UL16-MICB with the NKG2D-MICA and NKG2D-ULBP3 complexes
reveals that substitutions at a few central positions of MICB that are key to engaging
UL16 (e. g. Q169R) allow MICA and ULBP3 to bypass UL16 engagement without
significantly affecting NKG2D binding.
Can structural data provide support for the hypothesis that the diversification of NKG2D ligands
resulted from selective pressure exerted by viral immunoevasins?
 The finding that UL16 mimics a central binding motif of the NKG2D immunoreceptor
in order to engage MICB suggests that the UL16 escape variants among the NKG2D
ligands have evolved through alteration of key residues at strategic locations. Assuming
that ULBP1 and ULBP2 engage UL16 in a manner similar to MICB, this strongly
supports a scenario in which selective pressure exerted by viral immunoevasins such as
UL16 was and probably still is a major driving force of the NKG2D ligand
diversification.
Taken together this work provides new insights into the structural basis of the immunological arms
race between a persistent human pathogen (HCMV) and cellular surveillance systems (NK cells) of
the human immune system, exemplified by the promiscuous binding mode of the HCMV
immunoevasin UL16 and the diversification of NKG2D ligands.
Z u s a m m e n f a s s u n g
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6. Zusammenfassung
Der aktivierende Immunrezeptor NKG2D stimuliert antivirale und antitumorale Immunantworten
humaner zytotoxischer Lymphozyten wie etwa Natürlicher Killerzellen (NK Zellen), CD8 αβ T-
Zellen und γδ T-Zellen. NKG2D ist in der Lage mindestens acht in ihrer Sequenz zum Teil sehr 
unterschiedliche MHC Klasse I-ähnliche, körpereigene Liganden zu erkennen und zeigt somit ein
im Gegensatz zu vielen anderen Immunrezeptoren sehr promiskuitives Ligandenbindungsverhalten.
Zellulärer Stress wie beispielsweise eine virale Infektion oder eine maligne Transformation führt zu
einer Erhöhung der NKG2D Ligandendichte auf der Oberfläche der gestressten Zellen und
ermöglicht auf diese Weise die NKG2D-vermittelte Erkennung virusinfizierter bzw. bösartiger
Zellen. Die besondere Bedeutung der NKG2D-vermittelten Immunüberwachung wird unter
anderem durch den humanen Zytomegalovirus (HCMV) verdeutlicht, der zahlreiche
Evasionsmechanismen entwickelt hat, um einer Erkennnung durch NKG2D zu entgehen. Eine der
in diesem Sinne bekanntesten und bestuntersuchten Evasionsstrategien basiert auf dem HCMV
Glykoprotein UL16. UL16 wirkt einer NKG2D-vermittelten antiviralen Immunantwort entgegen,
indem es die in ihrer Sequenz zum Teil sehr unterschiedlichen NKG2D Liganden MICB, ULBP1,
ULBP2 und ULBP6 (RAET1L) im Inneren der Zelle zurückhält und somit eine Erhöhung der
Oberflächenexpression dieser Liganden verhindert. Interessanterweise existieren aber auch
NKG2D Liganden wie beispielsweise das zu MICB homologe MICA, das zu ULBP2 homologe
ULBP5 (RAET1G) sowie ULBP3 und ULBP4, die nicht von UL16 erkannt und in der Zelle
zurückgehalten werden. Basierend auf diesen Ergebnissen wurde die Hypothese formuliert, dass
die starke Diversifikation der NKG2D Liganden ihre Ursache möglicherweise weniger in einem
durch bösartige Zellen, als vielmehr in einem durch virale Immunevasine hervorgerufenen
Selektionsdruck hat.
Die hier präsentierte Arbeit beschreibt den Weg zur Lösung der Kristallstruktur des HCMV
Immunevasins UL16 im Komplex mit dem NKG2D Immunrezeptorliganden MICB. Die
Auflösung der Struktur beträgt 1.8 Å und ist, nach bestem Wissen des Autors dieser Arbeit, die
erste eines viralen Immunevasins im Komplex mit einem Liganden eines stimulierenden NK
Rezeptors. Zudem wurden die Affinitäten und Kinetiken der verschiedenen UL16-NKG2D
Ligandeninteraktionen mittels Oberflächenplasmonresonanz (SPR) ermittelt. Die auf Basis dieser
strukturellen und funktionellen Daten gewonnenen neuen Erkenntnisse werden auf den
nachfolgenden Seiten im einzelnen aufgeführt und insbesondere in Bezug zu den am Anfang dieser
Arbeit formulierten Ziele gesetzt.
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Wie sieht die dreidimensionale Struktur von UL16 aus?
 Bestimmung der Kristallstruktur des UL16-MICB Komplexes mit einer Auflösung
von 1.8 Å. UL16 zeigt eine immunglobulinähnliche (Ig-ähnliche) Faltung und bindet, ähnlich wie
der C-Typ lektinähnliche Rezeptor NKG2D, die α-Helices der MICB α1α2 Plattformdomäne. Trotz 
ihrer sehr ähnlichen strukturellen Faltung weisen Ig-ähnliche Proteine oft größere Unterschiede in
ihrer Aminosäuresequenz auf. Dies widerum macht deutlich warum die Ig-ähnliche Faltung des
UL16 Proteins nicht aufgrund seiner Aminosäuresequenz vorhergesagt werden konnte. Zudem
führte ein Vergleich des UL16-MICB Komplexes mit den ebenfalls bekannten Kristallstrukturen
von MICA und ULBP3 im Komplex mit NKG2D zu einer aufschlussreichen vergleichenden
Analyse der Interaktionsmodi von NKG2D bzw. UL16.
Welche strukturellen Eigenschaften erlauben es UL16 den promiskuitiven Ligandenbindemodus
von NKG2D partiell zu kopieren?
 In einem seltenen Beispiel von struktureller Mimikry (vermutlich das Resultat einer
konvergenten Evolution) imitiert UL16 mittels eines Satzes von Aminosäuren im
Zentrum seines BDE β-Faltblatts ein zentrales Bindemotiv des zu ihm strukturell 
völlig unterschiedlichen NKG2D Immunrezeptors, um so mit dessen
unterschiedlichen MHC Klasse I-ähnlichen Liganden interagieren zu können. Dieses
Ergebnis ist von allgemeinem Interesse, denn es zeigt, dass HCMV und der Mensch vollständig
unabhängig voneinander zwei strukturell völlig unterschiedliche Rezeptoren entwickelt haben, die
jedoch das gleiche zentrale Bindemotiv teilen, um so die promiskuitive Bindung an die MIC und
ULBP Moleküle zu gewährleisten. Während die große Mehrheit der bislang strukturell bekannten
Virulenzfaktoren lediglich homologe Versionen von Wirtsproteinen darstellen, die vom Virus durch
die Übernahme von Wirtsgenen erlangt wurden, sind nur zwei strukturell belegte Beispiele bekannt
bei denen die viralen Proteine, ähnlich wie UL16, wahrscheinlich das Produkt einer konvergenten
Evolution darstellen.
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Wie unterscheiden sich die Bindeparameter (kinetische Ratenkonstanten und Affinitäten) der
verschiedenen UL16-NKG2D Ligandeninteraktionen?
 Oberflächenplasmonresonanzmessungen haben gezeigt, dass UL16 die NKG2D
Liganden MICB, ULBP1 und ULBP2 mit ähnlichen, im nanomolaren Bereich
(12-66 nM) angesiedelten, Affinitäten bindet. Die Dissoziationsratenkonstanten, die ein
direktes Maß für die Stabilität eines Komplexes darstellen, lagen im Bereich zwischen 0,016 s-1 für
ULBP1 und 0,054 s-1 für MICBshort. Keine Bindung wurde zwischen UL16 und den NKG2D
Liganden MICA, ULBP3, ULBP4 und ULBP5 beobachtet. ULBP6 wurde nicht getestet.
Was ist die strukturelle Basis, die es UL16 erlaubt bestimmte NKG2D Liganden wie MICB,
ULBP1 und ULBP2 zu binden, während eine Bindung an andere NKG2D Liganden wie MICA,
ULBP3 und RAET1G nicht möglich ist?
 Ein Vergleich des UL16-MICB Komplexes mit den NKG2D-MICA und NKG2D-ULBP3
Komplexen zeigt, dass der Austausch einiger weniger MICB Aminosäuren an Positionen
die von zentraler Bedeutung für die UL16 Bindung sind (z. B. Q169R) es MICA und
ULBP3 erlauben einer UL16 Bindung zu entgehen ohne gleichzeitig negative
Auswirkungen auf deren Bindung an NKG2D zu haben.
Können strukturelle Daten die Hypothese untermauern, dass die Diversifikation der NKG2D
Liganden das Resultat eines Selektionsdruckes seitens viraler Immunevasine ist?
 Die Tatsache dass UL16 ein zentrales Bindemotiv des NKG2D Immunrezeptors
nachahmt um MICB binden zu können deutet darauf hin, dass sich UL16 „escape“
Varianten unter den NKG2D Liganden durch den Austausch von
Schlüsselaminosäureresten an für die Bindung an UL16 strategisch wichtigen Positionen
entwickelt haben. Unter der Annahme, dass ULBP1 und ULBP2 UL16 in ähnlicher
Weise binden wie MICB, kann man davon ausgehen, dass selektiver Druck durch virale
Immunevasine wie UL16 die treibende Kraft der NKG2D Ligandendiversifikation war
und vermutlich immer noch ist.
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Zusammengefasst liefert die vorliegende Arbeit am Beispiel des promiskuitiven Bindemodus des
HCMV Immunevasins UL16 und der Diversifikation der NKG2D Liganden neue Einblicke in die
molekulare Basis des immunologischen Wettlaufs zwischen einem persistierenden humanen
Pathogen (HCMV) und zellulären Überwachungssystemen (NK Zellen) des menschlichen
Immunsystems.
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9. Abbreviations
A absorbance
Å Angstrom (1Å = 0.1 nm)
aa amino acid
Ab antibody
AC affinity chromatography
ADCC antibody dependent cellular cytotoxicity
Amp ampicillin
APC antigen presenting cell
APS ammoniumperoxodisulphate
ASU asymmetric unit
ATP adenosine triphosphate
BCA bicinchoninic acid
BCR B cell receptor
bp base pair
BSA bovine serum albumin
BTP bis-tris propane
Cam chloramphenicole
CCD charge-coupled device
CHO Chinese hamster ovary
CID cytomegalic inclusion disease
conc. Concentration
CRD carbohydrate recognition domain
CRD carbohydrate recognition domain
CTL cytotoxic T lymphocyte
CTLD C-type lectin-like domain
CTLDcps C-type lectin-like domain containing proteins
CTLR C-type lectin-like receptor
Cyt cytoplasmic tail
Da Dalton
dd double distilled
DNA deoxyribonucleic acid
dNTP 2’-deoxynucleotide triphosphate
DPBS Dulbecco’s PBS
ds double-stranded
E. coli Escherichia coli
EDTA ethylenediaminetetraacetic acid
ELISA enzyme-linked immunosorbent assay
EndoH endoglycosidase H
Eq equilibrium
ER endoplasmic reticulum
FCS fetal calf serum
Fig. figure
FPLC fast Protein Liquid Chromatography
FT flow through
g earth gravity (9.81 m/s2)
GF gel filtration
GlcNAc N-acetylglucosamine
GSH glutathione, reduced
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GSSG glutathione, oxidized
GST glutathione S-transferase
h hour
HEPES N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid
His-tag histidine tag
HLA human leukocyte antigen
hrs hours
IB inclusion bodies
IEX ionexchange chromatography
Ig immunoglobulin
IL interleukin
IMAC immobilized metal affinity chromatography
IPTG  isopropyl β-D-1-thiogalactopyranoside 
ITAM immunoreceptor tyrosine-based activation motif
ITIM immunoreceptor tyrosine-based inhibitory motif
K Kelvin (0 K = - 273.15 °C)
ka dissociation rate constant (also off rate constant)
Kan kanamycin
kd association rate constant (also on rate constant)
KD dissociation constant
LB Luria Bertani
Lec lectin
LLG log likelihood gain
Man mannose residue
MBL mannose-binding lectin
MCS multiple cloning site
MEA mercaptoethylamine
MHC major histocompatibility complex
MIC MHC class I chain-related molecule
miRNA (miR) microRNA
MOPS 3-(N-morpholino)propanesulfonic acid
MR molecular replacement
Mw molecular weight
MWCO molecular weight cut off
n nucleotide
NAG N-acetylglucosamine
NCS non-crystallographic symmetry
NKc natural killer cells
NKC natural killer gene complex
NKD natural killer (NK) domain
NKG2D natural-killer group 2, member D
NKT natural killer T cells
NTA nitrilotriacetic acid
o/n overnight
OD optical density
ORF open reading frame
P20 polysorbate 20
PAGE polyacrylamide gel electrophoresis
PAMP pathogen associated molecular patterns
PBS phosphate buffered saline
PCR polymerase chain reaction
PEG polyethylene glycol
A b b r e v i a t i o n s
164 | P a g e
Pfu Pyrococcus furiosus
PI-3K phosphadidylinositol-3-kinase
PMSF phenylmethylsulfonyl fluoride
PRR pattern recognition receptor
PSP photostimulable phosphor plate
PVR poliovirus receptor
r. m. s. d. root mean square deviation
RNA ribonucleic acid
rpm revolutions per minute
RU resonance unit
s seconds
S 75 / 200 / 300 superdex 75 / 200 / 300
SDS sodium dodecyl sulphate
SEC size exclusion chromatography
SLS Swiss Light Source
SOB super optimal broth
SP signal peptide
SPR surface plasmon resonance
ST stalk region
SV40 simian virus 40
Tab. table
TAE tris-acetate EDTA
Taq Thermus aquaticus
TCR T cell receptor
TEMED N,N,N’,N’-tetramethylethylenediamine
Temp. temperature
Tet tetracycline
Tfb transformation buffer
Tm melting temperature
TM transmembrane domain
TM transmembrane region/domain
Tris tris(hydroxymethyl)aminomethane
UL unique long
ULBP UL16-binding protein
US unique short
UV ultraviolet
V volts
v/v volume per volume
vol. volume
w/v weight per volume
wt wild-type
β2m β2-microglobulin
β-ME 2-mercaptoethanol 
ε  extinction coefficient (M-1cm-1)
λ wavelength (nm) 
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